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The role of Vitamin D receptor (VDR) signalling within the osteoclast is not fully 
elucidated, with even the presence of VDR in the osteoclast debated. However, the 
presence of the enzyme, 25-hydroxyvitamin D 1α hydroxylase (CYP27B1) responsible for 
the final conversion step of the Vitamin D pro-hormone into active Vitamin D, within the 
osteoclasts, osteoblast and osteocytes, and the potential for modified activity and 
maturation within the bone cells under the effects of Vitamin D has been established.  
The aim of the studies within this thesis were to examine through the use of genetic knock 
out models (KO) the role(s) vitamin D plays in osteoclast proliferation, maturation, activity 
and the underlying potential genetic mechanisms. Experimental work first optimised 
osteoclast maturation from wild type (WT) littermate matched splenocytes and then 
focused on osteoclastogenesis from genetic KO models, Cyp27b1KO and VdrKO with the 
aim of identifying the role of autocrine vitamin D. This was expanded into the role of the 
V-ATPase pump as a compensatory mechanism for loss of autocrine function and the effect 
of vitamin D on mature osteoclasts through the Ctsk-Cre.Vdrfl/fl mouse model in co-culture. 
The deletion of the Cyp27b1 and Vdr genes and the subsequent impairment of the vitamin 
D metabolic pathway resulted in changes in TRAP-positive multinucleated cells (MNC) as 
well as per cell increase in osteoclast resorptive activity. Osteoclast related gene expression 
was significantly reduced in both gene KO models and deranged in the V-ATPase subunits. 
It is worth mentioning that several genes from both Cyp27b1 and VdrKO cultures had 
almost identical patterns of gene expression, reinforcing the notion that the effects seen 
were mediated through the loss of the vitamin D metabolic pathway. Ctsk-Cre.Vdrfl/fl 
osteoclast cultures indicated that mature WT osteoclasts resorptive activity is suppressed 
viii 
by the presence of the vitamin D receptor. The loss of VDR in mature osteoclasts in co-
cultures resulted in a deregulated increase in resorptive activity and aberrant maturation. 
Overall, the findings of this thesis establish that there is a role for autocrine vitamin D 
activity within the osteoclast lineage. The loss of the vitamin D metabolic pathway in the 
case of Cyp27b1KO and VdrKO, result in significant changes to osteoclast maturation, 
proliferation, activity and gene expression and it is evident that there are compensatory 
mechanisms present that help minimise the impact. Further experimentation is warranted 
to further elucidate the effects of vitamin D activity in the osteoclast lineage and to overall 
fully understand how vitamin D works in human bone and aging. 
ix 
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Chapter 1: Review of the Literature 
Chapter 1 is a review of the current literature pertaining to vitamin D metabolism and 
activity in bone, including the role of autocrine and endocrine vitamin D activities and the 
role of vitamin D in calcium and phosphate homeostasis. To understand the role of vitamin 
D specifically within the osteoclast lineage at the autocrine level, an understanding of the 
current state of knowledge, not just in the field of vitamin D but of bone cell biology, is 
required. This review is therefore divided into four sub-sections; the first sub-section 
focuses on vitamin D and its role in the endocrine system. The second sub-section reviews 
the current general knowledge in bone cell biology. The third sub-section examines the role 
of vitamin D at a cellular level in the three major bone cell types, osteoclasts, osteoblasts 








1.0 Introduction: Scope and Structure of the Literature Review 
The active form of vitamin D, 1α25-dihydroxyvitamin D3 (1,25D; calcitriol), is recognised 
as being essential in maintaining calcium homeostasis, principally by stimulating intestinal 
calcium absorption. By doing so, vitamin D indirectly contributes to maintaining 
mineralised bone. However, vitamin D also is known to directly regulate bone formation 
and resorption, in processes which appear to enhance bone formation under certain 
circumstances and promote bone resorption under other circumstances. In this review, we 
will briefly cover the known pathways related to the synthesis and actions of 1,25D with 
respect to the endocrine system. We will also cover the known actions of 1,25D on the 
autocrine activities of vitamin D in the various bone cell types. Finally, we will focus on 
the main topic of this thesis, the autocrine and paracrine actions of vitamin D metabolites 
on the major bone resorbing cell type, the osteoclast. 
Cellular effects of 1,25D are mediated following the ligation of the hormone to the vitamin 
D receptor, which is a member of the nuclear receptor family. Vitamin D has a diverse 
range of activities in bone and other tissues, which is attributed to the fact that the VDR is 
almost ubiquitously expressed, including in the three major bone cell types, osteoblasts, 
osteocytes and osteoclasts (1). This diverse expression pattern of the VDR is reinforced by 
the presence of putative vitamin D responsive elements (VDREs), occurring in the 
proximal and distal promoter regions of a large percentage of mammalian genes (1) . 
Recent studies have demonstrated that osteoblast-lineage cells contain the enzyme 
CYP27B1 which is required to convert 25D to active 1,25D (2). In addition, our group has 
been principal in demonstrating that cells of the osteoclast lineage also have the ability to 
convert 25D to 1,25D through the expression of CYP27B1 (3, 4), and are thus capable of 
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autocrine 1,25D signalling, as well as responding to paracrine or endocrine 1,25D-mediated 
signals.  
The osteoclast is a unique cell type, highly adapted for resorbing bone. As well as being 
multi-nucleated, it also has specialised internal structures that promote efficiency in bone 
resorption and ATP generation. These include an unusually dense electron transport chain 
within the mitochondria, high levels of expression of the multi-subunit V-ATPase pump 
and the ability to form an (Filamentous) F-actin ring, a specialised structure enabling a tight 
seal to form between the basolateral cell membrane of the osteoclast and the mineralised 
bone matrix (5). The various functional proteins of the osteoclast are potentially sensitive 
to regulation by 1,25D. Strong evidence for a paracrine role of vitamin D in the osteoclast 
is provided by the recognised regulation of expression of key cytokines, such as receptor 
activator of nuclear factor kappa-B ligand (RANKL) and colony stimulating factor (CSF-
1), also known as macrophage colony stimulating factor (M-CSF), which together are 
essential for the differentiation of osteoclast precursors into mature osteoclasts (5, 6). 
Recent studies from our group demonstrate that osteoclasts metabolise 25D to form active 
1,25D resulting in the modulation of osteoclastogenesis, the bone-resorbing activity and 
migration of osteoclasts (7). The proposed stages of osteoclast differentiation and function 
influenced by paracrine and autocrine signalling of vitamin D are depicted in Figure 1.1. 
However, little is known about the underlying molecular mechanisms responsible for these 
effects.  
Bone is an essential part of the human ambulatory system providing structure, support and 
tension, protecting critical organs and enabling movement from respiration to locomotion. 
Bones are fibrous mineralised tissues and structures consisting primarily of collagen type 
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I (90%) structured into an organic matrix. The organic matrix is mineralised with a calcium 
phosphate mineral, a biological analogue of hydroxyapatite. The matrix and mineral phases 
act in conjunction with each other, providing strength and flexibility, respectively. Bone is 
not a static tissue but is continually remodelled by coordinated cycles of resorption and 
formation in a process commonly referred to as bone remodelling. Resorption is undertaken 
by haematopoietic-derived osteoclasts and their precursors, and formation is carried out by 
mesenchymal-derived osteoblast-lineage cells. 
 
Fig. 1.1: Vitamin D activity in bone cells.  The role of vitamin D metabolism and activity 
in the various bone cell types. (Taken from (8) with permission) 
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This review of the literature examines the current understanding of vitamin D activity in 
calcium homeostasis, as well as the endocrine and autocrine effects of vitamin D on bone 
biology, with a major focus on the osteoclast lineage. 
 
1.1Vitamin D and the Endocrine System 
Vitamin D, bone and vascular pH are directly linked in a complex regulatory system (9). 
The bone acts as mineral storage for calcium and phosphate and in times of need calcium 
is liberated from the bone (10).  When vitamin D and calcium levels are insufficient over 
extended periods of time skeletal structural stability becomes affected. Since the primary 
role of vitamin D is regulation of calcium homeostasis, the maintenance of bone strength 
can be considered a secondary contrivance. Thus, calcium is preferentially removed from 
the bone in favour of calcium homeostasis over bone structural integrity. Extended calcium 
deficiency over a lengthy period of time causes the bone strength to become compromised, 
resulting in increased fracture rates due to reduced stress absorbing potential (11). 
Identifying the genetic mechanisms and biochemical pathways in bone cells regulated by 
vitamin D metabolism, potentially enables more accurate vitamin D dosage for 
osteoporosis patients. If these biochemical pathways and genetic mechanisms stimulated 
by vitamin D can be demonstrably related to the changes in fracture rates, this may allow 
modification of biochemical or genetic pathways to maintain or improve bone strength. 
This could also provide insight into stabilising bone remodelling in older age (12, 13).  
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1.1.1 Synthesis of Vitamin D3 in the Skin 
Vitamin D can be ingested through dietary intake in the calciferol D2 form and the 
cholecalciferol D3 form, the primary mechanism of vitamin D synthesis is through 
photolytic conversion in the skin. The vitamin D metabolite 7-dehydrocholesterol 
undergoes photolytic conversion with exposure to UV-B radiation within epidermal cells, 
in particular within the stratum basale and stratum spinosum, to become vitamin D3 (11, 
14, 15). 7-dehydrocholesterol absorbs UV-B radiation at the wavelengths of 290-320nm 
and converts to the pre-vitamin D3 (C27H44O) form, which under reversible thermal 
isomerisation rearranges its double bond structure over three days to the more 
thermodynamically stable form, cholecalciferol or vitamin D3 (16). Human body 
temperature naturally pushes this equilibrium towards the vitamin D3 form (8). vitamin D3 
requires two further hydroxylation steps before it becomes an active metabolite, each 
catalysed by a cytochrome P450 (CYP) enzyme CYP2R1, and CYP27B1 (8). Vitamin D3 
is hydroxylated at position C25 to 25D via CYP2R1 in the liver. 25D is the major 
circulating form of vitamin D. 25D is further hydroxylated at position C1 via CYP27B1 
activity to 1,25D in the kidney. 1,25D is the recognised active hormone form of vitamin D. 
Excess 25D and 1,25D are broken down by the cytochrome P450 enzyme, CYP24A1. 
CYP24A1 further hydroxylates 25D or 1,25D adding a hydroxyl group at C24, generating 
24,25-dihydroxyvitamin D and 1,24,25-trihydroxyvitamin D, respectively (17). These 
short-lived metabolites are then rapidly catabolised by CYP24A1 into calcitroic acid, 





Fig. 1.2.  Vitamin D metabolites. Identifies the chemical changes that occur in vitamin D 
metabolites from the skin to the active form of vitamin D. Recreated from (18) 
 
1.1.2 Synthesis of 25-hydroxy Vitamin D in the Liver 
Vitamin D3 produced in the skin is released into the blood bound to vitamin D binding 
protein (DBP), which both stabilises the metabolite and mediates delivery to the liver for 
further processing. The conversion of vitamin D3 to the metabolite 25D (calcidiol) is 
catalysed by the cytochrome P450 enzyme, CYP2R1 (19-21). Currently, the majority of 
conversion of vitamin D to 25D occurs within the liver, which under constitutive conditions 
releases 25D into the circulation. Circulating 25D levels are currently considered the most 
reliable indicator of an individual’s vitamin D status, as 25D has a long half-life of 15-35 




1.1.3 Synthesis of 1α,25-dihydroxy Vitamin D3 in the Kidney 
The final step in the synthesis of active vitamin D hormone is the conversion of 25D to 
1,25D, by the P450 enzyme CYP27B1, a critical regulatory step of the vitamin D endocrine 
system. The conversion of 25D to 1,25D has been demonstrated to take place almost 
ubiquitously throughout the human body (19). The kidney is the primary producer of 
circulating 1,25D levels in the blood  (23). 1,25D has a short half-life and also acts as a 
negative regulator of itself (24). 1,25D is a highly active metabolite and as such needs to 
be tightly regulated.  
 
1.1.4 Role of DBP in the Vitamin D Pathway 
The majority of 25D released from the liver is bound to the chaperon protein DBP. DBP 
also binds to 1,25D but has a higher affinity for 25D (7x108 M-1) than that of 1,25D (4x107 
M-1) (25).  The mechanism behind 25D entry into cells has not yet been fully elucidated. 
Free ligand diffusion and DBP mediated endocytosis are the current proposed mechanisms 
for the entry of bound 25D into cells (26). Free ligand diffusion proposes that the smaller 
percentage of unbound 25D in the blood limits the conversion of 25D to 1,25D (26). DBP 
mediated endocytosis hypothesises that DBP is taken up, following DBP binding to cellular 
receptors. The mechanism behind the uptake of DBP bound 25D has not yet been fully 





1.1.5: 1,25D as a Transcriptional Activator 
1,25D mediates its biological activity via high affinity binding to the VDR, which is 
expressed in most cells of the human body (14). Liganded VDR binds to retinoid X receptor 
(RXR) forming a heterodimer. This becomes conformationally changed allowing it to bind 
to specific Deoxyribonucleic Acid (DNA) sequences, usually in the promoter regions of 
responsive genes termed VDRE, allowing enhanced recruitment of co-factors for 
transcriptional activation (8). Renal-derived 1,25D acts upon key genes in intestinal 
enterocytes and renal proximal tubule cells, to mediate calcium absorption and re-
absorption respectively (27-29). However, there is to date little evidence that the relatively 
low affinity of 25D for VDR is sufficient at physiological levels to contribute to VDR 
mediated signalling.  
 
1.1.6: Endocrine actions of Vitamin D  
Vitamin D is a primary regulator of endocrine calcium and phosphate homeostasis (30). 
The effects of vitamin D on the endocrine system are well established (3, 4, 7, 30, 31). 
Levels of 25D at 20 nmol/l or less, result in secondary hyperparathyroidism due to 
improper 1,25D production and calcium absorption. Vitamin D endocrine activity is 
substrate limited. Chronically low vitamin D levels, below 20 nmol/l combined with low 
dietary calcium result in diseases, such as rickets and osteomalacia (9, 32). It has been 
demonstrated in multiple studies that decreased levels of 25D below 50 nmol/l result in 
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increased fracture risk (12, 33) (34). The Institute of Medicine report for nutritional 
guidelines state that 50 nmol/l is now considered the minimal healthy vitamin D level 
required under minimal sun exposure. This indicates the potential for vitamin D to have 
additional mechanisms that take affect when 25D is above 20 nmol/l but below 50 nmol/l. 
One of the currently proposed mechanisms for this is, the autocrine conversion of 25D to 
1,25D requires a higher circulating 25D level in order to become active.   
 
1.1.7 Endocrine Actions of Vitamin D on Bone  
Bone cells are targets of the vitamin D endocrine system and are also purported to be 
regulated by an internal autocrine/paracrine system within the cells themselves. In the case 
of the endocrine system, bone cells are directly affected by 1,25D produced from renal 
synthesis. Renal-derived 1,25D regulates osteoblast gene transcription, differentiation and 
mineralisation (35). It has been observed that 1,25D results in the induction of RANKL 
Messenger Ribonucleic Acid (mRNA) and the down regulation of Osteoprotegerin (OPG) 
mRNA expression. This decrease of OPG to RANKL ratio is known to promote 
osteoclastogenesis (36) and increase bone mineral resorption in humans. It was also 
reported that 1,25D may act to increase the progenitor pool of osteoblasts (37). 1,25D 
enhances the availability of osteoclast precursors for osteoclastogenesis (38). The next 





1.2.0 Bone Cell Biology 
1.2.1 Osteoblasts 
Osteoblasts in the axial skeleton are derived from mesenchymal stem cells. Interestingly, 
osteoblasts in the skull are likely derived from neural crest ectoderm (9). Osteoblasts are 
the bone matrix builders of the body and have prominent endoplasmic reticulum and Golgi 
organelles, indicative of a large protein manufacturing and transport capacity. This enables 
the osteoblast to rapidly produce and transport collagen and other protein components for 
the organic matrix of the bone. Osteoblasts lay down the organic matrix of the bone that 
primarily consists of collagen type 1 fibrils (9).  
Newly formed, un-mineralised bone matrix is termed osteoid and is the section of the bone 
that gives flexibility. The mineralisation of the bone is undertaken by pre- or osteoid-
osteocytes and the mineral composite of the bone provides the strength and load bearing 
capacity to the bone. Osteoblasts complete the organic matrix production and deposit bone 
mineral in a tightly regulated manner to form a strong elastic matrix (39). This matrix is 
capable of functioning as a load-bearing mechanical structure (39). Along with collagen 
type 1, osteoblasts secrete non-collagenous proteins that are essential for optimal bone 
formation including, tissue non-specific alkaline phosphatase (TNAP), bone sialoprotein, 
osteopontin and osteocalcin (40). TNAP is amongst one of the most important of these non-
collagenous proteins, as it converts the ubiquitous inhibitor of mineralisation, 
pyrophosphate to inorganic phosphate. This conversion enables the mineralisation of 
osteoid matrix to proceed. 
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Osteoblasts, while playing a critical role in the formation of bone, are also directly involved 
in the regulation of bone resorption. Osteoblasts are known to secrete OPG, a member of 
the tumour necrosis factor receptor (TNFR) family. OPG, unlike the other members of the 
TNFR family, is not bound to cellular membranes and acts as a decoy receptor for RANKL. 
As such, it is a competitive inhibitor of osteoclastogenesis (41). OPG’s structure has the 
standard amino terminal half ligand binding domain associated with the TNFR family 
members (42). Its carboxy terminal domain resembles that of a decoy receptor encoded in 
virulence as is often found in proxy viruses (42).  
The deletion of the Opg gene in mice results in severe osteopenia associated with excessive 
osteoclastic resorption (43-45). In mouse over-expression models of OPG, the bone 
becomes a near solid mass and presents with limited bone marrow space, a state termed 
osteopetrosis. OPG blocks the RANKL- Receptor Activator of Nuclear Kappa B (RANK) 
interaction and therefore the differentiation of osteoclasts resulting in a negative effect on 
osteoclastic bone resorption (42). OPG production is not solely the providence of 
osteoblasts and is produced by other cells. Along with the production of collagen and OPG, 
osteoblasts also produce numerous cytokines essential in efficient osteoclast differentiation 
and osteoclastogenesis (46). Current research suggests that these cytokines, such as M-
CSF, are also provided by the osteocytes (2).  
Previous scientific research has indicated that osteoblasts present osteoclasts with the 
majority of RANKL involved in their RANK/RANKL interactions (47). However, recent 
in vivo models have indicated the increased possibility that it is in fact the osteocytes that 
are the major source of RANKL for osteoclastogenesis in the adult skeleton, rather than 
the more immature osteoblasts. One of the most compelling pieces of evidence for this is 
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work done by Xiong et al. (48) that showed that mice whose osteocytes were unable to 
produce RANKL had a significant inhibitory effect on osteoclastogenesis. Supporting this 
is other studies showing that osteocytes are essential for the remodelling of bone through 
osteoclastic activation in mature animals (49). It is theorised that the hypertrophic 
chondrocytes and immature osteoblasts are also important sources of RANKL in growing 
animals (48, 49). 
In humans, osteoblasts have an average life span of three months. However, research has 
indicated that high levels, 120 nmol/l or greater, of 25D can potentially increase the life 
span of osteoblasts. As osteoblasts remain active for longer, more osteoid is laid down. In 
the case of increased life span an overall increase of bone osteoid is observed (9). This has 
been shown to produce lower quality osteoid.  During the process of laying down bone, 
around 5% of osteoblasts differentiate into osteocytes and become enveloped within the 
bone matrix (9). The remaining osteoblasts become bone lining cells or undergo cell 
mediated apoptosis (50). The bone lining cells remain on the bone surface and are 
interconnected with osteocytes (50). Currently knowledge about the role of the bone lining 




Osteocytes are long-lived cells that make up 90-95% of all bone cells, sometimes living in 
excess of 25 years (9). Osteocytes are considered one of the final stages of differentiation 
of the osteoblast. Late stage osteoblasts either undergo apoptosis, differentiate into bone 
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lining cells, or become embedded in the bone matrix as osteocytes. The embedding process 
occurs concomitantly with the differentiation of the osteocytes. Osteocytes are thought to 
transition from osteoblast to osteocyte through several interim stages, with each 
differentiation state being associated with altered functional modalities (51). 
Initially, a small percentage of osteoblasts become embedded in the bone matrix they 
secreted and will differentiate into pre-osteocytes or osteoid osteocytes. Pre-osteocytes are 
purported to regulate and lay down mineral in the formation of new bone. As the osteocyte 
matures, it extends dendrite-like processes throughout the organic matrix (51). Osteocytes 
have been observed to extend up to 50 of these processes, which are ostensibly used as an 
interlaced communication structure known as the osteocytic syncytium. The syncytium 
senses fluid dynamics in the bone, enabling responses to external mechanical stimuli. The 
processes in the syncytium facilitate intracellular communication via gap junctions similar 
to synapses, such as found in the nervous system and cardiac muscle (52). Gap junctions 
facilitate the transport of small signalling molecules (53). Examples of these molecules are; 
nitric oxide and prostaglandins which can interact with the opposing dendrite, resulting in 
alterations in cellular function and gene expression. It is theorised that osteocytes interact 
with other bone cell types including, bone lining cells, osteoclasts, other cells in the bone 
marrow (50) and possibly, bone neurons and vascular endothelial cells. 
Currently, there is debate on how osteocytes sense mechanical stress. Despite this it is 
accepted that, the ability to detect load on bone plays a critical role in bone remodelling. It 
is known that new bone matrix is added when load or stress is increased and that when load 
is reduced, bone matrix is reduced, such as, in microgravity or prolonged bed rest (52). It 
is currently thought that high frequency of use of the skeletal structure is necessary in order 
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to achieve peak bone mass. Several studies have shown that the use of imperceivable 
vibration on bovine bone increases the bone matrix density in comparison to a negative 
control (54). In effect, bone mass is regulated by peak tension and bone formation rate is 
regulated by frequency of use. 
Under conditions of everyday use, such as locomotion, bone is placed under mechanical 
stress. This stress results in micro-fractures in the bone matrix. These can over time result 
in a significant undermining of bone structure, unless the bone matrix is replenished. If 
bone is not repaired then micro-fracture propagation may occur potentially resulting in 
structural failure. Osteocytes are considered to be sensitive to micro-fractures and damage 
to the osteocytic syncytium (50). This results in the osteocytes undergoing apoptosis. When 
an osteocyte undergoes apoptosis, it results in the promotion of bone resorption around the 
site of damage. The mechanism for this up regulation is still unknown and several 
possibilities have been theorised. One, is that dead osteocytes may release or breakdown 
into vacuoles that contain promoters for osteoclasts, such as RANKL. Another possibility 
is that the process of apoptosis in the osteocytes results in osteoclast stimulating cytokines, 
principally RANKL, being produced by viable osteocytes neighbouring apoptotic cells 
(52). Osteocyte apoptosis also results in the up-regulation of the survival factor B-cell 
lymphoma 2 (BCL-2) in neighbouring osteocytes. The survival of the osteocytes restricts 





Osteoclasts, like macrophages, are derived from cells of the haematopoietic lineage due to 
identical progenitors. These cells have many similarities to one another. The addition of 
M-CSF to haematopoietic stem cells promotes the differentiation and survival of osteoclast 
precursors and macrophages in vivo (5). M-CSF regulates the motility and cytoskeletal 
organisation of both osteoclasts and macrophages. However, unlike macrophages, 
osteoclast precursors require  RANKL, Tumour Necrosis Factor Super Family Member 11 
(TNSF11), in order for differentiation into osteoclasts to occur (49). RANKL binds to the 
cell surface receptor Tumour Necrosis Factor Superfamily Member 11A 
(RANK/TNFRSF11A), a marker of committed pre-osteoclasts (55). 
Osteoclasts are the cells responsible for the majority of bone resorption. Osteoclasts 
liberate phosphate and calcium from the bone in times of calcium deficiency and resorb 
damaged or fractured bone. The resorption and proliferation of the osteoclasts are highly 
regulated. This regulation appears to primarily occur through the RANK/RANKL 
interaction (5). RANK transduces its signal through the TNF receptor associated factors 
(TRAFs), primarily TRAF6 (56), (6). It was originally proposed that the predominant mode 
of repetitive presentation of RANKL to osteoclasts was via the osteoblast, however 
evidence has emerged that mature osteocytes play a key role in regulating osteoclastic 
function (48). Other cell types express RANKL, including immature osteoblasts, bone 
marrow stromal cells, hypertrophic chondrocytes, certain subsets of T-lymphocytes and the 
osteoclasts themselves (48). It is also possible that osteoclastogenesis can be driven or 
partially regulated by other conditions, such as growth, fracture repair, inflammation and 
bone cancer, independently of, or in addition to, osteocytes and osteoblasts (48, 49).  
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Osteoclasts are one of the few multi-nucleated cell types and each typically contain 15-25 
nuclei. Very large osteoclasts, such as those present in Giant Cell Tumours of Bone 
(GCTB) or those derived under in vitro differentiation conditions, may contain a hundred 
or more nuclei (55). Osteoclasts have a large number of unique features in addition to their 
multinucleated nature (4). They have large cytoplasmic regions, increased vesicle transport 
capacity and a modular filamentous actin ring that enables the formation of a sealed isolated 
zone, under which is the ruffled border (57). The ruffled membrane is a specialised 
structure through which the osteoclast secretes; concentrated hydrogen and chloride ions 
forming hydrochloric acid and proteases to resorb the bone forming characteristic 
resorption ‘pits’, known as Howship’s Lacunae (9). This enables precise resorption of bone 
that has been fractured or weakened to be targeted (35). It is believed that the nuclei in the 
osteoclasts function together at the same transcriptional rate, enabling a massive output of 
mRNA, functional enzymes and proteins for the resorption of bone. In order to examine 
the effects of vitamin D on the osteoclast, it first must be understood how the osteoclast 
resorbs bone and how vitamin D may interact and affect this process, be it via the CYP27B1 
pathway or other alternatives. 
Osteoclasts are regulated by multiple complex mechanisms, of which the most prominent 
is the aforementioned RANKL/RANK pathway. Despite the essential nature of this 
pathway and the self-inducing properties of the major transcription factor, Nuclear Factor 
of Activated T-cells, Cytoplasmic One (NFATC1) once it has been acted upon via the 
RANK pathway other factors play critical roles in the regulation of osteoclasts. CSF-1/M-
CSF is essential for the regulation differentiation, proliferation and survival of osteoclast 
precursors and plays a role in the phosphorylation of pathways outside of the primary 
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RANK/RANKL pathway. Of these pathways several are immunoreceptor tyrosine-based 
activation motif (ITAM) regulated. The factors, osteoclast-associated immunoglobulin-like 
receptor (OSCAR) and triggering receptor expressed on myeloid cells 2 (TREM2) bind to 
the ITAM family member, TYRO protein tyrosine kinase binding protein also known as 
dap12 (58, 59). These together influence osteoclastogenesis and in double mutant (TREM2 
and OSCAR) mice the ability of osteoclasts to form are lost. In mice carrying a single 
mutation in either OSCAR or TREM2, osteoclast size and ability to resorb is reduced or 
lost. Further examination of the role of TREM2 in raw cells using TREM2 antibody to 
inhibit expression resulted in failure of mature osteoclasts to resorb. Interestingly, there are 
reports that the loss of TREM2 resulted in an increased rate of osteoclastogenesis (60). 
This implies that the presence of TREM2 played a critical role in not just osteoclastogenesis 
and resorption but also the rate of osteoclastogenesis. While the loss of TREM2 in murine 
KO models did not result in complete osteoclast failure, it did result in osteopetrotic cysts 
forming in the bone. TREM2 is of great interest in the osteoclast lineage as it has been 




Fig. 1.3: Signalling in the osteoclasts. Overview of the mechanistic pathways involved in 
RANKL and M-CSF signalling within the osteoclast. This was compiled from multiple 
























































1.2.3.1 V-ATPase subunits 
The V-ATPase pump is essential to the functioning of the osteoclast as it enables the 
acidification of the resorption zones without which the osteoclast would be unable to 
remove bone. The V-ATPase in mammals has at least 26 individually transcribed and 
translated subunits organised into two major functional domains, peripheral and internal. 
V-ATPase is a membrane bound hydrogen ion pump that uses the hydrolysis of ATP to 
adenosine diphosphate (ADP) to actively transport H+ from the cytoplasm of osteoclasts 
through the ruffled membrane and into the isolated acidified sealed zones (57). While the 
underlying concept of the V-ATPase pump in the active transport of H+ is well accepted, 
the activities and responses of the subunits within the pump are less well known. Hydrogen 
ion transportation is undertaken using rotational translocation. The central rotor of the 
hydrogen ion pump is bound to the peripheral rotors. Peripheral rotors are in turn attached 
to stator subunits that are bound into heterodimers of subunit, a and b bound to the central 
rotor d in the V1 domain and is located within the cytoplasm as seen in Fig 1.4. The V1 
rotary section converts ATP to ADP causing rotary motion. The central rotor of the V1 
section is directly bound to the corresponding central rotor in V0 domain of the pump 
located intracellularly. The V1 and V0 regions are bound via a heterodimer of v1e and v1g 
subunits. The V0 domain is bound within the plasma membrane and can spontaneously 
form within this membrane upon the adhesion of the v0c subunit. The rotation initiated by 
ATP to ADP conversion continues on to the v0d subunit which also is bound to the rotary 
subunit v1d. This binding causes the rotation of the subunit Ac45, which acts as the central 
rotor for V0 and is bound to the c subunits responsible for transporting the hydrogen ions 
with the rotational movement of the pump. Like passing through a revolving door, the 
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hydrogen ion is moved around and then exported through the v0a subunits. This entire 
system is regulated by v1h and v1f regulatory subunits (61). Literature has as yet only 
examined a few of the 26 subunits of the V-ATPase pump, others such as M8-9 and v0e 
have no reported role in hydrogen ion transport. However, this does not mean they lack 
importance. The gene knockout models of both M8-9 and v0e indicate severe failure of 
osteoclastogenesis when there is an inhibition in their overall function (61). In osteoclasts, 
expression of the subunit known as v1c is highly regulated by RANKL and M-CSF (57). 
The loss of v1c impairs acidification and causes the actin ring not to form. This inhibits 
osteoclast formation and prevents bone resorption. It was demonstrated that the V-ATPase 
pump as a whole has enhanced protein expression under 1,25D treatment (62). The 
individual subunits that respond to 1,25D however have as yet not been isolated (57). It is 
known that expression of the v0a3 subunit is up regulated 100-fold in osteoclasts. 
Impairment of subunit function can affect not only osteoclast resorption but also the ability 
for the fusion (57, 63-68) of the osteoclast precursors, indicating the essential role that the 








Fig.1.4:  V-ATPase Structure. Structural composition of the V-ATPase subunit with all 
of the primary subunits displayed (57). 
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1.2.3.2 Integrin αvβ3 and Formation of the Sealed Zone 
The recruitment of osteoclasts to the bone occurs through the interaction of the ανβ3 
integrin. The gene deletion of both subunits of the ανβ3 integrin results in the functional 
impairment of the osteoclast’s resorptive activity (69). Mice with non-functional ανβ3 
integrin present with an increasingly osteopetrotic phenotype that increases with age, 
consistent with bone resorption being impaired (46, 70, 71). The deletion of the ανβ3 
integrin results in a reduction of osteoclastogenesis, however it has been observed that M-
CSF is over-stimulated in these conditions in an apparent attempt to compensate for the 
impairment of osteoclastogenesis (5). As knockout mice β3-/- (72, 73) still display a mild 
osteopetrotic phenotype, it is clear that M-CSF does not fully compensate for the loss of 
the ανβ3 integrin. The ανβ3 integrin is known to be sensitive to vitamin D (5). This 
sensitivity entails that 1,25D may act upon the cytoskeletal arrangement of the osteoclast, 
possibly providing a mechanism for decreased resorption despite the increase in osteoclast 
number observed in RAW cells (3, 4). The loss of ανβ3 integrin results in impaired 
attachment. When attachment occurs incorrectly or the integrin is not present, then the 
osteoclast’s podosomes and actin ring complexes will not form correctly, resulting in the 
failure to resorb bone (5). 
Attachment of the osteoclast occurs through the ανβ3 integrin binding to osteopontin 
(OPN), which is found throughout murine and human bone, as well as dentine, enabling 
cross reactive osteoclast activity between mammalian species. The ανβ3 integrin is 
essential in the cytoskeletal rearrangement of F-actin to form a complex, known as a 
podosome. The podosomes form a ring like structure that is intertwined together with 
additional cross-linking actin filaments. This combined structure forms the sealing zone 
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and osteoclasts are able to form 2-3 sealing zones simultaneously. It has been shown that 
TRAP acts to dephosphorlyate OPN and causes the ανβ3 integrin binding to break down. 
It has been postulated that this enables the osteoclast to move to another location to start 
resorption anew (74).While the ανβ3 integrin is essential for the ring formation to take 
place, Geblinger et al. (75) have provided evidence that indicates that bone 
roughness/smoothness is directly responsible for the frequency of the rings that form, as 
well as, their overall duration. Irregular and coarse regions result in increased resorption 
corresponding to old bone sections or simulated breaks representing damaged bone (75). 
The regulation of ring shape and structure by bone surface is subsumed by the deletion of 
the ανβ3 integrin due to the inability to rearrange the F-actin preventing the formation of 
podosomes and the F-actin ring. The resulting osteoclasts also present with abnormal 
ruffled membranes (5). This is due to the function of ανβ3 integrin in activating small 
Guanosine Triphosphateases, Rho and Rac, essential in the formation of the F-actin ring 
(76). The characteristic ruffled border of the osteoclast forms within the sealed zone, under 
a resorbing osteoclast and constitutes the basolateral membrane.  
 
1.2.3.3 Acidification of the Bone Matrix 
After the osteoclast has attached to the bone matrix, the osteoclast forms its characteristic 
ruffled membrane beneath the bone cell. The basolateral plasma membrane consists of 
finger like projections which secrete protons and proteases (5). The formation of the sealing 
zone enables the osteoclast to acidify the bone matrix releasing charged hydrogen and 
chloride ions in a highly localised and controlled manner (Fig 1.5). Demineralisation of the 
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bone is undertaken using hydrogen ions produced by the cytoplasmic enzyme, carbonic 
anhydrase 2 (CA2) which functions by converting water and carbon dioxide into 
bicarbonate and hydrogen ions (77, 78). Osteoclastic resorption of bone requires the 
formation and activation of the V-ATPase which transports hydrogen ions through the 
ruffled membrane of the osteoclasts, causing the dissociation of calcium and phosphate 
from the bone matrix (79). In addition, this creates a suitable pH for the activity of the 
protease cathepsin K.  
In order to compensate for the change in membrane potential caused by the secretion of a 
large number of hydrogen ions, the ions are released in concert with a chloride channel 
(CLCN-7) (80). This channel promotes the movement of chloride ions into the sealed zone 
in exchange for sodium or potassium ions, depending on the surrounding extracellular 
matrix. This maintains the membrane potential of the osteoclast. The alteration of the 
membrane potential can alter the gradient of the cell causing an influx or loss of water 





Fig. 1.5: Actively resorbing osteoclast. Osteoclast resorption through the use of an 
integrin mediated sealing zone. (Image taken from A. Quin et al. 2006) 
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1.2.3.4 Degradation of the Bone Matrix 
The removal of the hydroxyapatite-like mineral component of the bone by hydrogen ions 
exposes the previously mineralised collagen fibrils (collagen type I) and non-collagenous 
bone matrix proteins to the activity of proteases. The micro-environment of the resorption 
zone is highly acidic requiring an enzyme optimised for low pH. Cathepsin K is an 
osteoclast-derived cystine protease that degrades type I collagen and can function in a low 
pH environment with an optimal pH being 5.5 with a functional range up to 7.5. Cathepsin 
K is produced as a zymogen and is converted to an active form as it is transported via 
vesicles from the Golgi (82). Vesicles containing cathepsin K fuse with the basolateral 
membrane releasing their contents through exocytic processes into the micro-environment 
between the osteoclast and the bone surface (83). Cathepsin K is a unique protease as it is 
able to target sites both inside and outside of the tri-helical fibrils that make up the structural 
components of collagen (84). Cathepsin K is a marker of mature osteoclasts as it is only 
produced by osteoclasts that are undergoing active bone resorption. Impairment or genetic 
deletion/inactivation of any one of the many components involved in the osteoclastic 
resorption of bone can result in diseases presenting with an osteopetrotic phenotype. In 
particular, the loss of cathepsin K results in a sclerosing bone disease, known as 
pycnodysostosis, in which collagen is unable to be degraded, resulting in the phenotype of 
short stature and brittle bones (84).  
Cathepsin K is secreted along with TRAP. TRAP is a glycosylated, iron-containing 
metalloenzyme that is highly expressed in osteoclasts and chondrocytes, and has optimal 
activity under low pH conditions (85). It has been proposed that TRAP regulates bone 
matrix phosphoproteins activity by dephosphorylation and plays a role in intracellular 
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collagen degradation through the formation of reactive oxygen species (86). Loss of TRAP 
expression in mice results in a mild osteopetrotic phenotype due to reduced function of the 
osteoclasts. The exact function of TRAP in osteoclasts is still surprisingly not fully known 
but is associated with osteoclast motility (85-87). Due to TRAP being highly expressed in 
osteoclasts it makes an ideal histological marker for these cells (85-87). 
 
1.2.3.5 Apoptosis and Autophagy in Osteoclasts 
Self-regulated apoptosis plays a significant role in osteoclasts function. As a destructive 
cell that actively removes the structural elements of the skeleton, the ability to regulate 
osteoclast activity is essential. Examples of unregulated osteoclast activity can be seen in 
GCTB that actively resorb the bone around them until the structure of the bone in question 
is compromised and fails. Osteoclasts, like many cells use, BCL-2 and BCL-2 associated 
X (BAX) proteins to regulate their survival (88). BCL-2 acts to prevent apoptosis and 
inhibits BAX and other pro-apoptotic proteins by binding to the B3 domain, altering their 
structure, preventing the activation of the apoptotic cascade. BAX serves the opposite 
function of BCL-2, in that, it activates apoptosis (89). BAX acts in the mitochondria and 
activates the cytochrome C pathway. BAX is bound by BCL-2 in the cytoplasm before it 
can pass into the mitochondria and initiate apoptosis. It is common practice to compare the 
ratio of BAX to BCL-2 protein or mRNA to indicate if a given cell culture is leaning 
towards apoptosis (90). As this ratio increases, the rate of apoptosis increases and, as the 
ratio decreases, then the rate of apoptosis also decreases. While BAX and BCL-2 are the 
major players in apoptosis, other proteins such as Induced Myeloid Leukemia Cell 
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Differentiation protein (MCL-1), BCL-2 Like protein Eleven (BIM) and B-cell 
Lymphoma-extra Large (BCL-XL) are also important in this regard. MCL-1 and BCL-XL 
bind to pro-apoptotic proteins inside the mitochondria and prevent their conformational 
change, preventing the activation of cytochrome C (91).  
Autophagy plays critical roles in cell remodelling and the regulation of cell survival. In the 
osteoclast, autophagy is essential for protease release, osteoclast motility and self-mediated 
apoptosis. Of particular note, BAX plays an essential role in autophagy. BAX has been 
indicated as a major player in the release of vesicles containing bone degrading elements. 
This enhances the importance of the BAX/BCL-2 ratio, as elevated BAX levels may be 
essential for osteoclast activity. It has been hypothesised that an osteoclast will require high 
levels of BAX to function and will require higher BCL-2 levels to offset this. Literature 
has indicated that vitamin D may play a role in multiple cell types in regulating apoptosis 
by altering the levels of BAX and BCL-2 (92). Thus the regulation of the loss or impairment 
of the vitamin D metabolic pathway may result in changes to apoptosis and may provide 









Fig. 1.6: Simplified signalling in the osteoclasts. Simplified overview of the mechanistic 
pathways involved in RANKL and M-CSF signalling within the osteoclast. This was 






























1.3 Autocrine Actions of Vitamin D in Bone 
The presence of the VDR has been established in multiple tissues using numerous 
techniques (93). The role of vitamin D in the osteoclast has been debated for almost as long 
as the osteoclast has been established as an essential bone cell. While it has been well 
established that the osteoblast and osteocyte has the ability to respond to the exogenous 
and autocrine vitamin D, the ability for the osteoclast to respond to vitamin D is debated 
(94). Contradictory articles can be found towards the presence of VDR receptors in 
osteoclasts (95) and (94). This reinforces the need for the clear establishment of the 
presence of VDR in the osteoclast and a way of identifying the presence of VDR using 
multiple techniques. 
 
1.3.1 Autocrine Actions of the Osteoblasts 
Vitamin D through its active metabolite 1,25D has been demonstrated to regulate osteoblast 
functions. 1,25D upregulates RANKL expression in immature osteoblasts (36). Atkins et 
al. (2) demonstrated that the presence of both 25D and 1,25D resulted in the inhibition in 
osteoblast proliferation and increased mineralisation. HOS cells combined with Small 
Interfering Ribonucleic Acid (siRNA) knockdown specifically targeting CYP27B1 was 
used to demonstrate the reliance of 25D conversion to 1,25D on CYP27B1 within the 
osteoblasts. Atkins et al. also demonstrated that human osteoblastic cell lines and primary 
cells constitutively expressed CYP27B1. The presence of autocrine vitamin D activity 
within the osteoblast indicated the potential for autocrine regulation to present within the 
other bone cells. 
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The osteoblast was reported by Van Driel et al. (96) to exhibit autocrine-paracrine activities 
under the local conversion of 25D to 1,25D. This conversion inhibits osteoblast 
proliferation and increases the expression of RANKL mRNA. Osteocalcin (OCN) and 
OPN are vitamin D responsive genes transcribed by the osteoblast and associated with 
ontogenesis, both of which are regulated by 25D (2). Cubilin and megalin were examined 
by Atkins et al. (2) and it was observed that cubilin mRNA, which is found at high levels 
in the osteoblast, was down-regulated upon exposure to 25D. Megalin was shown to be 
present basally but at low levels and no regulation of expression was observed (2). This 
finding was surprising as megalin is believed to operate with cubilin as co-transporters in 
the kidney (97). The down-regulation of cubilin expression however, indicates possible 
autocrine activities of 25D.  
CYP27B1 activity has been associated with key genes of osteoblast maturation and 
mineralisation. It has become apparent that autocrine activity of CYP27B1 plays an 
important role in the regulation of the osteoblasts at varying stages of development (96). 
CYP27B1 activity is higher in osteoblast derived cells that are mineralising than in 
osteoblasts that are proliferating. This is presumed to be due to the more immature 
proliferating osteoblasts mounting a RANKL response to 1,25D, unlike the mineralising 
osteoblasts that promote osteogeneic function (98). The significance of autocrine responses 




1.3.2 Autocrine Actions of Vitamin D in Osteoclasts 
Kogawa et al. (3) showed that CYP27B1 activity in the osteoclast results in the conversion 
of 25D to 1,25D and has an up-regulatory effect on many of the characteristic genes of the 
osteoclast. Overall, Kogawa et al. (3) suggested that increased CYP27B1 activity results 
in the increase of osteoclastogenesis while causing a reduction in resorption. In particular 
25D conversion altered the expression of many well-established osteoclast related genes. 
It was observed that 25D conversion resulted in the up-regulation of Nfatc1, Transcription 
Factor Proto Oncogene (C-Fos), Oscar, (Calcitonin Receptor) Ctr, Trap, Ctsk and Ca2 in 
the mouse macrophage cell line with osteoclastogenic potential, RAW 264.7 (4). In human 
cells, the expression of Nfatc1, C-Fos, Oscar, Ctr, Trap, Ca2, V-ATPase, Clcn-7 and 
(Dendrocyte Expressed Seven Transmembrane Protein) Dc-stamp were all up-regulated 
(4) (100, 101). The effect of 25D on apoptosis was also examined. 
Caspase 3 activity was measured in human peripheral blood mononuclear cells (PBMCs), 
a source of osteoclast precursors, to examine the effects of 25D on osteoclast apoptosis as 
a possible mechanism for 25D effects on osteoclastic resorption (102). While caspase 
activity was increased when 1,25D was present in early stage osteoclasts, 25D had no effect 
on caspase activity (102) and it was apparent that there was no increase in cell death above 
that of baseline cells treated with RANKL and M-CSF.  
In a previous study by Kogawa et al. (4), it was shown that in the presence of RANKL, 
25D time-dependently increased the levels of C-Fos, a critical component of the dimeric 
transcription factor Activator Protein 1 (Ap-1) and Nfatc1. Ap-1 and Nfatc1 are essential in 
osteoclastogenesis. The presence of 25D increases the levels of Ap-1 and Nfatc1 
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transcription factors resulting in the promotion of osteoclastogenesis. It was noted that the 
expression of osteoclast marker genes, such as Oscar (103), a co-stimulatory regulator for 
osteoclast differentiation, Ctr and Trap was also increased. The change in gene expression 
under 25D was modified under the addition of exogenous 1,25D. 
The paper presented by Kogawa et al.  (4) observed that 1,25D resulted in the suppression 
of osteoclast differentiation. The varying effects of 25D and 1,25D were suggested by 
Kogawa et al. to be due to CYP24A1 activity.  It was observed that 25D at 50 nmol/l 
stimulated Cyp24a1 mRNA expression 100-fold less than 1,25D at 1 nmol/l. The use of 
siRNA knockdown approach resulted in the reduction of Cyp27b1 and the subsequent 
impairment of the conversion of 25D to 1,25D causing the inhibition of osteoclastogenesis 
(4). As treatment with 25D resulted in an increase of gene function and did not instigate 
cellular apoptosis, decreases in resorptive activity of the osteoclast are hypothesised to be 
achieved via a modification of a post-translational mechanism. 
One of these proposed post translational mechanisms is the subunits of the V-ATPase pump 
that have been demonstrated to be sensitive to 1,25D (7). This is just one possible post-
translational mechanism, by which locally synthesised 1,25D might modulate osteoclast 
activity. Characterisation of such mechanisms will be critical in our understanding of the 
role of vitamin D metabolism in osteoclasts. 
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1.3.3 Mouse Models of Vitamin D Activity in the Skeleton: VdrKO and 
Cyp27b1KO 
Mouse lines carrying global deletions of the Vdr or Cyp27b1 genes have been used to study 
the effects of vitamin D on the skeleton, and have also provided proof of autocrine synthesis 
within bone cells. The VdrKO mouse was developed by Li YC et al. (104). These mice 
have difficulty maintaining calcium homeostasis and rapidly present with hypocalcaemia. 
By 35 days of age, the mice present with a significant amount of un-mineralised bone. The 
VdrKO mice also present with alopecia, which is apparently unrelated to the inability of 
these mice to respond to 1,25D (104). The usefulness of this mouse model was enhanced 
by the finding by Amling et al.  (105) that after weening the health of mice could be 
maintained through the use of a rescue diet. 
The gross phenotype of VdrKO mice can be normalised with a 2% calcium, 1.25% 
phosphate and 20% lactose ‘rescue’ diet. In Vdr-/- mice fed with a normal chow diet, 85% 
of their bone is composed of osteoid by day 70, the osteoid volume being 30-fold greater 
than that of their wild-type littermates. VdrKO mice that are fed the rescue diet have normal 
calcium homeostasis. The implication being that vitamin D is restricted to the role of 
maintaining calcium homeostasis in the endocrine system. However, there were limitations 
of the work done by Amling et al. (105), who only reported the phenotype of mice to the 
age of ten weeks. Further studies looked at mice in older age.  
Panda et al. (31), using the same strain as the Amling et al.  (105), reported on VdrKO mice 
to the age of 17 weeks. It was reported that mice fed the rescue diet until 17 weeks of age 
still had significantly decreased percentage of trabecular bone volume: tissue volume 
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(%BV/TV), in the range of 50%, compared to wild-type animals. From this it can be 
concluded that vitamin D is essential in maintaining bone health at older ages 
independently of endocrine actions on calcium homeostasis. This mouse model was useful 
in examining the effects of the loss of vitamin D.  
VdrKO mice lack the ability to respond to 1,25D (105) (Fig 1.8). Cyp27b1KO mice, on the 
other hand, lack the ability to synthesise the active form of vitamin D (Fig 1.7). Calcitriol 
however, can be introduced into experimental protocols and due to the functioning Vdr 
result in cells that respond to 1,25D. The inability of cells from these animals to convert 
25D to 1,25D enables the examination of vitamin D metabolism at the autocrine level 
within the osteoclast.  
The Cyp27b1KO model was first reported by Dardenne et al. (32), who stated that these 
mice had retarded growth, hypocalcaemia, secondary hyperparathyroidism and bone 
anomalies that included rickets and osteomalacia (32). The same group then published data 
showing that the Cyp27b1KO mice could also be rescued by the introduction of a high 
phosphate, calcium and lactose diet, as was seen in the VdrKO mice (106, 107). This paper 
also provided evidence that the use of a rescue diet completely restored Cyp27b1KO mice 
and indicated that vitamin D was only involved in endocrine calcium homeostasis. Panda 
et al. (31), extended the experimental protocol past ten weeks and showed that Cyp27b1KO 
mice of 17 weeks of age had reduced trabecular bone volume, implying that the 
aforementioned rescue diet in fact does not fully compensate for vitamin D loss.  
Panda et al. also used a CYP27B1, VDR, double KO mouse, which had a phenotype that 
was a combination of the deficiencies present in the other KO models (31). Panda et al. 
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hypothesised that vitamin D played a greater role than that of regulating calcium 
homeostasis (31). This conclusion was reached as the KO of CYP27B1 resulting in the 
inability to convert 25D to 1,25D did not have the same effect as that of the VdrKO mouse 
model.  Panda et al. observed that in both the double-knockout and the VdrKO mouse 
models that  Parathyroid Hormone (PTH) levels were elevated and that osteoclast size was 
reduced (31). It was proposed that the loss of 1,25D signalling resulted in the increase of 
PTH  causing an increase in osteoclast formation (31). High concentrations of PTH in the 
Cyp27b1 and VdrKO mice were observed. This was hypothesised to result in increased 
osteoclast numbers, however no changes were observed. Similar levels of increased PTH 
expression in a wild-type murine model would be expected to result in increased osteoclast 
numbers. This was not observed in the KO models (31).  
Spleen cells were selected preferentially over other potential sources of osteoclast 
precursors, such as RAW 264.7 cells and PBMCs. PBMCs were excluded as the ability to 
delete CYP27B1 in these cells is limited to siRNA knockdown methods. RAW 264.7 cells 
can be genetically modified to not express CYP27B1 but as it is an immortalised cell line, 
other significant changes to the underlying genetics are likely to be present. The animal 
models in mice for Cyp27b1 global knockout were available and have a well-established 
phenotype.  
Several types of cell culture from KO mice were considered. Co-culture of the spleen cells 
with other cells and bone marrow cultures were undertaken. The culture of splenocytes 
with bone marrow can provide insights into osteoclast behaviour. However, the global 
deletion of Cyp27b1 and Vdr results in modification to all of the cells in the bone marrow 
making it a less specific culture model. By using a splenocyte monoculture we were able 
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to observe the effect of Cyp27b1 deletion independent of the mesenchymal signalling. Co-
culture models are the predominant use for splenocytes.  
The addition of 1,25D to RANKL and M-CSF treated PBMCs has had contradictory reports 
of both inhibitory and stimulatory effects on osteoclast formation (3, 4). The addition of 
1,25D to raw 264.7 cells enhanced osteoclast formation. The effect of 1,25D addition on 
osteoclast formation is highly dependent on the model of osteoclast used. In this experiment 
we used spleen cells, therefore the direct comparison of these results to other models, such 
as PBMCs and RAW cells, must be undertaken with caution.  
The use of human derived PBMCs in particular are important, as they enable a direct 
comparison between autocrine effects in mouse osteoclasts and human osteoclasts. It is 
worth noting, that the cytokines used for this experiment were human derived but still work 
on murine cells, indicating the potential for similarity between the two models. However, 
the role of autocrine activity in osteoclasts is still being debated. The use of mouse models 
as a precursor step, especially as the modification of humans at the genetic level for the use 
of scientific experimentation is unethical, to establish autocrine activity in the osteoclast is 




Fig.1.7. Effect of Cyp27b1 deletion in osteoclast lineage cells. The effect of Cyp27b1 




Fig. 1.8. Effect of Vdr deletion in osteoclast lineage cells.  The effect of Vdr deletion 
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1.4 Aims and Hypotheses 
The aim of this thesis is to extend previous findings indicating the presence of an autocrine 
vitamin D response in the osteoclast lineage, particularly in murine osteoclast cultures and 
seek to elucidate the cellular pathways involved. This will be undertaken through the use 
of Vdr and Cyp27b1KO mouse models in the absence of stromal signalling. This enables 
the examination of potential autocrine vitamin D response through multiple experimental 
pathways including osteoclast activity, maturation, proliferation and gene expression.  
Overall, we hypothesise that the loss of vitamin D autocrine signalling will have a 
deleterious effect on osteoclast maturation and proliferation, and result in osteoclasts with 
greater bone resorptive activity. This overarching hypothesis is divided into multiple 
smaller hypotheses: Thus, we hypothesise: 
1) That the deletion of CYP27B1 will result in the failure of the autocrine vitamin D 
pathway in osteoclast lineage cells resulting in altered gene expression and 
increased resorption activity although osteoclasts formed will still be able to 
respond to exogenous 1,25D; 
2) That the deletion of VDR will result in the failure of both the autocrine vitamin D 
pathway and the ability to respond to exogenous 1,25D in osteoclast lineage cells,  
resulting in osteoclasts with altered gene expression and increased bone resorption 
activity;  
3) That the addition of exogenous 1,25D will be unable to completely restore 
functionality in both Cyp27b1KO and VdrKO-derived osteoclasts; 
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4) That the loss of vitamin D autocrine pathways in osteoclast lineage cells will result 






Materials and Methods 
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2.0 Materials and Methods 
2.1 Animals 
Mice with global gene deletions (knockout; KO) of either Cyp27b1 (Cyp27b1KO) (32) or 
Vdr (VdrKO) (104), or with conditional deletion of Vdr under control of the cathepsin K 
promoter (CTSK-Cre.Vdrfl/fl) (32) were housed at ambient temperature with free access to 
water and food, with established 12 hour day-night cycles. All mice were fed the KO 
‘rescue diet’, consisting of chow containing 2% calcium, 1.25% phosphate and 20% 
lactose, which prevents rickets and bone abnormalities associated with these models (107), 
until genotyped and removed for weaning. After weaning, confirmed KO mice were fed 
the rescue diet while heterozygous KO and wild-type (WT) mice were fed a standard chow 
diet. All animal procedures were approved and performed in accordance with the 
requirements of the animal research ethics committees of the University of Adelaide and 
the University of South Australia. 
 
2.2 Mouse Tail Processing 
The tip of all mouse tails were collected at 10 days of age using surgical clippers as there 
is no vascularisation at this age. Anaesthetic is not required and has no impact on the health 
of the animal. Tails were stored at -21°C. The removal of the tail tips has a minimal effect 
on animal health at this age. Tails were then processed in a digestion buffer consisting of 
500μl tail buffer (10% SDS, 1M Tris HCL, 500mM EDTA, 4M NaCl and Milli Q water) 
and 10μg Proteinase K. Tails were digested overnight at 55°C in a dry block heater (Ratek 
Instruments) until completely dissolved. Samples were then centrifuged for 5 mins at 
44 
1500g (Centrifuge 5417r Eppendorf 22331 Hamburg, Germany). 90% supernatant was 
transferred to a new Eppendorf tube and diluted in 1ml of 100% isopropanol (Sigma 
Aldrich Steinem, Germany 89552). Samples were spun at 5009g, then the supernatant 
discarded and the pellet dissolved in 75μl of Tris EDTA (TE) buffer. DNA levels were 
quantified using a nano-spectrophotometer (General Electric, Nano View +). Samples were 
diluted to 20ng/μl and then used in RT-PCR. 
2.3 RT-PCR of Genotype 
Real Time Polymerase Chain Reaction (RT-PCR) of Vdr and Cyp27b1KO mice used 
primers designed to detect the unmodified Cyp27b1 and Vdr gene and the genetically 
modified versions of these genes. The genetically modified form of this gene was 
manufactured through the use of restriction enzymes and the insertion of a neomycin 
cassette resulting in inactivity. 
Primers (Gene Works Australia, SA, Adelaide) were then run consecutively in a RT-PCR 
using SYBR green master mix (Qiagen Sciences Maryland, USA) in a thermocycler (Bio 
Rad CFX-Connect USA). Genotype was established through the presence and absence of 
gene amplification. Amplification of WT or KO genes only identified homozygous WT or 




Fig. 2.1. Amplification of mouse DNA. The amplification of WT mouse genetic material 
is highlighted in green. Amplification of mouse DNA from the KO genetic material is 
highlighted in red. It can be observed how WT heterozygous and KO mice can be identified 




Fig. 2.2. Amplification protocol. Amplification protocol for real time RT-PCR. Initial 
heating was done for 10 minutes at 95°C. Samples were amplified over 46 cycles with each 
cycle consisting of 95°C for 10 seconds, then 60°C for 30 seconds, followed by 72°C for 





Fig. 2.3. Melt Curves. Melting points for WT and Cyp27b1KO mice gene amplification. 
All samples are run in triplicate. It was observed that the melting points between these 
amplified genes were easy to identify as the melting points were different. This allowed 
easy identification of WT, heterozygous and KO mice from genomic DNA. The lower peak 
represented Cyp27b1KO melt curve and the second peak represented WT melt curve. 
Wild Type 
 melt curve 
Cyp27b1KO 
 melt curve 
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2.4 RNA/DNA Gel 
In order to confirm the quality of the DNA, genotyping samples were also run on agarose 
gels (1% w/v in TE buffer). For this, agarose was heated in a microwave until dissolved. 
Sodium hydrochloride (500μl) and 2-3μl of Gel Red TM (Sigma Aldrich Steinem, 
Germany 89552) was added to the agarose gel and the solution poured into a gel cassette. 
The DNA samples (6μl) were loaded individually and the gel run at 80-120 voltage on an 
electrophoresis unit. (Horizon 20.25, Life Technologies)  
 
2.5 Preparation of Splenocytes for Osteoclastogenesis Assays 
Mice were humanely euthanized through carbon dioxide euthanasia and dislocation of the 
vertebrae. The carcass was washed in 70% ethanol to minimise contamination and to 
prevent aerosolization of murine fur. The carcass was then placed in a Class II biohazard 
cabinet. Spleens were aseptically excised and placed in Minimal Essential Media-alpha 
(αMEM; Sigma Chemical Co., St Louis, MO, USA). Spleens were dissected with surgical 
scissors and the pieces gently ground between two sterile glass microscope slides in order 
to release the cells from the surrounding tissue. Alternatively, mouse spleens were 
dissected with surgical scissors and the pieces gently ground through a 20µm cell strainer 
using a 1ml syringe plunger. Red cell lysis buffer, consisting of Tris Buffered Ammonium 
Cholride (TBAC) was then added and cells washed three times in αMEM, containing 10% 
(v/v) charcoal stripped foetal bovine serum (S-FBS) (HyClone, Logan, UT, USA), 1% 
penicillin, 2mM L-glutamine and HEPES. Where indicated, cells from four 
spleens/genotype were pooled, counted using Trypan blue (0.4%) exclusion, and plated 
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into 96-well tissue culture plates for TRAP staining (section 1.8) and onto sperm whale 
dentine or onto OsteologicTM slides (BD Biosciences, Bedford, USA) for measuring 
osteoclastic resorption activity, at 2 x 105 cells/well. Alternatively, cells were added at 
1x106 cells/well into 24 well plates for TRIzol based RNA extraction (108). Cells were 
treated with differentiation media consisting of αMEM supplemented as above, with the 
addition of: recombinant M-CSF (Millipore, Temecula, CA, USA) (25 ng/ml = 
untreated/UT) or M-CSF + RANKL (Millipore) (100 ng/ml = positive control). In some 
experiments the effects of exogenous 1,25D and 25D (Wako Pure Chemicals, Japan) were 
assessed. The level of 1,25D used was 1 nM, which we have shown to be equivalent in 
efficacy to that of a physiological concentration of 25D (100 nM) in terms of inhibiting 
resorption in cultures of both RAW 264.7 cells and PBMC (4). All cell cultures and lines 
were maintained at 37C with 95% humidity and 5% CO2 to mimic physiological 
conditions.  
 
2.6 Preparation of Bone Marrow for Osteoclastogenesis Assays 
Mice were humanely euthanized and spleens excised and placed in αMEM (Sigma 
Chemical Co., St Louis, MO, USA), as described above. After the excision of the spleen, 
the tibia and femora were removed. Bones were removed carefully to ensure that they were 
structurally intact ensuring maximum yield of bone marrow. Additional care was taken 
with VdrKO mice as their bones were brittle. The distal and proximal ends of each bone 
were removed and the marrow was flushed with media using a 0.6mm diameter needle (BD 
Precision Glide). The bone marrow was combined from multiple mice of each genotype 
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(n=3) and from both femora and tibias. Cells were then pelleted by centrifugation at 176g 
(Megafuge 1.0R, Heraeus) in a 50ml sterile tube (Falcon) and then treated with lysis buffer 
(TBAC) to remove red blood cells. The cells were then washed by centrifugation three 
times in media before being resuspended in 10 ml of media containing FBS (10% v/v). 
Cells were then counted using the Trypan blue dye exclusion method and resuspended to 
a concentration of 1 x 106 cells/ml. Cells were then plated into 96-well plates for TRAP 
staining or into 24 wells plates for mRNA. 
 
2.7 Preparation of Osteoclast Cell Line RAW 264.7 for Culture 
RAW 264.7 cells were kindly supplied by Dr. David Thomas (Peter McCallum Institute, 
Melbourne, Australia) and were originally from the American Type Culture Collection. 
RAW 264.7 cells were thawed, cultured and frozen down as described previously (109). 
Briefly RAW 264.7 cells were thawed from cryogenic storage using a slow drip method of 
media of 1 ml over 1 minute at 5 minute intervals in order to dilute the freezing mixture 
and ensure cell survival of the cryogenic storage. RAW 264.7 cells were cultured in t-75 
(Interpath Sheehan Rd, Heidelberg West, VIC, Australia) flasks under media and FBS 
(10% v/v) until confluent. Cells were scraped using a cell scraper (7-9 Summit Road, Noble 
Park North, VIC, Australia 3174,). Cells were collected, then counted using the Trypan 
blue dye exclusion method and resuspended to a concentration of 1x106 cells/ml for further 
passage or resuspended to 1x103 cells/ml for 96 well plates for osteoclast assays. Excess 
raw cells were frozen down using DMSO freezing mix and an insulated container in a -
80°C freezer (TSE Series, Thermo Scientific) before being transferred to a liquid nitrogen 
storage facility for long-term storage. 
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2.8 TRAP Staining of Osteoclast Cultures 
TRAP staining was performed, as described previously (4). Briefly, quadruplicate cultures 
were stained for TRAP using a commercial kit (Sigma). Cell cultures were fixed with 10% 
formaldehyde for 10 minutes before being washed. TRAP stain was then added to cultures 
for 46 minutes after which cultures were washed three times and then counted (TRAP 
staining Kit Sigma-Aldrich, Steinem, Germany). Osteoclasts were defined as magenta 
stained cells containing three or more nuclei. Osteoclast nuclei numbers were assessed 
using light microscopy (Nikon Eclipse Te300). TRAP staining was examined at multiple 
time points during the experiment. Osteoclast nuclei were counted at the same time and 
divided into categories of size, this being 3-10, 11-25 and 25+ nuclei. Data was analysed 
using two way ANOVAs and Tukey post hoc tests. Images were taken using Olympus 




Fig. 2.4.  RAW 264.7 cells. Confocal light microscopy images of RAW 264.7 cells under 




Fig. 2.5. Spleen cells. Confocal light microscopy images of spleen cells under 





2.9 Resorptive Activity 
Resorptive activity was measured as described previously (4). Briefly, following the 10 
day (d) culture period, OsteologicTM slides resorption sites were visualised using Von 
Kossa staining which stains the non-resorbed mineral background, highlighting areas of 
osteoclastic activity. Resorption was quantified using light microscopy and Image J 
software (V 1.47, National Institute of Health) analysis. 
 
2.10 Von Kossa Staining 
Sodium hypochlorite (1 %) was added to the culture to remove cells without impacting on 
the hydroxyapatite layer on the bottom of the slides. Silver nitrate (5%) wash was added to 
the wells under a bright lamp for 30 min (110). The wells were then rinsed with reverse 
osmosis (RO) water and then the stain was developed by adding a drop of 5% sodium 
carbonate in 25% formalin. The stain was fixed through the addition of 5% sodium 
thiosulphate; culture plates were washed and left to dry. After drying, the culture plates 
were imaged using light microscopy.  
Image analysis was performed using Image J software. Images were taken with Adobe 
Photoshop software in black and white. These were then imported back into Image J. The 
area of the image was selected, measured and then inverted to white on black, with black 
sections now being representative of resorption. Inbuilt tools within Image J allow the 
identification of the area and size of each section. This, together with the total area from 




Fig.2.6. Osteologic TM  slides. Images of Osteologic TM  slides with and without the Von 
Kossa staining. 
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2.11 Osteoclastogenesis Cultures 
25D and 1,25D was purchased from Wako (Osaka, Japan). All cultures were seeded at the 
equivalent of 2 x 105 cells per well. Cultures were checked daily and fed every three days. 
This was identical for bone marrow, spleen cells and PBMC cultures. RAW 264.7 cells 
were seeded at 1 x 103 cells/well.  Cultures were divided into four treatment groups; M-
CSF (25 ng/ml) ; M-CSF (25 ng/ml) + RANKL (100 ng/ml) ; M-CSF (25 ng/ml) + RANKL 
(100 ng/ml) + 25D (100 nM) ; and  RANKL (100 ng/ml) + M-CSF (25 ng/ml) + 1,25D (1 
nM). Cultures were run for 9-12 days and analysed by TRAP staining and processed for 
total RNA isolation and RT-PCR, dependent on peak observation of osteoclasts and 
dentine. Bone resorption cultures using either Osteologic TM cultures or dentine were run 
for 14 or 22 days as indicated.  
2.12 Dentine Processing 
Mouse spleen cells were also cultured on sperm whale dentine as a resorption substrate. 
Dentine after being cut using a diamond-edged saw with ethanol lubricant, using a Sloco 
speed saw, was cut into smaller pieces approximately 4 x 4 mm using a scalpel. Slices were 
marked in graphite pencil with an ‘F’ in order to identify the side of the dentine that 
osteoclast precursors were plated onto. Dentine was sterilized with 80% ethanol and sterile 
PBS washes to ensure no contamination was present. Dentine was then moved into 96-well 
culture plates and immersed in neat FBS for 24 hours to enhance cellular adhesion to the 
dentine. The FBS was removed and osteoclast cultures were added and fed every three 
days. Dentine resorption assays were run for 22 days. At this time point, dentine slices 
were removed from the plate, and the surrounding cells were TRAP-stained, as described 
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previously (2.8). The dentine was washed with Extran (Decon Laboratories Limited 
Sussex) to lyse all remaining cells and remove cell debris. Dentine was subjected to 
multiple washes of PBS mixed with ethanol, starting at 50% ethanol and increasing by 10% 
until reaching 100%. Following air drying, dentine was mounted on stubs, and coated with 
carbon/pallidum depending on availability. Dentine was imaged using scanning electron 
microscopy (Adelaide Microscopy X-L30 SEM) (Fig. 2.7). Images were analysed using 




Fig. 2.7. Dentine under scanning electron microscopy. Images of dentine under 500x 
magnification using scanning electron microscopy with a voltage of 10kv. Top image 
represents dentine without resorption and bottom image dentine with typical clusters of 
resorption pits or lacunae. The scale bar in each image indicates 100 µm. 
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2.13 Peripheral Blood Mononuclear Cells (PBMCS) 
Human PBMC were obtained from healthy volunteers and isolated using Lymphoprep 
Gradient Media (Nycomed Pharma, Oslo, Norway), as previously described (4) and with 
Human Research Ethics approval (RAH Protocol No: 140216a). Briefly, 15 ml of 
heparinised peripheral blood was diluted in 25 ml pre-warmed HANKS solution. 
Lymphoprep (15 ml) was under layered into a 50ml tube using a cannula (Uno Medical). 
Tubes were centrifuged at 277xg for 30 minutes (Megafuge 1.0R Heraeus) and stopped 
without using a brake. The aqueous interface layer was collected and transferred to another 
50ml sterile tube using a cannula. This was topped up to 50ml with HANKS solution and 
then centrifuged again at 277xg for 5 minutes with the centrifuge brake on. Cells were then 
washed twice with HANKS by centrifugation and the third and final wash was with α-
MEM (Sigma). Cells were counted and plated at 1 x 106 cells/ml in either 96-well (0.2 
ml/well; TRAP assays) or 24-well (1.0 ml/well; RNA isolation) tissue culture plates. 
PBMCs were cultured and treated under the same conditions as spleen cells, with the 
exception of the addition of Dexamethasone (Aspen Pharmacare, St Leonards, NSW 
Australia) at 10-8 M. 
 
2.14 RNA Extraction  
Osteoclastogenesis was performed, as described above, and cells were cultured for  the 
times indicated. Media was removed and TRizol (Life Technologies, Carlsbad, CA, USA) 
was added for 5 minutes before being transferred to 1.5 ml tubes. Chloroform (100 μl) 
(Analytic R) was added and tubes centrifuged at 11269 g for 15 minutes (Centrifuge 
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5417R, Eppendorf) at 4°C. The aqueous layer was then removed and transferred to another 
1.5 ml tube. Glycogen (2 μl) (Roche Diagnostics, Manheim, Germany) and isopropanol 
(250 μl) (Merik Millipore) were added to the tube and left for 30 minutes at 4°C and the 
tubes centrifuged at 11269g for 30 minutes. Pelleted RNA samples were then washed with 
75% ethanol (500 μl) (Merik Millipore) with centrifuging at 11269 g. RNA was then 
redissolved in diethylpyrocarbonate (DEPC) treated water (15μls at 63°C) (dry block 
heater, Ratek Instruments). This process was unchanged for all cell types used in this thesis. 
2.15 Reverse transcription 
In order to generate cDNA, RNA concentrations from the TRizol extractions were 
measured using a Nano-spectrometer (NanoVue Plus, General Electric, Boston, MA, 
USA). Total RNA (1.0 μl) was diluted in DEPC-water and made up to a volume of 16 μl. 
Reverse transcription mastermix Iscript (4 μl) (Bio Rad, CA, USA) was then added and 
cDNA generated, as per the manufacturer’s instructions.  
2.16 RT-PCR 
RT-PCR was performed using the SYBR Green (Qiagen Maryland USA) incorporation 
technique, as described previously (4). RT-PCR was performed for Nfatc1, Trap, Ctr, Ca2, 
Cathepsin K and C-fos mRNA expression using previously published oligonucleotide 
primer sequences (4) in a real-time thermocycler (CFX-Connect, Bio-Rad, NSW, 
Australia).The Bcl-2 and Bax mRNA ratio was also measured using RT-PCR. mRNA 
expression was compared against the housekeeping genes Beta 2 Microglobulin (B2m) and 
Hypoxanthine Phosphoribosyltransferase One (Hprt1). RT-PCR was used to compare 
mRNA expression of mouse spleen cells from day 1 before any pro-osteoclastic factors 
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had been added to the media using primers for Cluster of Differentiation (CD) markers 
CD4, CD8, B220, CD3 and CD11b (Table 2.1). 
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Name Forward Primer Reverse Primer Annealing Size 
Mouse Bcl-2 5’ GACTGAGTACCTGAACCGGC 3’ 5’ ATAGTTCCACAAAGGCATCCCAG 3’ 60 74bps 
Mouse Bax 5’ TGCTACAGGGTTTCATCCAGG 3’ 5’ TTGGATCCAGACAAGCAGCC 3’ 60 383bps 
Mouse Hprt1 5’ GGTTAAGCAGTACAGCCCCA 3’ 5’ TGCAGATTCAACTTGCGCTC 3’ 60 234bps 
Mouse Trem-2 5’ CACAGCACCTCCAGGAATCAA 3’ 5’ ACTTGCTCAGGAGAACGCAG 3’ 60 82bps 
Mouse CD3 (antigen) Variant 1 5’ TTCAGAAATGAAGTAATGAGCTGGC 3’ 5’ TCGTCACTGTCTAGAGGGCA 3’ 60 206bps 
Mouse Atp6V1h 5’ CGAGGCTATCCAGGTCTGTG 3’ 5’ TTTAGCACACTGGCTGCCTT 3’ 60 134bp 
Mouse Atp6V0D2 5’ ATTCTTGAGTTTGAGGCCGACA 3’ 5’ CAGCTTGAGCTAACAACCGC 3’ 60  
Mouse Atp6V1f 5’ CGCCACCCTAATTTCCTGGT 3’ 5’ AGAAATTGCCTGAAAGTGTCTTCG 3’ 60  
Mouse C-fos 5’ GTGAAGACCGTGTCAGGAGG3’ 5’ CTGTCTCCGCTTGGAGTGTA3’ 60 175bps 
Table 2.1. Previously unpublished mRNA-specific oligonucleotide primers, designed to flank at least one intron/exon boundary.   
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2.17 Designing mRNA-Specific Oligonucleotide Primers 
Primer sequences were designed to set characteristics to ensure optimal amplification, 
including ensuring the amplified sequences spanned an intron/exon binding site with a 
maximum of three overlapping base pairs. This prevented genomic sequences from being 
amplified along with the mRNA. Primers were tested in silico with Primer Blast (National 
Library of Medicine, USA) to check for specificity to the desired target gene. They were 
then examined with Amplify software (Bill Engels, 2015, University of Wisconsin) to test 
for predicted secondary binding to the target gene and for the potential amplification of 
primer dimers that would have caused amplification of alternate products in the PCR. 
Finally, primer sequences were analysed with an electronic amplification program E-PCR 
(retired) (National Library of Medicine, USA) to confirm that there was no binding to 
unrelated genomic sequences. Primers that failed were redesigned until they met the 
required specifications. Primers were ordered from and produced by Geneworks 
(Thebarton, SA, Australia, 5031). All primers were tested empirically by RT-PCR for 




2.18 V-ATPase Methods 
For RT-PCR amplification of the multiple subunits of the mouse V-ATPase, primers were 
kindly donated by Professor Minghao Zheng (University of Western Australia). These 
primers consisted of a forward and reverse set for all 26 known subunits of the V-ATPase 
pump. Messenger RNA from day 8 Cyp27b1KO and WT osteoclast monocultures were 
then subjected to RT-PCR for the entire primer set. Identification of changes in mRNA 
observed from this analysis was used as a basis for more in-depth analysis of defined 
subunits of the V-ATPase hydrogen ion pump. Sub-units that showed changes in their 
mRNA expression due to the deletion of Cyp27b1 or changes under 25D or 1,25D 
treatment were further analysed. This was done through the designing of alternative 
primers specific for these genes.  
 
2.19 Dentine, Scanning Electron Microscope (SEM) 
Dentine after being washed, as described previously (Section 2.2), was then transferred to 
a SEM aluminium stub with an adhesive patch applied. Dentine was attached to individual 
stubs according to treatment and genotype. Dentine was coated with carbon to provide the 
appropriate surface for SEM and imaged, using a 10kv voltage at a magnification of both 
500x or 200x under an Olympus XL30 electron microscope. 200x images were used as a 
map for collating the 500x images together. This prevented double counting of osteoclast 





MLO-Y4 cells are derived from murine long bone osteocytes. They are an osteocyte-like 
cell line known for producing pro-osteoclastogenic cytokines. MLO-Y4 cells were 
obtained and handled, as described previously (111). Briefly, cells were thawed from 
cryogenic storage using a slow drip method of media in order to dilute the freezing mixture 
and ensure cell survival of the cryogenic storage. MLO-Y4 cells were cultured in rat tail 
type 1 collagen-coated T-75 tissue culture flasks under media conditions of FBS 2.5% 
(v/v), New Born Calf serum 2.5% (v/v) and ascorbate, until confluent. Cells were removed 
from the flask using trypsin and then counted using a haemocytometer. Cells were 
transferred to collagen coated 96-well flat bottomed tissue culture plates for osteoclast 
assays or to another collagen coated T-75 for further passages. For experiments, MLO-Y4 
cells were seeded at 1 x 103 cells/96-well plate. 
 
2.21 SAOS2 
SAOS2 are a human osteosarcoma derived osteoblast-like cell line. SAOS2 osteosarcoma  
were obtained as previously described (112). Cells were thawed from cryogenic storage 
using a slow drip method of media in order to dilute the freezing mixture and ensure cell 
survival of the cryogenic storage. SAOS2 cells were cultured in T-75 flasks under media 
of FBS 10% (v/v) and ascorbate. Cells were removed from the T-75 using trypsin. Cells 
were collected then counted. Cells were transferred to 96 well plates for osteoclast assays 






Co-cultures were undertaken with splenocytes isolated from Ctsk-Cre.Vdrfl/fl mice and the 
cell lines MLO-Y4 or SAOS2. The cell lines were seeded at 1 x 103 cells/96 well plate. 
Cell lines were seeded onto 96-well plates with and without dentine slices. Cells were 
incubated overnight at 37°C, 5% CO2 under media conditions appropriate for each cell 
type. Spleen cells were added in fresh cellular media at previously determined optimal 
density of 2 x 105 cells/96-well. Cells were incubated overnight then media was changed 
to remove non-adhered cells. Cells were fed every three days with α-MEM media with 1% 
(v/v) HEPES, 1% (v/v) L-glutamate, 1% (v/v) penicillin and streptomycin, FBS 10% (v/v) 
and ascorbic acid. Treatment groups included two monoculture controls, one of spleen cells 
and one of either MLO-Y4 or SAOS2 cell lines.  Additional treatments included 25D (100 
nM) and 125D (1 and 100 nM). The SAOS2 culture was identical except for the final 
treatment group. This group was treated with 1nM of 1,25D and potassium di-hydrogen 
orthophosphate (Ajax Chemicals, Sydney, Australia), which is known to stimulate mineral 
precipitation under defined media conditions.  
 
2.23 Statistical Analysis 
Statistical analysis was performed using Graph Pad Prism software (GraphPad Prism, La 
Jolla, CA, USA). Statistical significance was tested using Student’s T-Test or 2-way 
ANOVA, as appropriate. Statistical significance was defined as p less than or equal to 0.05. 
All experiments were performed a minimum of four times. Each experiment utilised 
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between three and four individual spleens in each treatment group. All RT-PCR assays 




2.24 Addendum on Cyp27b1 and Vdr KO Mouse Colonies. 
The maintenance of VdrKO and Cyp27b1KO mice require the administration of a special 
(rescue) diet. This diet ensures that the mice survive past the weening stage at four weeks. 
It does not however restore the mouse phenotype to wild-type. This means that 
homozygous Cyp27b1KO and VdrKO mice have specific phenotypic traits that are still 
present on the rescue diet. Cyp27b1KO mice show minimal phenotype on the rescue diet, 
however the most noted of these is reduced fertility. This is also observed in VdrKO mice. 
The other noted effect is that KO mouse pairs do not breed well and KO and heterozygous 
mouse pairs breed infrequently. This results in heterozygous breeding pairs being essential 
for mouse breeding. This breeding strategy ensures a supply of specific WT littermates to 
compare against homozygous VdrKO and Cyp27b1KO mice.  
It was noted that mice of the Vdr strain had a tendency to develop neurological defects in 
the offspring of the breeding pairs and had to be re-derived before more mice were 
availableCtsk-Cre.Vdrfl/fl and Ctsk-Cre.Cyp27b1fl/fl mice did not show the reduced fertility 













Osteoclasts like most cells are influenced by a myriad number of variables which are 
specific to the type of culture and often to the laboratory in which experiments are 
performed. 
This Chapter resulted from observations made in initial experiments using previously 
derived experimental protocols to artificially stimulate osteoclastogenesis. Experiments 
performed using identical experimental protocols often yielded quite different levels of 
success for unknown reasons. In order to maximise experimental outcomes and minimise 
wastage of resources, optimisation of multiple aspects of osteoclastogenesis was 
undertaken. This chapter examines the variables of sex, cytokine administration, foetal 
bovine serum, media, cell density and splenocyte source derivation on osteoclastogenesis. 
Surprisingly, the most effective modification was the pooling of the primary spleen cells 
from multiple genetically-identical mice, which significantly reduced experimental 




Optimisation of Osteoclastogenesis 
 
3.0 Introduction  
The direct action of the cytokines M-CSF and RANKL when added to primary 
haematopoietic cell cultures in the formation of mature resorbing osteoclasts is well 
established and has revolutionised the ability to study osteoclasts (5). Until this discovery, 
experimental observations were restricted to bone marrow cultures and in vivo 
experimental observations. The addition of recombinant RANKL and M-CSF to precursors 
found in the blood, bone marrow, liver and spleen stimulates osteoclastogenesis (113) (114) 
(115). In addition to RANKL and M-CSF concentration, the time of cytokine 
administration, L-Glutamine availability, presence of vitamins, concentration of FBS, 
percentage of oxygen available, cell density, folate concentration and culture medium are 
some of the large effectors on osteoclastogenesis. 
However, despite numerous articles investigating osteoclastogenesis, variation in optimal 
conditions between experimental protocols are observed in cultures and between cell types. 
Examples of these variations include: concentration of cytokines; length of culture; oxygen 
concentrations. Due to the lack of a defined optimal protocol for the formation of mature 
osteoclasts, optimisation for each individual experimental protocol is required when 
undertaking experimental work with hematopoietic stem cells. Even cell line models such 
as RAW 264.7 cells have been  demonstrated to be highly dependent on the additives 
present in FBS (109). Further, more complex experimental procedures, such as co-cultures, 
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must take into account dual cell survival requirements and even the optimal number of cells 
for both cell types. 
Experimental optimisation is essential, particularly when using cells derived from a 
primary source. Primary cells are often less robust than immortalised cell line counterparts 
and are more likely to respond negatively to minute changes in their surrounding 
environments. This often results in major physiological changes, such as, inhibited 
differentiation, altered cellular function or more commonly cell mediated apoptosis. The 
optimisation of experimental protocol minimises unwanted changes reducing cell death, 
while maximising potential experimental outcomes.  
The osteoclasts’ ability to respond to numerous signals likely prohibits true optimal 
conditions being achieved, due to the large number of potential variables, expense and the 
lack of full elucidation in the interactions the osteoclast undertakes with other bone cells. 
Osteoclast cultures can be obtained from multiple sources, such as, mouse spleen cells, 
mouse or human bone marrow cells, human PBMCs and RAW 264.7 cells. All have 
varying optimal conditions. Mouse spleen cells and PBMCs were undertaken as 
monocultures in this study. Spleen cells were also co-cultured with either MLO-Y4 or 
SAOS2 cells. The use of co-cultures in this ex vivo work enables the examination of the 
osteoclasts under functioning osteocytic signalling which is not possible in global KO 
models and monocultures. Additionally the use of SAOS2, a human derived cell line, to 
stimulate murine cells would allow the isolation of mRNA in a species independent manner 
while potentially isolating other factors that influence osteoclasts. 
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Optimisation here focused on varying cell density, sex variations, cytokine concentration, 
culture medium and the type of FBS used. It also briefly examines the effects of SAOS2 
and MLO-Y4 as when co-cultured with mouse spleen cells. 
It should be noted that there are limitations in the comparison of ex vivo artificially induced 
osteoclasts to that of in vivo models, and vice versa. This chapter sought to optimise 
osteoclastogenesis using isolated splenocytes form each genotype through the use of 
recombinant cytokines. The in vitro system has the advantage of being controllable and 
independent of the confounding effects of various other cell types and factors that influence 
the formation and activity of these cells. Indeed, the discovery of RANKL and the 
requirement of M-CSF, and determination of the basic culture conditions required (116, 
117)  revolutionised osteoclast research and was responsible for an explosion of research 
in this field. However, in some instances, the in vitro model can be considered 
oversimplified. Some features are non-physiological. For example, it has been noted that 
osteoclasts in the bone rarely exceed sizes of 20-25 nuclei in healthy animals. However, in 
this experimental protocol osteoclasts with more than 100 nuclei were often seen. This 
could potentially be due to alterations in the osteoclast adhesion to the plastic substrate of 
the culture plates or could be caused by unregulated access to the osteoclastogenesis 
cytokines RANKL and M-CSF. Additionally, osteoclasts of this size were not observed in 
the later co culture work performed. This however does raise the possibility that the 
artificial induction of osteoclasts may result in an exaggerated response from osteoclast 
precursors. Further investigation of this would be required to identify what alterations if 




3.1 Materials and Methods 
3.1.1 Cell Number Optimisation 
Initial experiments used Sigma α-MEM with normal FBS 10% (v/v) (HyClone, Logan, UT, 
USA) with the additives of L-glutamine, penicillin and streptomycin mix and Hepes, all at 
1% (v/v) to establish the most effective cell concentration. Recombinant RANKL 
(Millipore, Temecula, CA, USA) was given at 100ng/ml. Cells were fed every three days. 
Cells scavenged from murine spleens as described in section 2.5 of Chapter 2 were 
administered at concentrations of 1x105, 1.5x105, 2x105 and 2.5x105 cells/ml. They were 
placed in a dark incubator at 37°C at 5% CO2. M-CSF only negative controls were used 
alongside RANKL + M-CSF treatments. Cell cultures were checked daily by phase contrast 
light microscopy for the appearance of multinucleated cells. Experiments were performed 
in quadruplicate in 96 well plates. 
3.1.2 RANKL Concentration Optimisation 
In order to establish an optimal RANKL concentration, spleen cells were treated with 25, 
50, 75 and 100 ng/ml RANKL. M-CSF was maintained at 25ng/ml. Of the two cytokines 
essential for osteoclastogenesis, it was considered that RANKL was more likely to show 
an apparent effect. Cells were fed every three days. Basal cell culture medium was Sigma 
α-MEM with normal FBS 10% (v/v). Cell concentration of 2 x 105 was utilised before 
optimisation of cell density assays had been undertaken and was used as was indicated in 
Kogawa et al. (3, 4). Cells were cultured as above 3.1.1 
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3.1.3 Media and FBS Optimisation 
Cells were cultured under three variations of media. Two of the media batches were Sigma 
α-MEM with two different batch numbers, an externally sourced (ES-MEM), and an 
internal batch used for the majority of cell cultures within the lab (S-MEM). The third 
variation was a Gibco α-MEM batch (G-MEM). FBS at 10% (v/v) was used for both normal 
FBS (FBS) and charcoal stripped FBS (S-FBS), resulting in six treatment groups. Cells 
were treated with 100ng/ml RANKL and 25ng/ml M-CSF. M-CSF negative controls were 
used alongside RANKL + M-CSF treatment. Cells were cultured at 1.5 x 105 cell/ml. Cells 
were cultured as described in section 3.1.1 
3.1.4 TRAP Staining 
TRAP staining was performed on quadruplicate wells using a commercial kit (Sigma 
Chemical Co.), as described previously (4). Osteoclasts were defined as magenta stained 
TRAP+ cells containing three or more nuclei. Osteoclast number and size were assessed 
using light microscopy (Nikon Eclipse TE300) at a minimum of three time points between 
days 6 and 9, encompassing early and peak formation periods.  
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3.2 Results and Discussion 
The optimisation of osteoclastogenesis cultures was an essential step in ensuring that the 
experimental work undertaken used an effective, reproducible methodology. The effect of 
the cell density of the starting population of splenocytes on osteoclastogenesis was 
undertaken through TRAP staining and light microscopy. Cell density was observed to play 
a critical role in the formation of osteoclasts. Wells seeded with densities below 1.5 x 105 
cells/well and above 2 x 105 cells/well resulted in a significant reduction in osteoclast 




Fig. 3.1: Cell density cultures. The effect of varying mouse splenocyte concentration on 
resulting TRAP+ MNC. Splenocytes seeded at 1x105, 1.5x105, 2x105 and 2.5x105 
cells/well of a 96-well tissue culture plate were treated with recombinant human RANKL 
(100 ng/ml) and M-CSF (25ng/ml) and cultured and assayed for TRAP+ MNC at a) 7 days, 
b) 8 days and c) 9 days. Data are means ± SEM of quadruplicate wells. Significant 
difference is indicated by *, **, # = p<0.05 indicating difference to the 2x105 treatment 
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Fig. 3.2: Cell density images. Representative light microscopy images of TRAP stained 
MNC under varying spleen cell density. Splenocytes in a 96-well tissue culture plate were 
treated with recombinant human RANKL (100ng/ml) and M-CSF (25ng/ml) and cultured 
for ten days.  
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3.2.1 Cell Density  
Cell density was found to be one of the most critical factors in osteoclast formation (Fig. 
3.1). Despite consistent levels of M-CSF and high levels of RANKL the alteration of cell 
density had drastic effects on osteoclast formation. Optimal osteoclastogenesis was 
confined to a range of cell density that peaked at 1.5 x 105 (75000cell/cm2). The reduction 
in osteoclast formation due to a lower number of cells was expected, as lower precursor 
density means fewer differentiating mononuclear cells are available for fusion.  
The inhibition due to a higher cell density, however, was unexpected. It is possible that 
high cell density may simulate the conditions in the spleen resulting in cell to cell signalling 
that inhibits osteoclastogenic differentiation. 
 
3.2.2 Effect of Recombinant RANKL Concentration  
Osteoclastogenesis assays are highly dependent on the cytokines, RANKL and M-CSF. 
Having established optimal cell density under cytokine replete conditions, it was identified, 
as expected, that the TRAP-positive MNC number decreased as the RANKL concentration 
decreased (Fig. 3.3). A significant reduction was observed in a linear regression pattern 
such that the TRAP+ MNC number was directly proportional to the RANKL concentration 
administered. Indeed, an approximate 50% reduction in cell number was observed for every 
25 ng/ml reduction in of RANKL concentration. Potential variation due to gender under 
both cytokine replete and reduced conditions in mouse spleen cells were examined 




Fig. 3.3: The effect of RANKL concentration and mouse sex on osteoclast survival and 
differentiation. Mouse splenocytes were seeded at a density of 2 x 105 cells/well into 96 
well culture plates with α-MEM and FBS 10% (v/v) with M-CSF (25ng/ml) and RANKL 
(25-100ng/ml). *, Significant difference between treatments, combined sex data (p < 0.05). 
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Overall, the addition of 100 ng/ml of RANKL combined with 25 ng/ml of M-CSF was the 
most effective at producing osteoclasts from mouse splenocytes with the three day feeding 
cycle and culture conditions employed.  
3.2.3 Precursor Cells  
Another important contributor to experimental outcomes is variability due to the quality of 
the cell populations used. The time taken to remove spleens from euthanised mice and 
isolate splenocytes was subtlety but potentially importantly different between individual 
mice. This may have impacted on splenocyte viability of metabolic state due to effects such 
as hypoxia. Indeed, it was observed that within each genotype of wild-type, heterozygote 
and homozygous knockout in the Cyp27b1KO mice, there was variability in TRAP+ MNC 
formation (data not shown). It was also observed that the spleens of Cyp27b1KO mice were 
more likely to form dark clots on their surface than WT mice. In order to overcome this 
individual variability, pooling of spleens was tested. 
Individual spleens were taken from either WT, KO or heterozygous genetic backgrounds 
of either sex. Each individual mouse spleen was plated in quadruplicate with a minimum 
of four individual spleens used per experiment. In the pooled experimental protocol up to 
three and at least two mouse spleens were used to create the pool of spleen cells depending 
on availability. Three sets of pooled spleen cells were used in each experimental replicate 
and these were plated in quadruplicate. Each experiment was replicated a minimum of three 
times for each genotype. 
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The use of two or more spleens resulted in increased osteoclast formation and reduced 





Fig. 3.4: The effect of pooled spleen precursors on osteoclast formation and inter-well 
variation. A) Spleen cells were seeded at a density of 2x105 cells/well into 96 well culture plates 
with α-MEM and FBS 10% (v/v) with M-CSF (25ng/ml) and RANKL (100ng/ml). *, denotes 
significant difference between treatments (p < 0.05). B) The standard error of the mean from 




























































Pooled Spleen Cell Data






It was predicted that the use of multiple spleens would result in a more homogenised balance of 
osteoclast precursors, and that by combining these pools the ratio of motile to stationary osteoclast 
precursors was enhanced, resulting in increased and more stable osteoclastogenesis, as supported 
by the findings of Geblinger et al. (75). 
 
3.2.4 Foetal Bovine Serum  
The type of FBS used was also tested as a variable. FBS is a poorly defined source of nutrients, 
hormones and growth factors that promotes cell growth in vitro but may also contain inhibitors of 
certain processes, including osteoclastogenesis. Steroid hormones can be removed from FBS by 
charcoal stripping. Charcoal stripped FBS was compared against normal FBS combined with 
Sigma or Gibco α-MEM for the propensity to support osteoclastogenesis. There was a significant 
increase in osteoclast formation when stripped FBS was used (Fig. 3.5). Interestingly both Gibco 
and Sigma α-MEM promoted nearly identical osteoclast growth under osteoclastogenic conditions 
when used with normal FBS (Fig. 3.6). However, for unknown reasons Gibco α-MEM when 






Fig. 3.5: The effect of charcoal stripped FBS on osteoclastogenic cultures. Mouse splenocytes 
were seeded at a density of 1.5x105 into 96 well tissue culture plate with α-MEM with recombinant 
human RANKL (100 ng/ml) and M-CSF (25ng/ml) with either FBS 10% (v/v) or S-FBS 10% 











































Fig. 3.6. The effect of S-MEM and G-MEM under FBS or S-FBS. Mouse splenocytes were 
seeded at a density of 1.5x105 into 96 well tissue culture plates with either G-MEM or S-MEM, S-
FBS 10% (v/v) or FBS 10% (v/v) with recombinant human RANKL (100 ng/ml) and M-CSF 
(25ng/ml). Plates were assayed for TRAP staining over multiple time points. Data are means ± 
SEM of quadruplicate wells. Significance is indicated by * = P<0.05 using Two Way ANOVA 
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Table 3.1 identifies some of the more significant changes in chemical composition documented 
due to charcoal stripping. The largest change in stripped FBS is a reduction in folate (folic acid) 
concentration. It has been reported that folate inhibits osteoclastogenesis (118) which is a possible 
explanation for the effect seen. However, the observed increase in osteoclastogenesis could also 




Post Treatment  
Testosterone 30 <3 Ng/dl 
Oestrogen 26 2.5 Pg/ml 
Vitamin D, 1,25D 90 41 Pg/ml 
Pteroylglutamic 
Acid (folate) 
545 2.3 nM/L 
 
Table 3.1. FBS composition before and after charcoal stripping. Focusing on substances that 
have demonstrated the ability to influence osteoclastogenesis and activity. Data was provided by 
the manufacturer of the Stripped FBS. 
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The effects of varying the source of α-mem was unexpected. The formula of Gibco and Sigma α-
MEMs are similar with only minor changes in salt concentrations. The reduction in TRAP positive 
osteoclast formation observed when 10% (v/v) stripped FBS and Gibco α-MEM were used in 
conjunction, cannot be readily explained but should be noted for future experimentation. Stripped 
FBS in Sigma α-MEM was used for all subsequent experimental work in mouse splenocyte 
cultures. 
The optimisation of osteoclastogenesis assays enhanced the results and repeatability. However, 
there are many additional aspects that were not investigated due to time and financial constraints. 
One example of those is the influence of hypoxic conditions. Hypoxia has been demonstrated to 
enhance osteoclastogenesis (115). However, no hypoxia incubator was available at the time of 
experimentation.  
 
3.2.5 Osteoclast-Forming Co-Cultures  
Attempts were also made to develop osteoclast forming co-culture cross-species assays. Cross-
species assays have proven useful for identifying cell specific effects during osteoclastogenesis 
(119, 120). In particular, the use of human derived cells enables the detection of mRNA from the 
stromal and osteoclast components through species-specific gene variations. Here, the human 
SAOS2 was investigated as a potential stromal layer for murine osteoclast formation because of 
its known expression of RANKL (112). Co-cultures demonstrated that the SAOS2 cells were not 
sufficiently adept at stimulating osteoclastogenesis through both TRAP staining and resorptive 
assays on dentine analysed using SEM. The addition of 25D, 1,25D and ascorbic acid all failed to 
osteoclastogenesis when SAOS2 cells were co-cultured with splenocytes. The mouse osteocyte-
like cell line MLO-Y4 was also investigated, as this has been demonstrated previously to support 
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osteoclastogenesis form both splenocytes and human PBMC (111, 121). The use of MLO-Y4 
enables the production of murine based cytokines as well as the potential for the signalling between 
osteoclasts and osteocytes to be present.  MLO-Y4 cells were able to initiate the maturation of 
osteoclasts. MLO-Y4/splenocyte co-cultures showed resorptive events on dentine confirming the 
presence of mature osteoclasts in these cultures. The addition of 25D concentration increased the 
number of osteoclasts formed but to a much lower extent than that of 1,25D at both 1 and 10nM 
(See Chapter 7a Fig 7a.1). It was observed that the presence of 1nM 1,25D was optimal for 
osteoclast formation from splenocytes under MLO-Y4 co-culture. 
 
3.2.6 PBMCs  
In separate experiments designed to test the effects of vitamin D metabolism on osteoclastogenesis 
the use of PBMCs was investigated as an addition to the spleen cells. PBMCs successfully formed 
osteoclasts from the addition of RANKL and MCS-F as expected. Large scale experimentation 
was undertaken in order to observe the effect of vitamin D metabolites on PBMCs and to replicate 
previous work undertaken by our group (3, 4, 7) on a large scale. Our PBMCs were collected from 
male volunteers ranging from their late twenties to the late fifties. There was great disparity 
between PBMCs formed from different individuals. This was not surprising as variation between 
non-genetically related individuals is usually high. Unfortunately due to this high variation 
between individuals minimal significance was observed. We did not observe any significant 
changes in cell number under 25D treatment. We did confirm that there was a significant effect of 
1,25D on osteoclast formation in PBMCs (Fig. 3.7) as reported previously (3, 4, 7). To overcome 
the variation observed, the use of a higher n value in future studies may be useful to explore this 







Fig. 3.7. The effect of Vitamin D metabolites on PBMCs. PBMCs were cultured under seven 
treatments; control, pro-osteoclastogenic conditions, pro-osteoclastogenic conditions + 100nM 
25D, pro-osteoclastogenic conditions + 1nM 1,25D, pro-osteoclastogenic conditions + 25nM 25D, 
pro-osteoclastogenic conditions + 50nM 25D, pro-osteoclastogenic conditions + 200nM 25D as 
described in Materials and Methods for the times indicated and assayed for TRAP+  multinucleated 
cell formation. Total TRAP+ cell numbers were combined from two independent experiments, 
each using PBMCs from the same donor, and shown as means ± SEM. Significant differences 
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Evidence for altered osteoclastogenesis in splenocyte cultures from Cyp27b1 
knockout mice 
Based on previous studies by our group, it was considered ideal to examine the effect of vitamin 
D at an autocrine level. Cyp27b1KO mice are unable to undertake autocrine vitamin D conversion 
but are still able to respond to endocrine vitamin D. Because of the germline deletion of Cyp27b1 
in these mice, they were an ideal source of osteoclast progenitors to test for the effects of loss of 
CYP27B1 activity. This chapter is represented by a published manuscript and covers the effect of 
the deletion of Cyp27b1 in a mouse model in ex vivo splenocyte cultures. This is examined through 
TRAP assays, analysis of mRNA expression and bone resorption assays on a mineralised substrate. 
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A B S T R A C T
The association between increased serum 25-hydroxyvitamin D (25D) and reduced osteoclastic bone
resorption is well known. Previously, we have demonstrated that mechanism by which this occurs, may
include the conversion of 25D to 1,25-dihydroxyvitamin D (1,25D) by osteoclasts, catalysed by the
CYP27B1 enzyme. Local 1,25D synthesis in osteoclasts was shown to regulate osteoclastogenesis and
moderating resorptive activity. Thus, we hypothesised that osteoclasts differentiated from mice with
global deletion of the Cyp27b1 gene (Cyp27b1 KO) would display enhanced resorptive capacity due to the
lack of an ameliorating effect of 1,25D. Splenocytes isolated from Cyp27b1 KO mice or their wild-type
(WT) littermates between 6 and 8 weeks of age were cultured under osteoclast-forming conditions for up
to 14 days. Osteoclast formation was measured by staining for the osteoclast marker tartrate resistant
acid phosphatase (TRAP). Bone resorption activity was measured by plating the cells on a bone-like
substrate. In Cyp27b1 KO cultures, osteoclastogenesis was reduced, as indicated by fewer TRAP-positive
multinucleated cells at all time points measured (p < 0.05) when compared to wild-type (WT) levels.
However, Cyp27b1 KO osteoclasts demonstrated greater resorption on a per cell basis than their WT
counterparts (p < 0.03). In addition, the ratio of expression of the pro-apoptotic gene Bax to the
pro-survival gene Bcl-2 was decreased in Cyp27b1 KO cultures, implying that these smaller osteoclasts
survive longer than WT osteoclasts. Our data indicate abnormal osteoclastogenesis due to the absence of
CYP27B1 expression, consistent with the notion that endogenous metabolism of 25D optimises
osteoclastogenesis and ameliorates the resulting activity of mature osteoclasts.
ã 2015 Elsevier Ltd. All rights reserved.
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Osteoclasts are the cell type responsible for the majority of
targeted bone resorption. Their multinucleated nature combined
with a large cytoplasm and endoplasmic reticulum enables the
rapid production of enzymes, proteins and ions in order to resorb
bone [1]. Vitamin D metabolism through the conversion of 25-
hydroxyvitamin D (25D) to 1a,25-dihydroxyvitamin D (1,25D) via
renal CYP27B1 activity is known to increase calcium uptake in the
small intestine [2]. In addition to the endocrine effects of vitamin
D, autocrine/paracrine pathways of vitamin D metabolism also
exist in the skeleton [2]. Previous studies have demonstrated that
bone cells including both osteoblasts [3,4], osteocytes [5] and
osteoclasts [6] express the vitamin D receptor (VDR) and CYP27B1,
and are capable of metabolising 25D into 1,25D.
A major effect of 1,25D activity in bone is thought to be the
regulation of expression by osteoblast lineage cells of cytokines
that regulate osteoclastogenesis, such as RANKL and osteoprote-
gerin (OPG) [7–9]. Furthermore, the net effects of 1,25D activity
appear to depend on the differentiation stage of the osteoblast in
question, with the pro-osteoclastic effects appearing to be
mediated by relatively immature osteoblasts, perhaps as a function
of the proximity of these cells to the bone surface [10–13].
However, we previously demonstrated that 25D metabolism by
osteoclast-lineage cells also has direct consequences for osteoclast
formation and activity, and while osteoclast differentiation was
enhanced in the presence of 25D at concentrations above 60 nM,
osteoclast resorptive activity was reduced [6,14]. These findings
suggested that adequate 25D levels are necessary in order to
ameliorate osteoclastic bone resorption. Consistent with these
findings, previous studies have demonstrated that the deletion of
the Cyp27b1 gene in mice and the subsequent loss of the autocrine
vitamin D pathway results in reduced osteoclast number and
decreased osteoclast size [15].
In the current study, we examined the influence of autocrine
vitamin D metabolism in the osteoclast lineage using the global
gene knockout (KO) mouse model, Cyp27b1 KO [16]. Mouse
splenocytes were used to generate osteoclasts ex vivo by treating
with recombinant RANKL and M-CSF, enabling the examination of
the intrinsic ability of haemopoietic cells to form osteoclasts and
the assessment of their resultant bone resorbing activity without
the influence of osteoblastic stromal cells. Various markers of gene
expression relating to osteoclast formation, activity and survival
were analysed.
2. Materials and methods
2.1. Animals
Global Cyp27b1 KO mice [16] were housed at ambient
temperature with free access to water and food, with established
12 h day–night cycles. All mice were fed the KO ‘rescue diet’,
consisting of chow containing 2% calcium, 1.25% phosphate and
20% lactose, which prevents rickets and bone abnormalities
associated with this model [15], until genotyped and removed
for weaning. After weaning, confirmed Cyp27b1 KO mice were fed
the rescue diet while wild-type (WT) mice were fed a standard
chow diet. All animal procedures were approved and performed in
accordance to requirements of the animal research ethics94committees of the University of Adelaide and the University of
South Australia.
2.2. Osteoclastogenesis
All experiments conducted were repeated at least 3 times. Mice
were humanely euthanised and spleens excised and placed in
Minimal Essential Media-alpha (aMEM; Sigma Chemical Co., St
Louis, MO, USA). Spleens were dissected and the pieces gently
ground between two glass slides in order to release the cells from
the surrounding tissue. Red cell lysis buffer was then added and
cells washed three times in aMEM, containing 10% charcoal
stripped FCS (HyClone, Logan, UT, USA), 1% penicillin,
2 mM L-glutamine and HEPES. Cells from four spleens/genotype
were then pooled, counted using trypan blue exclusion, and plated
into standard 96 well tissue culture plates for TRAP staining and
into OsteologicTM slides (BD Biosciences, Bedford, USA) at 2  105
cells/well, or at 1 106 cells/well into 24 well plates for TRIzol
based RNA extraction [6]. Cells were treated with differentiation
media consisting of aMEM supplemented as above, with the
addition of: recombinant M-CSF (Millipore, Temecula, CA, USA)
(25 ng/ml = untreated/UT) or M-CSF + RANKL (Millipore)
(100 ng/ml = positive control). In some experiments the effects of
exogenous 1,25D and 25D (Wako Pure Chemicals, Japan) were
assessed. The level of 1,25D used was 1 nM, which we have shown
to be equivalent in efficacy to that of a physiological concentration
of 25D (100 nM) in terms of inhibiting resorption in cultures of
both RAW 264.7 cells and peripheral blood mononuclear cells
(PBMC) [14].
2.3. TRAP staining
TRAP staining of quadruplicate wells was performed using a
commercial kit (Sigma Chemical Co.), as described previously [14].
Osteoclasts were defined as magenta stained TRAP+ cells contain-
ing three or more nuclei. Osteoclast number and nuclearity were
assessed using light microscopy. TRAP staining was examined at at
least 3 time points between days 6 and 9, encompassing early and
peak formation periods in both genotypes, as determined in
preliminary optimisation experiments (data not shown). Stained
cells were imaged using a 4 objective on an Olympus CKX41 light
microscope attached to a camera (Olympus DP20).
2.4. Analysis of gene expression by real-time RT-PCR
RT-PCR was performed, as described previously [6] with some
modifications. Briefly, RNA was extracted using 0.5 ml TRIzol
(Invitrogen, Carlsbad, USA), as per the manufacturer’s instructions.
Real-time RT-PCR was performed using the SYBR Green incorpo-
ration technique for nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 1 (Nfatc1), Trap, calcitonin receptor (Ctr),
carbonic anhydrase 2 (Car2) and Cathepsin K (Ctsk) mRNA
expression using previously published oligonucleotide primer
sequences [6] in a real-time thermocycler (MyIQ, Bio-Rad, NSW,
Australia). Custom primers for the amplification of monocyte
chemotactic protein 1 (Mcp1), Bax and Bcl2 mRNA were designed
in-house and purchased from Geneworks (Thebarton, SA,
Australia). Oligonucleotide sequences were: Mcp1: forward 50-
ggctggagagctacaagagg-30, reverse 50- ttgagcttggtgacaaaaactacag-
30; Bax: forward 50-tgctacagggtttcatccagg-30, reverse 50-
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30, reverse 50-atagttccacaaaggcatcccag-30, Voa3: forward 50-gctgca-
gagcggctcaag-30, reverse 50-aaggggaatgtgatgatggtgtag-30. For the
purpose of normalisation of gene expression of the above genes,
the house keeping genes B2m and Hprt1 were chosen, as these have
been shown to be stably expressed during osteoclast differentia-
tion [17]. Oligonucleotide sequences were: B2m forward 50-
ctgctacgtaacacagttccaccc-30 reverse 50-catgatgcttgatcacatgtctcg-
30; Hprt1 forward 50-ggttaagcagtacagcccca-30 reverse 50-tgcagatt-
caacttgcgctc-30.
2.5. Resorption activity
Resorptive activity was measured, as described previously [14].
Briefly, following the 14 day culture period on OsteologicTM slides,
resorption was visualised using Von Kossa staining, which stains the
non-resorbed mineralised collagen background, highlighting areas
of osteoclastic activity. Light microscopic images were converted to
black and white then resorption was quantified using Image J (V 1.47,
National Institutes of Health) software. Resorption assays were also
undertaken under the above conditions, using whale dentine slices
tailored to fit 96 well plates, which were subsequently examined by
scanning electron microscopy, as previously described [18].
2.6. Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (v6.05 GraphPad Software, San Diego, CA, USA). Analysis
was performed using two-way ANOVA followed by Holm–Šídák
multi-comparison post-hoc tests or multiple or standard Student’s
T-tests.
3. Results
3.1. Relative osteoclastogenic potential of Cyp27b1 KO splenocytes
n this study, we analysed the ability of splenocytes isolated
from mice deficient in CYP27B1 activity or from their WT
counterparts to differentiate into osteoclasts. Following stimula-
tion with recombinant RANKL/M-CSF, conditions well known to
stimulate osteoclastogenesis, TRAP staining at four time points,
chosen to capture the early, mid- and late stages of multinucleated
cell formation (Fig. 1), indicated that Cyp27b1 KO osteoclastFig. 1. The effects of Cyp27b1 deletion on TRAP-positive osteoclast formation. Splenocyt
Section 2 for the times indicated and assayed for TRAP+multinucleated cell formation. Tot
each using splenocytes pooled from at least 4 animals/group and shown as means  SE
95differentiation was consistently reduced compared to WT by
approximately 50%.
The addition of exogenous 1,25D (1 nM) to WT cultures
inhibited the number of TRAP+ multinucleated osteoclasts formed,
to approximately the same number as seen in untreated Cyp27b1
KO cultures (Fig. 1). The addition of 1,25D to Cyp27b1 KO cultures
resulted in a trend for decreased osteoclast formation on day 8,
consistent with these cells retaining responsiveness to exogenous
1,25D. The addition of 25D to WT cultures caused a decrease in
osteoclast formation at day 8 and a significant increase at day 9. As
expected, 25D had no effect on Cyp27b1 KO cultures (Fig. 1).
As depicted in Fig. 2, osteoclast size was decreased in the Cyp27b1
KO cultures compared with WT.1,25D treated WTcultures appeared
similar to the untreated and 1,25D treated Cyp27b1 KO cultures
(Fig. 2). 25D had little noticeable effect on osteoclast size in cultures
of either genotype. The difference due to genotype alone translated
into fewer average nuclei per cell in Cyp27b1 KO TRAP+ cells than in
WT cultures (Fig. 3A). Analysis of osteoclast size distribution based
on the number of nuclei/cell showed significantly more small
osteoclasts (3–10 nuclei/cell) present in Cyp27b1 KO culturesthan in
WT cultures at day 9 of culture (Fig. 3C). The most prominent
difference seen was a marked decrease in larger osteoclasts
(containing >25 nuclei) seen in Cyp27b1 KO cultures (Fig. 3D).
3.2. Effect of genotype on resorptive activity
The ability of osteoclasts formed in these experiments to resorb
a bone-like matrix was confirmed on whale dentine and quantified
on a mineralised collagen substrate (OsteologicTM) (Fig. 4A).
Despite fewer osteoclasts formed from Cyp27b1 KO splenocyte
cultures, the total area resorbed per well was not significantly
different compared to WT, although there was a trend for less
resorption in the case of Cyp27b1 KO cultures (p = 0.07; Fig. 4B).
However, by correcting for the peak numbers of TRAP+ osteoclasts
formed in replicate wells, observed at day 8, Cyp27b1 KO
osteoclasts resorbed 1.55  0.12-fold more per osteoclast when
compared to WT (Fig. 4C).
3.3. Effect of genotype on osteoclast gene expression
The analysis of the mRNA expression of the osteoclast-
associated genes Trap, Nfatc1, Car2 and Ctsk revealed that gene
expression within the Cyp27b1 KO osteoclast cultures wases were cultured under control or pro-osteoclastogenic conditions, as described in
al TRAP positive cell numbers were combined from three independent experiments,
M. Significant differences from WT are indicated by asterisks (p < 0.05).
Fig. 2. Representative micrographs of TRAP-positive multinucleated cells from both WT and Cyp27b1 KO cultures under multiple treatments. Splenocytes were cultured
under control or pro-osteoclastogenic conditions, as described in Section 2 for the times indicated and assayed for TRAP+MNC formation. WT splenocytes treated with (a) M-
CSF, (b) M-CSF + RANKL, (c) M-CSF + RANKL + 1,25D; Cyp27b1 KO splenocytes treated with (d) M-CSF, (e) M-CSF + RANKL, (f) M-CSF + RANKL + 1,25D. Images were taken using a
4 objective.
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(Fig. 5A–D), consistent with reduced total osteoclast numbers in
the Cyp27b1 KO cultures. However, the expression of the markers
Ctr and of the VoA3 subunit of the V-ATPase was not significantly
different in Cyp27b1 KO cultures compared with WT (Fig. 5E and F).96Gene expression of Mcp1 was increased in the Cyp27b1 KO cultures
(Fig. 5G).
We also examined the possible influence of loss of Cyp27b1
expression on cell survival. The expression ratio of Bax:Bcl2 mRNA
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Fig. 3. The effects of Cyp27b1 deletion on TRAP positive osteoclast nuclei number.
Splenocytes were cultured under control or pro-osteoclastogenic conditions, as
described in Section 2 and stained for TRAP. The number of nuclei per osteoclast was
counted by light microscopy and categorised into groups: (a) combined average
nuclei per cell, (b) osteoclasts containing 3–10 nuclei/cell, (c) osteoclasts containing
11–25 nuclei/cell and (d) osteoclasts containing >25 nuclei/cell. Data shown are
combined counts from three independent experiments, each using splenocytes
pooled from at least 4 animals/group, and shown as means  SEM. Significant
differences from WT are indicated by asterisks (p < 0.05).
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97increased survival of the osteoclasts that formed relative to WT
cells (Fig. 5H). Using two-way ANOVA, all four experimental
replicates demonstrated a reduced ratio of Bax:Bcl2 mRNA on day
6, while in two of the experimental replicates, significant decreases
were also observed on days 7 and 8.
4. Discussion
Splenocytes isolated from Cyp27b1 KO mice displayed de-
creased potential to form osteoclasts in vitro under standard
culture conditions, suggesting an intrinsic defect in osteoclasto-
genesis in the absence of CYP27B1 activity. This is consistent with
our previous finding that Cyp27b1 mRNA knockdown in RAW 264.7
cells inhibited osteoclast formation [6]. This finding is also
consistent with the treatment of WT osteoclast precursors with
25D resulting in enhanced osteoclastogenesis [14].
Consistent with expectations[14,19,20], treatmentofWTcultures
with 1,25D inhibited osteoclast formation. Osteoclast formation in
Cyp27b1 KO cultures was similarly affected by 1,25D although the
effect did not achieve statistical significance (p = 0.07). This may
indicate that there is a maximum threshold of reduction that can be
achieved in this model through modifications to either the vitamin
D autocrine or endocrine pathways. The addition of 25D to WT
cultures appeared to alter the kinetics of osteoclast formation, with
fewer osteoclasts at day 8 but increased numbers at day 9. This is
generally consistent with our previous findings that the addition of
25D enhanced TRAP positive osteoclast formation in RAW 264.7
cultures, although not in peripheral blood mononuclear cell (PBMC)
or splenocyte-derived osteoclast cultures, however gene expression
markers for osteoclastogenesis were increased by 25D in all models
tested [6,14]. As expected, 25D had no discernible effect on Cyp27b1
KO cultures. The observation that isolated osteoclasts are inhibited
by 1,25D while osteoblasts are stimulated to express pro-
osteoclastogenic cytokines, including RANKL and M-CSF [7–9],
indicate two competing actions of 1,25D on osteoclastogenesis. This
may be in order to exert tight control of the activity of osteoclasts
that form in vivo.
Analysis of the osteoclast-like cells that formed in Cyp27b1 KO
cultures demonstrated reduced average nuclei number per osteo-
clast, with a clear reduction in the number of large (>25 nuclei)
osteoclasts. Size is thought to play an important if not fully
elucidated role in osteoclast activity. Large osteoclasts possess
greater bone resorbing machinery and are therefore capable of
forming larger resorption pits, however, they may be less motile
than their smaller counterparts. This may in part explain our
resorption data that indicated, despite the reduction in TRAP+ cell
number and size, Cyp27b1 KO cells had increased resorptive activity
per osteoclast formed. This is consistent with our previous findings
that local 1,25D synthesis in osteoclasts, derived from human
peripheral blood mononuclear cell precursors, inhibits the resorp-
tive activity of WT osteoclasts [14]. That the effect on the resorbing
activity of Cyp27b1 KO derived osteoclasts was due to their inability
to metabolise 25D into 1,25D is supported by our previous finding
using splenocytes derived from Vdr-null mice, which also generated
osteoclasts with enhanced resorption activity [14].
Consistent with our previous study showing that CYP27B1
activity was associated with increased expression of osteoclasto-
genesis-related genes in the resulting cultures [6], here we
observed decreased mRNA expression of several key markers
including Trap, Nfatc1, Car2 and Ctsk. The reduction of the
transcription factor NFATC1 may explain the decreased expression
of the other markers and the reduction in osteoclast size and
number. The reduction in expression of these genes would be
expected to result in a reduction in resorptive activity, however the
converse was found. Interestingly, gene expression of V0a3 and Ctr
were unchanged while the expression of Mcp1 mRNA was
Fig. 4. The effect of Cyp27b1 deletion osteoclast resorptive activity. Splenocytes were seeded at the same density into either dentine, OsteologicTM slides or 96-well assay
plates and cultured under osteoclastogenic conditions or in the presence of M-CSF alone, as described in Section 2. After 14 days of culture, wells were stained for TRAP and
slides were stained to reveal resorption areas: (A) Von Kossa stained OsteologicTM slides; dentine was cleaned and analysed by scanning electron microscopy; (B) quantified
total area resorbed; (C) resorption per TRAP-positive osteoclast. Quantified data are means  SEM of quadruplicate wells and are representative of 2 independent
experiments. Significant differences between genotypes are indicated by asterisks (p < 0.05).
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Fig. 5. The effect of Cyp27b1 deletion on osteoclastogenic gene expression. Splenocytes pooled from four mice of each genotype were seeded into 24-well tissue culture plates
at 1 106 cells/well and cultured under osteoclastogenic conditions, as described in Section 2. Gene expression by real-time RT-PCR was performed for the mRNA expression
of (a) Nfatc1, (b) Trap, (c) Ctsk, (d) Car2, (e) Voa3, (f) CTR, (g) MCP-1 and (h) Bax/Bcl-2 data shown are means  SEM of 3 independent experiments. Significant differences
between genotypes are indicated by asterisks (p < 0.05).
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fusion [21], however its increased expression was in direct contrast
to the observed TRAP staining, suggesting that its expression may
be elevated as a potential negative feedback mechanism to
overcome the effect of Cyp27b1 deletion.
The observed decrease in the number of large osteoclasts and
increased number of smaller osteoclasts in the Cyp27b1 KO cultures
indicated that CYP27B1 may influence cell fate in terms of osteoclast
apoptosis or survival. Apoptosis in many cell types, including
osteoclasts [22,23], is regulated in part through the interplay
between the pro-survival/anti-apoptotic factor B Cell lymphoma-2
(BCL-2) and the pro-apoptotic BCL-2 associated X protein, (BAX);
BAX acts to increase the porosity of the outer mitochondrial99membrane and promote the release of factors leading to caspase
activation and apoptosis, an activity that is inhibited by BCL-2
[24,25]. We therefore examined the mRNA expression ratio of Bax:
Bcl2 as a surrogate measure for osteoclast survival. The reduction in
this apoptotic index indicated that net Cyp27b1 KO osteoclast
survival is increased. Given that Cyp27b1 KO cultures contained a
greater number of small osteoclasts, this may indicate that in this
model while large multinucleated osteoclasts do not form, the
smaller cells that do form have increased survival potential.
Increased osteoclast survival leading to increased resorptive
activity has been demonstrated in several pathways, such as
signalling through the osteoclastic protein-tyrosine phosphatase
(PTP-oc) [26] and through the integrin/c-Cbl and Cbl-b pathways
360 D.C. Reinke et al. / Journal of Steroid Biochemistry & Molecular Biology 164 (2016) 353–360[27]. However, the converse has also been demonstrated, where
decreased osteoclast survival was associated with increased
resorptive activity [28,29]. Alternatively, we cannot rule out that
the decreased Bax:Bcl2 ratio may indicate that cell types other than
osteoclasts have increased survival in these cultures.
A limitation of this study is that experiments were undertaken
with only haemopoietic cells present, in order to examine the
effect of Cyp27b1 deletion independently of effects in other cells
that influence osteoclastogenesis, such as osteoblasts and osteo-
cytes. This approach means that the observed osteoclast behaviour
from these cultures may not be identical to those observed in vivo.
However, a previous study [15] reported that the number of
osteoclasts present in TRAP-stained bone taken from mice with
global Cyp27b1 deletion was unusually low for the very high levels
of parathyroid hormone present. As well as the tendency for
reduced osteoclast number it was observed that Cyp27b1 KO mice
lacking the rescue diet had smaller osteoclasts than their WT
counterparts [15], consistent with the findings presented here.
Overall, these findings are further supportive of an important
intrinsic role for autocrine vitamin D metabolism regulating the
formation and activity of osteoclasts. At the same time, our
findings imply that endocrine-derived 1,25D, independent of
effects on mesenchymal-derived cells, has an inhibitory role on
osteoclast formation.
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Further examination of osteoclastogenesis in the Cyp27b1KO mouse model 
 
This chapter covers additional work undertaken with the Cyp27b1KO mouse model that was not 
included in Reinke et al., J. Steroid Biochemistry and Molecular Biology, 2016 as seen in Chapter 
4, due to journal constraints on manuscript length, and as such represents an addendum to that 
chapter. The data consists predominantly of mRNA expression, examining genes not covered in 
the published paper, as well as the effects of vitamin D metabolites 25D and 1,25D and their 
subsequent effects on gene expression. Using the remaining mRNA from this work we examined 
vitamin D sensitivity of the V-ATPase and all 26 of its individual subunits in the osteoclast using 
techniques as described. Subunit gene expression is examined for alterations either due to global 





As discussed in Chapter 4, CYP27B1 is a critical component of vitamin D metabolism in both 
endocrine and autocrine vitamin D synthesis. We sought to gain insight into its autocrine role in 
osteoclasts through the use of Cyp27b1 global osteoclast KO mice (Cyp27b1KO). This chapter 
presents the results that were not included in the published paper by Reinke et al. (122).  
Here, we examined the mRNA expression of multiple genes from Cyp27b1KO osteoclasts with 
results also for both 25D and 1,25D treatments. Our published study reported mRNA expression 
for WT cells against Cyp27b1KO osteoclasts for a set of seven genes, as well as the ratio of Bax 
to Bcl-2 expression as a molecular readout of propensity for cell death (122). However, results 
were also obtained for the mRNA expression of a number of other genes related to osteoclast 
formation, function and survival. As well as osteoclast related genes, all 26 individual subunits in 




Subunits Gene Acronym Function 
V1A ATP6V1a Catalytic ATP binding site 
V1B1 ATP6V1b Non-catalytic ATP binding 
site 
V1B2 ATP6V1b2 Non-catalytic ATP binding 
site 
V1C1 ATP6V1c Peripheral stator 
V1C2 ATP6V1c2 Peripheral stator 
V1D ATP6V1d Central Rotor 
V1E1 ATP6V1e Peripheral stator 
V1E2 ATP6V1e2 Peripheral stator 
V1F ATP6V1f Central Rotor/torque 
generation 
V1G1 ATP6V1g Peripheral stator 
V1G2 ATP6V1g2 Peripheral stator 
V1G3 ATP6V1g3 Peripheral stator 
V1H ATP6V1h Catalytic Subunit 
V0A1 ATP6V0a H+ ion Translocation 
V0A2 ATP6V0a2 H+ ion Translocation 
V0A3/TCIRG ATP6V0a3 H+ ion Translocation 
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V0A4 ATP6V0a4 H+ ion Translocation 
V0B ATP6V0b H+ ion Translocation 
V0C ATP6V0c H+ ion Translocation 
V0D1 ATP6V0d Coupling ATP hydrolysis 
and proton translocation 
V0D2 ATP6V0d2 Pre osteoclast fusion 
V0E ATP6V0e Maturation and bone 
resorption 
V0E2 ATP6V0e2 Unknown 
Ac45 ATP6AP1 Regulation 
M8-9 ATP6AP2 C-terminal truncation 




5.1.1 C-fos  
C-fos is a member of the AP-1 family of transcription factors. It is part of the signalling cascade 
that results in osteoclast maturation from RANKL/RANK and M-CSF/c-FMS signalling, and acts 
directly on NFATC1 altering Nfatc1 expression (123). C-fos null mice have been shown to be 
unable to form osteoclasts. The presence of C-fos directs precursor cells toward an osteoclastic 
maturation pathway (5). 
 
5.1.2 Clcn-7  
CLCN-7 is a chloride channel present on the osteoclast that ensures membrane potential is 
constant. The CLCN-7 chloride channel is used to exchange hydrogen carbonate ions for chloride 
ions to ensure that the membrane potential of the osteoclast remains constant during resorption 
(124, 125). 
 
5.1.3 Mcl-1  
Mcl-1 is a member of the BCL-2 family that was identified as an early expressed gene in myeloid 
cell lines. It has been demonstrated to enhance cell viability and bone resorption in osteoclasts. 
The mechanistic pathways behind this are as yet not fully elucidated (91). 
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5.1.4 Bim  
Bim is a pro-apoptotic member of the BCL-2 family and induces apoptosis via cytochrome C 
release from mitochondria. It has been demonstrated that Bim is essential for osteoclast apoptosis 
(126, 127). 
 
5.1.5 Bcl-xl  
Bcl-xL is an anti-apoptotic family member of the BCL-2 family and acts to prevent apoptosis by 
inhibiting the function of the pro-apoptotic members of the BCL-2 family. The role of Bcl-xL is 
still being elucidated, as mice that are Bcl-xL-null die in utero. However it has been reported that 
osteoclast maturation and their resorptive activity are regulated by Bcl-xL (128, 129). 
 
5.1.6 V1F  
The role of v1f is as yet not fully elucidated. However v1f cross-links with the v1h subunit forming 
a tether, to inhibit rotary movement of the stators against the V-ATPase pump’s rotary components 
(130). Additionally, the v1f subunit has been established to be critical in ensuring maximum torque 
in rotational movement of the subunit. The loss of the v1f subunits results in 120° backward 
rotation and the failure to produce ADP (65). 
 
5.1.7 V1H  
The v1h subunit-cross links with the v1f subunit to lock down rotary action in free V1 domains 
(131), resulting in v1h being considered as a regulatory subunit within the V-ATPase pump. This 
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is reinforced by deletion of v1h resulting in unregulated V-ATPase activity (131).  However, the 
role of v1h in osteoclasts is as yet not fully elucidated. 
 
5.1.8 V0D2  
The subunit, v0d2, is well investigated, including its role within the osteoclast. The deletion of v0d2 
results in defective murine bone resorption and an osteopetrotic phenotype (64). V0d2 has two 
identified functions in the osteoclast; precursor fusion and the acidification of the resorptive zones 
(68). We have observed previously (3) that NFATC1 is down regulated by 1,25D in the osteoclast 
in the absence of stromal signaling. Furthermore, NFATC1 has been shown to up-regulate the 
expression of v0d2 transcript (63). It was therefore hypothesized that v0d2 would demonstrate 




Methods are as indicated in Chapters 2 and 3, unless otherwise stated.  
 
5.2.1 Oligonucleotide primers 
Oligonucleotide primers for all 26 subunits of the V-ATPase were kindly provided by Professor 
Ming-Hao Zheng (University of Western Australia). A representative time point was selected for 
analysis, corresponding to peak osteoclast TRAP-positive cell numbers in WT cultures. Messenger 
RNA expression was undertaken for both WT and Cyp27b1KO splenocyte cultures in the single 
time point assays. Messenger RNA-specific primers (Table 6.2) were designed as previously 
described (section 2.18), for further in-depth assays for v1f, v1h and v0d2. 
 
5.2.2 Statistics 
Gene expression was analysed using Student T-tests for the single time point experiments. Two 
way ANOVAs were used to analyse the gene expression for mRNA over time course with 
appropriate post-hoc tests (Tukey's). All statistical analyses were performed using GraphPad Prism 
software (v6.05 GraphPad Software, San Diego, CA, USA). Analysis for TRAP staining assays 




Name Forward Primer Reverse Primer Annealing Size 
Atp6V1h 5' CGAGGCTATCCAGGTCTGTG 3' 5' TTTAGCACACTGGCTGCCTT 3' 60 134bp 
Atp6V0D2 5' ATTCTTGAGTTTGAGGCCGACA 3' 5' CAGCTTGAGCTAACAACCGC 3' 60 145bp 
Atp6V1f 5' CGCCACCCTAATTTCCTGGT 3' 5' AGAAATTGCCTGAAAGTGTCTTCG 3' 60 74bp 




5.3.1 Gene expression analysis 
In our previous report (122) we excluded results obtained for Clcn-7, Mcl-1, Trem-2, 
Cyp24, Bim, Bcl-xl and C-fos due to space restrictions. C-fos and Clcn-7 mRNA showed 
significant reduction in expression due to the deletion of Cyp27b1 compared to WT. Cyp24 
and Trem-2 both showed trends towards the reduction in mRNA expression due to the 




Figure 5.1: The effects of Cyp27b1KO deletion on osteoclast gene expression. 
Splenocytes were cultured under control of pro-osteoclastogenic conditions, as described 
in Chapter 2, for the times indicated. mRNA was combined from at least three experiments 
each using splenocytes pooled from at least 4 animals/group and shown as means ± SEM. 
Housekeeping genes are denoted along the Y axis in this case being Hprt1 and B2m. (a) 
Clcn-7 (b) Mcl-1 (c) Trem-2 (d) Cyp24 (e) C-fos. Significant differences are indicated by 



































































































































The expression of other genes were examined but showed no significant changes; this 
included Hif1-α, Oscar, Sost and Dc-stamp (data not shown), thus, they were not pursued 
further. Gene expression was also examined for the genes shown in Fig 5.1 for both 25D 
and 1,25D treatments. For all of the above genes, mRNA expression was unchanged in 
Cyp27b1KO mice when 25D was added to osteoclastogenic cell culture media. The 
addition of 25D to WT littermate-matched cultures similarly resulted in no significant 
changes (data not shown). 
Gene expression was also examined after 1,25D (1 nM) was added to osteoclastogenic 
culture media. The addition of 1,25D to WT osteoclast cultures at days 0, 3 and 6 resulted 
in an increase in Mcl-1 mRNA expression at early (d6) and late (d9) time points. It also 
resulted in a trend towards reduced C-fos expression on d7 (Fig 5.2). 
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Figure 5.2. The effects of 1,25D addition to WT osteoclast gene expression. Splenocytes 
were cultured under control of pro-osteoclastogenic conditions, as described in Chapter 2, 
for the times indicated. mRNA was combined from at least three experiments each using 
splenocytes pooled from at least 4 animals/group and shown as means ± SEM. 
Housekeeping genes are denoted along the Y axis in this case being Hprt1 and B2m. 
Significant differences are indicated by asterisks (P<0.05) and trends by #(P<0.10). (a) 











In Cyp27b1KO mice, the presence of 1,25D resulted in a reduction in Trem-2 mRNA 
expression on day 7, increased Mcl-1 mRNA expression on day 7, with strong increases in 




Figure 5.3. The effects of 1,25D addition to Cyp27b1KO osteoclast gene expression. 
Splenocytes were cultured under control of pro-osteoclastogenic conditions, as described 
in Chapter 2, for the times indicated. mRNA was combined from at least three experiments 
each using splenocytes pooled from at least 4 animals/group and shown as means ± SEM. 
Housekeeping genes are denoted along the Y axis in this case being Hprt1 and B2m. 
Significant differences are indicated by asterisks (P<0.05) and trends by #(P<0.10). (a) 










The deletion of Cyp27b1 had no significant effect on Bim and Bcl-xL mRNA expression in 
these stromal-free osteoclast cultures. A trend was observed for increased Bcl-xL 
expression in the Cyp27b1KO cultures. The addition of 25D and 1,25D resulted in a 
significant decrease in Bcl-xL mRNA expression in WT cultures but had no effect in 
Cyp27b1KO cultures. The addition of 25D and 1,25D also resulted in a significant decrease 
in the expression of Bim mRNA in WT cultures but had no effect on Cyp27b1KO cultures 
(Fig 5.4 and 5.5). 
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Figure 5.4. The effects of Cyp27b1KO deletion combined with the addition of Vitamin 
D metabolites on Bcl-xl gene expression in osteoclasts.  
Splenocytes were cultured under pro-osteoclastogenic conditions, as described in Chapter 
2, for the times indicated. mRNA was combined from at least three experiments each using 
splenocytes pooled from at least 4 animals/group and shown as means ± SEM. 
Housekeeping genes are denoted along the Y axis in this case being Hprt1 and B2m. (a) 
WT against Cyp27b1KO, (b) WT under 25D, (c) Cyp27b1KO under 25D, (d) WT under 
1,25D, (e) Cyp27b1KO under 1,25D. Significant differences are indicated by asterisks 
































Figure 5.5. The effects of Cyp27b1KO deletion combined with the addition of Vitamin 
D metabolites on Bim gene expression in osteoclasts.  
Splenocytes were cultured under pro-osteoclastogenic conditions, as described in Chapter 
2, for the times indicated. mRNA was combined from at least three experiments each using 
splenocytes pooled from at least 4 animals/group and shown as means ± SEM. 
Housekeeping genes are denoted along the Y axis in this case being Hprt1 and B2m. 
Significant differences are indicated by asterisks (P<0.05) and trends by # (P<0.10). (a) 
WT against Cyp27b1KO, (b) WT under 25D, (c) Cyp27b1KO under 25D, (d) WT under 













5.3.2 V-ATPase Subunit gene expression analysis 
In this study, we examined mRNA expression of individual V-ATPase subunits from a 
single time point, day 8 corresponding with peak osteoclast formation. The deletion of 
Cyp27b1 resulted in an increase in v1a, v1b1, v1b2, v1c1, v1c2, v1d, v1g2, v0a1, v0a2, v0a4, v0d1, 
v0d2 and v0e1 gene expression. Conversely, the v1f, v1h and v0c subunits were shown to be 
decreased due to the deletion of Cyp27b1. The gene expression of the remaining subunits 
v1e, v1e2, v1g1, v1g3, v0a3, v0e2, AC45, M8-9 showed no significant changes due to the 
deletion of Cyp27b1 (Fig. 5.6). Subunits showing changes in gene expression were 
preferentially selected for further analysis. The deletion of Cyp27b1 resulted in a genotype 
change in the subunits v1a2, v1b1, v1g2, v1g3, v0a1, v0a3, v0a4, v0d1, and v0d2.  This change was 
consistent with an increase in expression in all these subunits, indicating that the loss of 
Cyp27b1 at the germline level results in deregulation in eight of the subunits of the V-
ATPase. 1,25D was added to cultures in order to by-pass the deletion of Cyp72b1 and act 
directly on the VDR ideally resulting in the restoration of the autocrine vitamin D pathway. 
It was observed that in WT cultures exogenous 1,25D increased the expression of 50% of 
the subunits and decreased the expression of only two. Of particular note v1h considered a 
regulatory subunit was one of the few subunits decreased. The actions of 1,25D in 
Cyp27b1KO cultures was remarkably similar to that of the WT cultures although there was 
often a greater level of change in the KO cultures. The major exceptions were v1c and v1h. 
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Figure 5.6: Gene expression of V-ATPase subunits in WT and Cyp27b1KO osteoclast 
cultures. Mouse splenocytes were seeded at a density of 1x106 cells per well into 24 well 
culture plates with α-MEM and FBS 10% (v/v) with M-CSF (25ng/ml) and RANKL 
(100ng/ml), in the presence or absence of 1,25D (1nM). a)V1a,  b) V1b, c) V1b2, d) V1c1, e) 
V1c2, f) V1d, g) V1e, h) V1e2, i) V1f, j) V1g, k) V1g2, l) V1g3, m) V1h, n) V0a1, o) V0a2, p) 
V0a3, q) V0a4, r) V0c1, s) V0c2, t) V0d1, u) V0d2, v) V0e1, w) V0e2, x) AC45, y) M8-9  
Significant differences between genotypes are indicated by (a). Differences between WT 
and exogenous 1,25D are indicated by (b). # indicates a trend instead of significance, 


































































































































































































































































































































































































































































































































































































































































































































































5.3.3 V1F subunit 
Analysis of v1f gene expression revealed decreased expression in Cyp27b1KO osteoclast 
cultures compared to WT match littermates. A decrease in gene expression was observed 
under M-CSF/RANKL treated Cyp27b1KO cultures on day 7 and in VdrKO cultures on 
day 6 when compared against WT littermate matched controls.  
The addition of 1,25D to Cyp27b1KO osteoclast cultures resulted in increased expression 
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Figure 5.7. Gene expression over time for V-ATPase subunit v1f under the effect 
of Vitamin D metabolites and Cyp27b1KO. Mouse splenocytes were seeded at a 
density of 1x106 into 24 well culture plates with α-MEM and FBS 10% (v/v) with M-
CSF (25ng/ml) and RANKL (100ng/ml). mRNA was combined from at least three 
experiments each using splenocytes pooled from at least 4 animals/group and shown as 
means ± SEM.  a) WT splenocytes control and 1,25D treatment b) Cyp27b1KO 




5.3.4 V1H subunit 
Analysis of v1h gene expression revealed decreased expression in Cyp27b1 osteoclast 
cultures compared to WT-matched littermates on day 6 (Fig. 5.8). The addition of 
exogenous 1,25D resulted in a significant increase in v1h gene expression on day 8 in 
WT splenocytes. The addition of 1,25D to Cyp27b1KO osteoclast cultures however, 
had no significant effect on v1h expression. Significant increase in VdrKO expression 
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Figure 5.8: Gene expression over time for V-ATPase subunit v1h under the effect 
of vitamin D metabolites VdrKO and Cyp27b1KO. Mouse splenocytes were seeded 
at a density of 1x106 into 24 well culture plates with α-MEM and FBS 10% (v/v) with 
M-CSF (25ng/ml) and RANKL (100ng/ml). mRNA was combined from at least three 
experiments each using splenocytes pooled from at least 4 animals/group and shown as 
means ± SEM. 
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5.3.5 V0D2 subunit 
Analysis of v0d2 gene expression revealed no significant changes in expression in 
Cyp27b1KO osteoclast cultures compared to WT-matched littermates (Fig. 5.9). The 
response to 1,25D of both genotypes was also similar. In WT cultures, expression of 
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Figure 5.9: Gene expression over time for V-ATPase subunit v0d2 under the effect 
of vitamin D metabolites and Cyp27b1KO. Mouse splenocytes were seeded at a 
density of 1x106 into 24 well culture plates with α-MEM and FBS 10% (v/v) with M-




5.4.1 Osteoclast related genes 
Our previous study (122) indicated that deletion of Cyp27b1 increased osteoclast 
number, resorptive activity per osteoclast and resulted in a decrease in gene expression 
of Nfatc1, Trap, Ctsk and Ca2. The exception to this general decrease observed in most 
genes was Mcp-1 expression, which was increased. Cyp27b1KO osteoclast potential 
for survival appeared to be increased based on the ratio of Bax/Bcl-2 mRNA (122). 
Cyp27b1KO cultures displayed a trend towards reduced basal expression of Cyp24a1 
mRNA, which may be a result of the absent basal autocrine production of 1,25D in 
these cells (3, 7). However, Cyp27b1KO cultures responded robustly to exogenously 
added 1,25D with respect to Cyp24a1 mRNA induction, consistent with no impairment 
of 1,25D signalling. 
Gene expression was significantly reduced for Clcn-7. This was unexpected, 
particularly as we observed increased resorptive activity per osteoclast in Cyp27b1KO 
osteoclasts. As discussed, deletion of Clcn-7 in mice results in abnormal bone 
dissolution and it was expected that the levels of Clcn-7 would increase rather than 
decrease, as resorptive activity increased (124, 125). However, it is also possible that 
while Clcn-7 is significantly reduced, other chloride channels such as Chloride Channel 
Three were unaffected or increased to compensate (132). It is also possible that the 
prolonged survival of Cyp27b1KO osteoclasts is solely responsible for the increased 
resorption observed independent of chloride channel activity. 
C-fos mRNA expression was significantly decreased in early Cyp27b1KO 
osteoclastogenic cultures, as expected due to the decrease in Nfatc1 expression, 
135 
 
encoding the primary regulator of osteoclastogenesis, which we reported was also 
decreased in these cultures (122). The reduced expression of C-fos and Nfatc1 would 
have a follow-on effect, resulting in a subsequent decrease in mRNA expression for 
other genes regulated by these transcription factors. Surprisingly, the addition of 1,25D 
had no effect on C-fos gene expression. It was expected to be decreased under 1,25D 
signalling as the presence of 1,25D has been shown by our previous studies (122, 133) 
to reduce osteoclast number and gene expression. The lack of change in C-fos may 
indicate that exogenous 1,25D acts directly on NFATC1 or other upstream members of 
the cascade pathway. 
Trem2 expression was examined since its gene product is part of an ITAM receptor that 
assists in the regulation of osteoclast maturation and formation, and TREM-2-null mice 
are demonstrated to have decreased osteoclast formation (58). A trend towards reduced 
expression of Trem-2 was observed. While not statistically significant, this may have 
contributed to the reduced osteoclast formation and numbers observed. The addition of 
1,25D however had no effect on Trem2 gene expression, suggesting that its reduction 
could not be a direct result of Cyp27b1KO. There was no significant change in Cyp24a1 
mRNA levels in Cyp27b1KO, as expected (3, 7).  
A trend towards increased Mcl-1 expression under the treatment of 25D was consistent 
with previous observations that 25D increased osteoclast TRAP-positive numbers in 
RAW 264.7 cells (3, 134).The addition of 1,25D, unexpectedly, had direct effects on 
Mcl-1 mRNA levels in WT and Cyp27b1KO splenocyte cultures. It has been 
established that MCL-1 acts to suppress apoptosis and increased levels in response to 
1,25D would therefore be expected to result in reduced osteoclast apoptosis (135), an 
opposite effect to what we observed. The increased Mcl-1 mRNA expression under 
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1,25D may act as a compensatory mechanism in an attempt to limit the increased cell 
apoptosis via down-regulating the Bcl-2 and Bax mRNA expression ratio that also 
occurs under 1,25D treatment (136), and as seen in our previous study (122). It has been 
noted that 1,25D has an alternate action on mitochondria, acting to increase MCL-1 and 
decrease cytochrome C levels (135). The osteoclast has a unique mitochondrial 
structure, that includes an unusually dense electron transport chain and the ability to 
produce higher levels of ATP, and increases in MCL-1 may be a normal action to 
increase cell survival as the cell increases in size through fusion of mononuclear 
precursors. It would be interesting to observe Mcl-1 expression in a co-culture of MLO-
Y4 and splenocytes under 1,25D. The increase in Mcl-1 in both WT and Cyp27b1KO 
osteoclasts under the treatment of 1,25D may be part of a mechanistic pathway that acts 
in conjunction with osteocyte produced factors to limit the 1,25D initiated RANKL 
presentation inhibiting osteoclast formation. 
Bim (pro-apoptotic) and Bcl-xl (anti-apoptotic) expression were also examined, as 
additional members of the BCL-2 like family. BCL-XL, an alternate splicing of BCL-
X, has been demonstrated to play a role in the regulation of osteoclast survival and 
resorption in both in vivo and in vitro (137). Furthermore, Iwasawa et al. (137) indicates 
that the ratio of BCL-XL and BIM protein critically regulates osteoclast survival. BIM 
and BCL-XL have directly opposite effects on osteoclast resorptive activity to that of 
apoptosis. The almost identical patterns of increased and decreased expression 
respectively observed in Bim and Bcl-xl indicates that mRNA expression levels are 
unaffected by the loss of vitamin D signalling pathways. The results also potentially 
indicate a 1:1 ratio for mRNA is required for equilibrium in the osteoclast. It was 
identified that both of these genes strongly respond to 1,25D and 25D treatments in WT 
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osteoclasts. The reason for the almost identical increase in mRNA expression in both 
genes is unknown but may indicate that Bim and Bcl-xl have functions beyond the 
regulation of apoptosis and resorption in response to 1,25D. Regardless, these findings 
indicate that the maintenance of this particular gene expression ratio is in some way 
important for the osteoclast.  
The loss of Cyp27b1 expression prevented the increase in mRNA expression of Bim 
and Bcl-xL under 1,25D and 25D treatments. The inability of 1,25D to stimulate the 
response seen in WT osteoclasts when Cyp27b1 was knocked out was surprising. Our 
previous findings showed (3, 4) that exogenous 1,25D can act on Cyp27b1KO 
osteoclasts through the VDR. This indicates that the global deletion of Cyp27b1 may 
affect the way Bim and Bax respond to vitamin D in mature osteoclasts.  
 
5.4.2 V-ATPase subunits 
The V-ATPase subunits gene expression from a single peak time point, corresponding 
to peak osteoclast formation, in WT and Cyp27b1KO mouse splenocyte cultures and 
1,25D treatments indicated increased gene expression in 50% of the known V-ATPase 
subunits and decreased expression of the regulatory elements v1h and v1f in Cyp27b1KO 
cells. This was consistent with the increased resorptive activity observed in 
Cyp27b1KO mouse splenocyte cultures (122). V1h gene expression was strongly 
increased in WT cultures by the addition of 1,25D as would be expected of a vitamin D 
responsive subunit. V1f however was unchanged by the addition of 1,25D. This was 
unexpected, but as v1f and v1h function in tandem to form a tether between the two 
subunits, changes to v1h would also likely have affected the pump activity regardless. 
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V0c gene expression was not significantly altered or decreased under Cyp27b1 deletion 
which was unexpected as it is the only repeated subunit in the V0 domain that was not 
decreased. The lack of response of v0c to 1,25D in the WT was surprising, especially as 
the V0C protein is currently the only subunit recognised as able to instigate the assembly 
of the V0 domain (130, 138) and that the Cyp27b1KO responded to 1,25D and may be 
worth further investigation. 
The remaining subunits of the V-ATPase pump showed no changes in gene expression 
due to the deletion of Cyp27b1. This was unexpected as it is possible that the lack of 
changes in gene expression in these subunits is due to a lower number of subunit 
proteins in the V-ATPase superstructure, and this should be investigated further. 
We examined the subunits of v1f, v1h and v0d2 in further depth. The v0d2 subunit was 
selected for its well established role in literature (63). The KO of Vdr and Cyp27b1 had 
no significant effect on v1f gene expression. This was not expected. While no 
significance was observed, there were indications that a higher number of experimental 
replicates may have enhanced the ability for the detection of changes in v1f mRNA 
expression.  
WT cultures under the treatment of 1,25D had increased expression of v1f. This is highly 
supportive of vitamin D sensitivity being present within v1f. It is clear that vitamin D in 
stromal free osteoclast cultures acts to ensure the regulation of the V-ATPase pump is 
present. The deletion of Cyp27b1 resulted in the loss of vitamin D sensitivity. What is 
particularly unusual is that v1f under 1,25D treatment in Cyp27b1KO cultures still loses 
it sensitivity. This may imply that the activation of the vitamin D metabolic pathway 




The deletion of Cyp27b1 had no significant effect on v0d2 expression. This was 
unexpected as v0d2 has been demonstrated to be critical to the V-ATPase pump and 
osteoclast formation (64, 68, 130, 138).  
Cyp27b1KO and WT splenocytes in the absence of stromal signalling responded to 
1,25D treatment with the up-regulation of v0d2 expression indicating that v0d2 is highly 
sensitive to the active form of vitamin D. This was unexpected as v0d2 plays an integral 
role in osteoclast fusion and 1,25D treated samples from previous chapters has 
continuously indicated reduced osteoclast numbers. An increase in v0d2 expression 
alters osteoclast fusion to less than optimal conditions.  
The reduction in v1h expression in Cyp27b1KO osteoclast cultures was not unexpected. 
The decrease in v1h potentially indicates the loss of regulation in a percentage of V-
ATPase pumps. Literature has demonstrated (138) that the deletion of v1h does not 
prevent pump assembly and ATPase activity. There is however indications that the 
pump is no longer stable, resulting in uncontrolled hydrogen ion release. This would fit 
well with the increased resorptive activity observed in KO model osteoclast cultures 
(122, 133).  
There are indications that the V-ATPase pumps may cease to function in cells due to 
ADP inhibition. Cells have a set capacity to generate energy. Cells that are unable to 
convert sufficient ADP to ATP to keep up with the demand of the pumps would result 
in a lower level of hydrogen ion release than expected. However the osteoclast unique 
mitochondrial structure has higher electron transport chain density than that of any other 
cell. This combined with multiple mitochondria from cell fusion means that the 
osteoclast is uniquely capable of converting large volumes of ADP to ATP. This 
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indicates that unlike in most other cells, hydrogen ion transport would either take much 
longer to be or not be inhibited through limitations on energy production.  
vitamin D sensitivity was observed in v1h with 1,25D increasing gene expression. In 
the majority of cases the addition of 1,25D results in decreased gene expression. 
However, in this case the increase in v1h gene expression was expected. The addition 
of 1,25D reduced osteoclast numbers and gene expression responsible for resorption in 
the stromal free osteoclast cultures (122, 133). Increased regulation of hydrogen ion 
pumps would be expected in cells that have reduced resorptive activity. 
 
5.5 Conclusion 
The deletion of Cyp27b1 resulted in reduced expression in the majority of osteoclast 
related genes examined. The addition of 1,25D was expected to restore gene expression 
in the Cyp27b1KO osteoclast, thus we expected to observe significant increases in gene 
expression under the treatment of 1,25D in Cyp27b1KO osteoclasts. We observed no 
changes in gene expression of C-fos, and Clcn-7. We observed a further decrease in 
Trem-2 expression, indicating the potential for a further decrease in osteoclast number. 
The increase of Mcl-1 expression under 1,25D was unexpected and potentially worth 
further investigation. Lastly Bim and Bcl-xl were demonstrated to both be vitamin D 
sensitive and to have a basal level of expression independent of vitamin D, and this may 
also be worthy of future investigation. Of particular interest would be the effect of Bim 
and Bcl-xl mRNA in osteoclasts that have Cyp27b1 deleted only in mature osteoclasts, 
such as in a Cathepsin K - Cre conditional deletion model. 
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These experiments did not examine the effect of Cyp27b1 deletion in congruence with 
mesenchymal-derived cells, and as such further experimental work to identify if the 
loss of Cyp27b1 expression is as detrimental to osteoclastogenesis when stromal 
signalling is intact would be of future interest. 
vitamin D regulation is clearly present within the V-ATPase pump with multiple 
subunits responding to vitamin D. The V-ATPase pump has indicated the potential for 
independent vitamin D regulation through alternate pathways on v1h and v0d2. V1f and 




Evidence for altered osteoclastogenesis in splenocyte cultures from 
Vdr knockout mice. 
 
This chapter presents work undertaken with the VdrKO mouse model and is represented 
by published manuscript. This chapter covers the effect of the deletion of VDR in a 
mouse model in ex vivo splenocyte culture. This is examined through TRAP positive 
assays, mRNA and bone resorptive cultures on an artificial bone resorptive substrate. 
This chapter is represented by a published manuscript and covers the effect of the 
deletion of VDR in a mouse model in ex vivo splenocyte culture  
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A B S T R A C T
The indirect action of 1α,25(OH)2-vitamin-D3 (1,25D) on the osteoclast through stromal signalling is well es-
tablished. The role of vitamin D in osteoclasts through direct 1,25D-VDR signalling is less well known. We
showed previously that local 1,25D synthesis in osteoclasts modified osteoclastogenesis and osteoclastic re-
sorptive activity. In this study, we hypothesised that osteoclasts lacking VDR expression would display an en-
hanced resorptive capacity due to the loss of 1,25D signalling. Splenocytes were cultured under osteoclast-
differentiating conditions from mice with global deletion of the Vdr gene (VDRKO) and this was compared with
age-matched wild-type littermate controls (WT). In VDRKO cultures, osteoclastogenesis was reduced, as in-
dicated by fewer TRAP-positive multinucleated cells at all time points measured (p < 0.05) compared to WT
levels. However, VDRKO osteoclasts demonstrated greater resorption on a per cell basis than their WT coun-
terparts. VDRKO cultures expressed greatly increased c-Fos mRNA compared to WT. In addition, the ratio of
expression of the pro-apoptotic gene Bax to the pro-survival gene Bcl-2 was decreased in VDRKO cultures,
implying that these osteoclasts may survive longer than WT osteoclasts. Our data indicate abnormal osteo-
clastogenesis due to the absence of Vdr expression, consistent with direct effects of vitamin D signalling being
important for regulating the maturation and resorptive activities of osteoclasts.
1. Introduction
Primary regulation of calcium homeostasis occurs through the vi-
tamin D receptor (VDR) in the kidney, the small intestine and the bone
[1]. Kidney expressed CYP27B1 converts 25-hydroxyvitamin D3 (25D)
to 1α,25-dihydroxyvitamin D3 (1,25D), the active circulating metabo-
lite that binds to the VDR in target tissues, resulting in the regulation of
gene expression [2]. The VDR has been demonstrated to be almost
ubiquitously expressed in mammalian cells [3]. Despite this, the most
clinically defined role for vitamin D is its role in calcium homeostasis
and the related effects on bone regulation [4]. The focus of the current
study is the effect of vitamin D on the osteoclast. Osteoclasts are spe-
cialised monocyte/macrophage-derived multinucleated cells that per-
form the critical function of bone resorption [5]. While the expression
of VDR in osteoclasts is controversial [6], osteoclasts have been shown
to respond to directly vitamin D and regulate osteoclast formation and
resorption activity [7–9].
In the present study, the role of 1,25D activity in osteoclasts was
addressed using the global VDR knockout mouse (VDRKO) [10].
VDRKO mice exhibit hypocalcaemia and an under-mineralised ske-
leton, phenotypically similar to rickets [11]. Normal bone mineralisa-
tion can be achieved in these mice when fed a high calcium, phosphate
and lactose diet [12]. However, older VDRKO mice raised on the rescue
diet demonstrate osteopenia despite achieving normal calcium levels,
which involves dysregulated bone remodelling [13,14]. We hypothe-
sised that the deletion of Vdr in osteoclast precursors present in sple-
nocytes in VDRKO animals would result in aberrant osteoclastogenesis
and osteoclastic resorption, similar to that we reported for mice with a
global deletion of Cyp27b1 [15]. We examined the importance of VDR
mediated signalling in osteoclast and its effects on osteoclast matura-
tion, proliferation, activity and gene expression.
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2. Materials and methods
2.1. Animals
Global VDRKO mice [16] were housed at ambient temperature with
unrestricted access to water and food, with established 12 h day-night
cycles. VDRKO mice were fed the rescue diet containing 2% calcium,
1.25% phosphate and 20% lactose [12]. WT mice were fed a standard
chow diet. All animal procedures were approved and performed in
accordance to requirements of the animal research ethics committees of
the University of Adelaide and the University of South Australia.
2.2. Osteoclastogenesis
Mice were humanely euthanized at 8 weeks of age using carbon
dioxide and vertebral dislocation. Spleens were removed and placed in
Minimal Essential Medium-Alpha (αMEM; Sigma Chemical Co., St
Louis, MO, USA). Spleens were dissected and the pieces gently ground
through a 20 μm cell strainer using a 1 cc syringe. Red cell lysis buffer
was then added and cells washed three times in αMEM, containing 10%
charcoal stripped FCS (HyClone, Logan, UT, USA), 1% penicillin, 2 mM
L-glutamine and HEPES. Cells were extracted from four spleens per
genotype and then pooled, counted using trypan blue exclusion, and
plated into standard 96-well tissue culture plates for TRAP staining and
into Osteologic™ slides (BD Biosciences, Bedford, USA) at 2 × 105
cells/well, or at 1 × 106cells/well into 24 well plates for TRIzol based
RNA extraction [17]. Some cells were plated onto sperm whale dentine
slices (16 mm2) and cultured for 21 days to visualise the extent of bone
resorption [18].
Cells were fed using differentiation media consisting of αMEM
supplemented as above, with the addition of: recombinant human M-
CSF (Millipore, Temecula, CA, USA) (25 ng/ml = untreated/UT) or M-
CSF + RANKL (Millipore) (100 ng/ml = positive control). The effects of
exogenous 1,25D (1 nM) were assessed in some experiments (Wako
Pure Chemicals, Japan), a concentration we have shown to have
equivalent effects to that of a physiological concentration of 25D
(100 nM) in terms of inhibiting resorption in cultures of both RAW
264.7 cells and peripheral blood mononuclear cells (PBMC) [9].
2.3. TRAP staining
TRAP staining was performed on quadruplicate culture wells using a
commercial kit (Sigma Chemical Co.), as described previously [15].
Osteoclasts were defined as cells containing three or more nuclei that
stained magenta. Osteoclast number and multinuclearity were assessed
using light microscopy at 3 time points between days 6 and 9, en-
compassing early and peak formation periods in WT cells [15].
2.4. Analysis of gene expression by real-time RT-PCR
RT-PCR was performed essentially as described previously [15].
Briefly, RNA extracted was isolated using the TRIzol method (In-
vitrogen, Carlsbad, USA). Real-time RT-PCR was performed undertaken
using the SYBR Green incorporation technique for multiple genes in a
real-time thermocycler (MyIQ, Bio-Rad, NSW, Australia). These in-
cluded nuclear factor of activated T-cells, cytoplasmic, calcineurin-de-
pendent 1 (Nfatc1), tartrate resistant acid phosphatase (Trap), calci-
tonin receptor (Ctr), carbonic anhydrase 2 (Car2), cathepsin K (Ctsk),
monocyte chemotactic protein 1 (Mcp1), Bax and Bcl2. Expression was
normalised to that of the housekeeping genes B2m and Hprt1, which
have been shown to be stably expressed during osteoclast differentia-
tion [19]. All primers (Table 1) were designed to be mRNA-specific and
were purchased from Geneworks (Thebarton, SA, Australia).
2.5. Resorption activity
Resorptive activity was measured, as described previously [18].
Briefly, after 14 days of culture under osteoclastogenic conditions re-
sorption on Osteologic™ slides was visualised using Von Kossa staining.
Light microscopic images were converted to black and white then re-
sorption was quantified using Image J (V 1.47, National Institutes of
Health) software. Resorption was also assessed by seeding cells onto
whale dentine slices cut to 16 mm2, culturing for 21 days under os-
teoclastogenic conditions in 96-well plates, then processing dentine for
scanning electron microscopy [18].
2.6. Statistical analysis
Data were analysed using either two-way ANOVA followed by
Holm-Šídák multi-comparison post-hoc tests, or multiple or standard
Student’s T-tests, using GraphPad Prism software (v6.05 GraphPad
Software, San Diego, CA, USA). In all cases a value for p < 0.05 was
considered significant.
3. Results
3.1. Relative osteoclastogenic potential of VDRKO splenocytes
In this study, we examined the osteoclastogenic potential of sple-
nocytes derived from VDRKO mice or WT littermate controls. As shown
in Fig. 1, the deletion of VDR resulted in decreased TRAP+ multi-
nucleated osteoclast formation. The addition of exogenous 1,25D
(1 nM) to WT osteoclasts resulted in the reduction of TRAP+ osteoclast
number by 77% on day 6 and 48% on day 9. A 34% reduction in total
osteoclast number was observed on day 7 (Fig. 1). Exogenously treated
1,25D (1 nM) WT cultures retained a higher level of TRAP+ osteoclasts
than VDRKO cultures on days 8 and 9 (Fig. 1B). The addition of 1,25D
to WT cultures resulted in a similar decrease in osteoclast number as
that seen in untreated VDRKO cultures. Phenotypic analysis of sple-
nocytes at day 0 using PCR amplification of the myeloid/osteoclast
progenitor marker CD11b, indicated that there was no difference in
expression, suggesting that the defect in osteoclastogenesis is likely at a
late stage of progenitor development (data not shown). As expected, the
addition of exogenous 1,25D to VDRKO osteoclast cultures had no ef-
fect on osteoclastogenesis (Fig. 1B).
3.2. Effects of VDR deletion on osteoclast size
Analysis of the number of nuclei/cell showed significantly more
small osteoclasts (3–10 nuclei/cell) present in VDRKO cultures than in
WT cultures at days 6 and 7 (Fig. 2). An increase in the percentage of
larger TRAP+ osteoclasts (11–25 nuclei/cells) were observed in WT
cultures at days 6 and 7 (Fig. 2).
3.3. Effect of genotype on resorptive activity
The ability for resulting osteoclasts to resorb mineralised bone-like
substrate was confirmed using whale dentine (Fig. 3A) and was quan-
tified on a mineralised collagen substrate (Osteologic™). No difference
in the total area resorbed per well was observed between genotypes
(Fig. 3B). By correcting for the peak numbers of TRAP+ osteoclasts
formed in replicate wells observed at day 8, VDRKO-derived osteoclasts
were calculated to have resorbed more surface per osteoclast when
compared to WT (Fig. 3C).
3.4. Effect of genotype on osteoclast gene expression
Analysis of osteoclastogenesis associated gene expression revealed a
complex change in VDRKO cultures. C-fos is a transcription factor ex-
pressed upstream of Nfatc1 and is essential in the maturation and
D.C. Reinke et al. Journal of Steroid Biochemistry and Molecular Biology 177 (2018) 96–102
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formation of osteoclasts; expression of this gene was strongly elevated
in VDRKO cultures throughout the time course examined (Fig. 4A).
Expression of the master osteoclast transcription factor, Nfatc1, was
stable in WT cultures but trended downwards in VDRKO cultures, with
significantly reduced expression at day 7 (Fig. 4B). The osteoclast
marker Trap increased with time in cultures of both genotypes but
however was mildly decreased at day 7 in VDRKO culture (Fig. 4C). No
differences were observed for Clcn7, encoding the chloride channel
critical for maintaining the membrane potential of osteoclasts during
resorption (Fig. 4D). Levels of Ctsk mRNA, encoding the critical major
protease expressed by osteoclasts, were significantly decreased in
VDRKO cultures compared to WT on days 7 and day 8 (Fig. 4E). Levels
of the osteoclast marker Ctr were elevated at days 0 and 8 in VDRKO
cultures (Fig. 4F). Mcp-1, also known as Ccl2, is a chemokine known to
accelerate osteoclast maturation and is thought to act during osteoclast
fusion; expression of Mcp-1 was increased in VDRKO osteoclasts com-
pared to WT (Fig. 4G). The expression of triggering receptor expressed
on myeloid cells two (Trem-2), another regulator of osteoclast
formation and activity was not altered in VDRKO cultures (Fig. 4H).
We also examined the possible influence of loss of Vdr expression on
cell survival. The expression ratio of Bax:Bcl2 mRNA in the VDRKO
cultures was found to be decreased at day 6 and day8, consistent with
increased survival of the osteoclasts that formed, relative to WT cells
(Fig. 4I).
4. Discussion
In this study, osteoclasts derived from VDRKO mouse splenocytes
showed a decreased potential to form osteoclasts relative to cells from
WT littermates, indicating an intrinsic defect in osteoclastogenesis in
the absence of VDR activity. A similar defect was demonstrated pre-
viously in CYP27B1KO osteoclasts, indicating that impairment of the
autocrine vitamin D signalling pathway in osteoclasts resulted in an
intrinsic defect in osteoclast formation [15]. In our previous study [15],
WT osteoclasts that formed in the presence of 1,25D were smaller, si-
milar to both CYP27B1KO and VDRKO osteoclasts. In the case of WT,
Table 1
Oligonucleotide primers used in this study.
Gene Forward Primer (5′–3′) Reverse Primer (5′–3′) Annealing Temp (°C) Product Size (bp)
B2M CTGCTACGTAACACAGTTCCACCC CATGATGCTTGATCACATGTCTGG 60 214
Bax TGCTACAGGGTTTCATCCAGG TTGGATCCAGACAAGCAGCC 60 383
Bcl-2 GACTGAGTACCTGAACCGGC ATAGTTCCACAAAGGCATCCCAG 60 74
Ca2 GAGCTTCACTTGGTTCACTGG TGTGAGGCAGGTCCAATCTTC 60 133
Cd11b TGATGCTTACCTGGGTTATGCT GAAGAGCTTCACACTGCCAC 60 329
C-fos GTGAAGACCGTGTCAGGAGG CTGTCTCCGCTTGGAGTGTA 60 175
Clcn-7 TCCATGTCCTACCCACTCCAGC CAGGCCGAGAGTCATGGGATTATAG 60 144
Ctr GCCCTCTTATGAAGGAGAAGGT GATAGGCTGTGGCTCCAGCG 60 92
Ctsk TCTCTGTACCCTCTGCATTTAGC GGCCAACTCAAGAAGAAAACTG 60 230
Hprt11 GGTTAAGCAGTACAGCCCCA TGCAGATTCAACTTGCGCTC 60 234
Mcp-1 GGCTGGAGAGCTACAAGAGG TTGAGCTTGGTGACAAAAACTACAG 60 73
Nfatc1 AGGACACCCCATTGTGCAGCT CGTCAGCCGTCCCAATGAACA 60 80
Trap CGACAAGAGGTTCCAGGAGAC GGGAAGTTCCAGCGCTTGGAG 60 113
Fig. 1. The effects of VDR deletion and 1,25D addition on TRAP+ osteo-
clast formation. Splenocytes were cultured under control or pro-osteo-
clastogenic conditions in the absence or presence of 1,25D (1 nM), as
described in Materials and Methods for the times indicated, and assayed
for TRAP+ multinucleated cell formation: A) Representative images of WT
littermate control and VDRKO osteoclast cultures (10x objective). B)
Osteoclast formation from WT and VDRKO splenocytes. Total TRAP+ cell
numbers were combined from three independent experiments, each using
splenocytes pooled from at least 4 animals/group, and shown as
means ± SEM. Significant differences from WT are indicated by asterisks
(p < 0.05).
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this translated into inhibition of activity. However, when either of the
Cyp27b1 or Vdr genes are deleted, the resulting osteoclasts have in-
creased resorptive activity. These observations are consistent with there
being at least two distinct roles for VDR signalling in the osteoclast
lineage: optimisation of osteoclastogenesis and inhibition or ameliora-
tion of mature osteoclastic resorbing activity, as we have previously
suggested [9]. Previous histological analysis of both VDRKO and CY-
P27B1KO mouse bone revealed defective osteoclast formation relative
to WT in response to hypocalcaemia and elevated PTH levels [13].
Studies targeting the specific actions of VDR in the osteoclast lineage
are emerging. Nakamichi et al. [20] used a cathepsin K-Cre knock-in
transgenic mouse model to delete Vdr selectively in osteoclasts; in this
model one allele of the cathepsin K open reading frame is replaced with
Cre. They reported an apparent increase in bone mineral density in
these mice together with a decreased number of osteoclasts (N.Oc/BS),
although neither finding was commented upon [20]. In an accom-
panying paper [21], our group used a more traditional cathepsin K-Cre
mouse model, where Cre is expressed under a transgenic cathepsin K
promoter, to similarly delete Vdr in osteoclast lineage cells. We found
no difference in osteoclast number, however these mice had reduced
trabecular number (Tb.N) suggestive of increased resorptive activity. In
the current study, osteoclasts derived from VDRKO mice also had re-
duced overall size compared to that of their WT counterparts. Osteo-
clast fusion requires several physiological conditions to be met, in-
cluding the availability of sufficient numbers of osteoclast precursors
and then a number of complex interactions at the cell membrane and
cytoskeletal levels [22,23]. Cell size is thought to play a role in osteo-
clast resorptive capabilities. Larger osteoclasts, in particular those with
more than 20 nuclei, have more bone resorptive machinery but are
considered to be less motile, and decreased motility reduces the number
of resorption events that can be performed [24–27]. Consistent with
this concept, our results indicate that the smaller VDRKO osteoclasts
have increased resorptive capacity per osteoclast formed compared to
WT.
Defects in the ability of osteoclasts to fuse have been demonstrated
to involve genes such as Mcp-1 [28,29] and Trem-2 [30]. However, the
expression of Trem-2 was unchanged in VDRKO osteoclast cultures
compared with WT, and VDRKO osteoclast cultures exhibited increased
expression of Mcp-1 mRNA at day 6, which together argue against these
genes being causative of the observed effects. Intriguingly, we observed
strongly increased c-fos mRNA expression in VDRKO cells, both at
baseline and throughout osteoclastogenic culture. C-fos encodes a major
transcription factor induced as a direct consequence of RANKL signal-
ling through the RANK receptor, and is directly upstream of Nfatc1
expression. The increased expression of c-fos in VDRKO mice indicates
Fig. 2. The effects of Vdr deletion on osteoclast nuclei number. Splenocytes from either
WT or VDRKO mice were cultured and stained for TRAP, as described in Materials and
Methods. The number of nuclei per TRAP+ cell were counted at days 6–9 by light mi-
croscopy and categorised into osteoclasts containing A) 3–10 nuclei/cell or B) 11–25
nuclei/cell. Data shown are combined counts from three independent experiments, each
using splenocytes pooled from at least 4 animals/group, and shown as means ± SEM.
Significant differences from WT are indicated by asterisks (p < 0.05).
Fig. 3. The effect of Vdr deletion on osteoclast resorptive activity. Splenocytes were
seeded at identical density onto either dentine, Osteologic™ slides or 96-well assay plates
and cultured in the presence of M-CSF alone or under osteoclastogenic conditions, as
described in Materials and Methods. After 14 days of culture, wells were stained for TRAP
and slides were stained to reveal resorption areas: (A) appearance of either Von Kossa
stained Osteologic™ slides visualised by light microscopy or dentine visualised by scan-
ning electron microscopy; (B) quantified total area resorbed; (C) resorption corrected for
the numbers of TRAP+ osteoclasts formed in replicate wells. Quantified data are
means ± SEM of quadruplicate wells and are representative of 2 independent experi-
ments. Significant differences between genotypes are indicated by asterisks (p < 0.05).
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that the splenocytes in culture should have a stronger potential for
osteoclastogenesis than WT cells. Increased C-fos expression would be
expected to result in increased Nfatc1 expression and there was a trend
for increased Nfatc1 mRNA expression in VDRKO cultures at day 0.
Nfatc1is considered to be a master transcriptional regulator in osteo-
clasts [31,32]. The expression of genes such as Oscar, Ctsk, Ca2, Trap,
Clcn-7 and Nfatc1 itself are all dependent on NFATC1 activity [33].
While the reduction in Nfatc1 mRNA expression observed at day 7 is a
robust indicator that osteoclast behaviour has been modified due to the
loss of VDR signalling, and a similar reduction in Nfatc1 mRNA levels at
this time point was observed in mice lacking CYP27B1 expression [15],
further investigation will be required to determine the mechanisms
affected by this change. It is also possible that the loss of the VDR re-
sults in modifications to pathways in addition to the RANKL/C-fos/
Nfatc1 pathway [34].
Loss of VDR signalling was also associated with decreased Trap and
Fig. 4. The effect of VDR deletion on osteoclasto-
genic gene expression. Splenocytes pooled from four
mice of each genotype were seeded into 24-well
tissue culture plates at 1 × 106 cells/welland cul-
tured under osteoclastogenic conditions, as de-
scribed in Materials and Methods. Gene expression
by real-time RT-PCR was performed for the mRNA
expression of a) C-fos, b) Nfatc1, c) Trap, d) Clcn7, e)
Ctsk, f) Ctr, g) Mcp1, h) Trem-2 and i) the Bax/Bcl-2
mRNA ratio. Data shown are means ± SEM of 3
independent experiments. Significant differences
between genotypes at specific time points are in-
dicated by asterisks (p < 0.05).
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Ctsk mRNA expression at day 7, which may relate directly to the re-
duction in Nfatc1 levels at this time point. TRAP is an essential protein
in osteoclast function involved in both resorptive activity [35], and
providing the stimulus for the detachment of osteopontin (OPN) from
the bone surface with effects on osteoclast motility [36,37]. Cathepsin K
is a protease that is highly efficient in the degradation of type 1 collagen
[38] and Ctsk-null mice present with a phenotype of osteopetrosis [39].
The reduced expression of Ctsk mRNA observed here was expected to
result in decreased bone resorption, however the converse was found. It
may be that the observed decreased Trap and Ctsk mRNA expression
were part of a homeostatic negative control response to ameliorate the
increased osteoclast resorptive activity; we previously reported similar
reductions in the expression of these genes in osteoclasts derived from
the CYP27B1KO mouse [15].
The expression of other components of the resorption machinery in
osteoclasts was unchanged, including that of carbonic anhydrase 2
(Ca2), the enzyme responsible for the generation of hydrogen ions es-
sential for bone mineral dissolution; this was unexpected, as the Ca2
gene contains a VDR binding site [40–42]. While Ca2 is essential for H+
production, it is the V-ATPase hydrogen pump, a complex bi-domain
ion transporter that consists of 26 identified subunits [43], that is re-
sponsible for secreting acid. Here, only the expression of the largest
subunit, Voa3 [43], was examined, and this was found to be unchanged
in VDRKO cultures. However, it remains possible that one or more other
subunits were altered, contributing to a more active or dysregulated V-
ATPase in VDRKO osteoclasts. Chloride channel Clcn-7, deletion of
which results in failure of osteoclasts to secrete H+ [44], was also
unchanged in VDRKO cultures.
Calcitonin receptor (CTR) expression demonstrated increased ex-
pression at baseline and at day 8 of osteoclastogenesis. Calcitonin
binding to CTR results in inhibition of osteoclast activity through the
dissolution of the sealed zone and ruffled membrane [45]. The trend
towards increased Ctr expression indicates that the VDRKO osteoclasts
are potentially more sensitive to regulation by calcitonin, however it is
difficult to see how this could result in a change in activity ex vivo.
Both increased and decreased cell survival have been demonstrated
to increase osteoclastic resorptive activity [46–49]. We thus assessed
the effect of Vdr deletion on osteoclast survival through the examina-
tion of the expression ratio of Bax to Bcl-2 mRNA [50]. Bax is a pro-
apoptotic protein that increases the porosity of the mitochondrial
membrane and promotes caspase activation. Bcl-2 promotes cell sur-
vival through its ability to bind pro-apoptotic proteins such as Bax. We
observed a decrease in this apoptotic index for VDRKO osteoclast cul-
tures, indicating that these cells may have increased survival propensity
compared to WT. It is potentially this increased survival that con-
tributes to the observed increased number of resorption events per os-
teoclast in VDRKO cultures. However, further work will need to be
conducted, perhaps including tracking the lifespan of individual os-
teoclasts, to confirm this.
While further work will be required to elucidate the precise mole-
cular mechanisms responsible for the effects of Vdr ablation, overall,
our findings suggest that VDR signalling in osteoclast precursors is
critical for normal osteoclastogenesis and for ameliorating mature os-
teoclast activity. The current findings are consistent with those we re-
ported previously for osteoclastogenesis in the CYP27B1KO mouse
[15], thus disruption of VDR signalling due to either endocrine or au-
tocrine sources of 1,25D appear critical in this regard. Because of the
additional established role for vitamin D in stromal osteoblast and os-
teocyte regulation of osteoclastogenesis [51], our findings support the
concept that vitamin D has multiple roles in bone resorption, with vi-
tamin D signals deriving from either, or all of, endocrine, autocrine and
local paracrine sources.
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Absence of Vitamin D in mature osteoclasts results in altered 
osteoclastic activity and bone loss. 
 
This chapter looks at in vivo osteoclasts activity in mice that lack CYP27B1 and VDR 
in mature osteoclast and osteocytes. The CtskCre/Vdr−/− and CtskCre/Cyp27b1−/−  mice 
were developed in order to study osteoclast cells with intact signalling in precursor cells 
but impaired signalling in maturity as a way to isolate the role of vitamin D in 
osteoclasts and it precursors. 
This chapter utilises multiple techniques involving the analysis of the femoral bone, 
osteoclast numbers and mRNA expression.  This chapter is represented by a published 
manuscript and covers the effect of VDR and CYP27B1 ablation through the use of 
conditional CtskCre receptor KO mice in an in vitro mouse model.  
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A B S T R A C T
Mature osteoclasts express the vitamin D receptor (VDR) and are able to synthesise and respond to 1,25(OH)2D3
via CYP27B1 enzyme activity. Whether vitamin D signalling within osteoclasts is necessary for the regulation of
osteoclastic bone resorption in an in vivo setting is unclear. To determine the requirement for the VDR- and
CYP27B1-mediated activity in mature osteoclasts, conditional deletion mouse models were created whereby
either Vdr or Cyp27b1 gene was inactivated by breeding either Vdrfl/fl or Cyp27b1fl/fl mice with Cathepsin K-Cre
transgenic mice (CstkCre) to generate CtskCre/Vdr−/− and CtskCre/Cyp27b1−/− mice respectively. To account for
potential CtskCre-meaited off-target deletion of Vdr, Dmp1Cre were also used determine the effect of Vdr deletion
in osteocytes. Furthermore, CtskCre/Vdr−/− mice were ovariectomised (OVX) to assess the role of VDR in os-
teoclasts under bone-loss conditions and bone marrow precursor cells were cultured under osteoclastogenic
conditions to assess osteoclast formation. Six-week-old CtskCre/Vdr−/− female mice demonstrated a 15% de-
crease in femoral BV/TV (p < 0.05). In contrast, BV/TV remained unchanged in CtskCre/Cyp27b1−/− mice as
well as in Dmp1Cre/VDR−/− mice. When CtskCre/Vdr−/− mice were subjected to OVX, the bone loss that oc-
curred in CtskCre/Vdr−/− was predominantly due to a diminished volume of thinner trabeculae when compared
to control levels. These changes in bone volume in CtskCre/Vdr−/− mice occurred without an observable his-
tological change in osteoclast numbers or size. However, while cultured bone marrow-derived osteoclasts from
CtskCre/Vdr−/− mice were marginally increased when compared to VDRfl/fl mice, elevated expression of genes
such as Cathepsin K, Nfatc1 and VATPase was observed. Collectively, these data indicate that the absence of VDR
in mature osteoclasts causes exacerbated bone loss in young mice and during OVX which is associated with
enhanced osteoclastic activity and without increased osteoclastogenesis.
1. Introduction
1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is well known to reg-
ulate calcium homeostasis and skeletal health. In addition to the well-
known activities of 1,25(OH)2D3 in stimulating the intestinal absorp-
tion of calcium, we and others have identified roles for 1,25(OH)2D3 in
directly regulating serval bone cell types including osteoblasts, osteo-
cytes and osteoclasts [1,2].
A current view is that 1,25(OH)2D3 promotes both increasing the
expression of the key osteoclast differentiation factor RANKL, and
decreasing the expression of its antagonist, OPG [3]. While some con-
troversy exists as to the presence of VDR in osteoclasts [4], over-
whelming in vitro evidence supports the notion that vitamin D directly
controls the resorptive activity of osteoclasts. 1,25(OH)2D3 has been
shown to facilitate adhesion of osteoclast precursors to stromal osteo-
blasts via induction of inter-cellular adhesion molecule, ICAM-1 [5] and
osteoclast adhesion molecule, αVβ3 integrin [6]. As well, 1,25(OH)2D3
directly supports RANKL-induced osteoclast formation from the mouse
osteoclast precursor cell line, RAW 264.7 [7]. In addition, human os-
teoclast precursors can metabolise 25(OH)D3 into 1,25(OH)2D3 by the
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enzyme CYP27B1 and this is required for the expression of a number of
important osteoclast markers, and transcription factors, NFATc1 and c-
FOS [2]. However, the resorptive activity of mature osteoclasts, was
also shown to be inhibited by both 25(OH)D and 1,25(OH)2D3 [2].
Consistent with these findings, splenocyte derived osteoclastic pre-
cursor cells derived from either VDR-null or CYP27B1-null mice de-
monstrate markedly reduced osteoclastogenesis [8,9]. While fewer os-
teoclasts form in these from VDR-null or CYP27B1-null mice, osteoclasts
that do form exhibited greater resorptive activity per osteoclast and
increased survival as indicated by lower BAX:BCL-2 ratio [8–10]. The
findings from these studies suggest a role for the synthesis and activity
of vitamin D being able to directly regulate both the formation and in
turn the subsequent activity of osteoclasts.
Whether these in vitro and ex vivo observations translate in a role for
vitamin D activity within osteoclasts in an in vivo setting is unclear.
Thus, to assess the role for VDR- and CYP27B1-mediated activity in
osteoclasts in vivo, osteoclast-specific VDR and CYP27B1 knockout
mice, CtskCre/Vdr−/− and CtskCre/Cyp27b1−/−, respectively, were
generated. We demonstrate the relative impact of VDR and CYP27B1
deletion within mature osteoclasts on bone structure, osteoclast gen-
eration and subsequent bone resorption. These data expand the evi-
dence that vitamin D activity contributes to the regulation of bone re-
sorption via direct activities within osteoclasts.
2. Materials and methods
2.1. Animals
All animals used in the generation of both Osteoclast-specific mouse
models (CtskCre/Vdr−/− CtskCre/Cyp27b1−/− and Dmp1Cre/Vdr−/−
were of C57B6 background. Cathepsin-K-Cre (CtskCre) mice [11] were
obtained from Assoc. Prof. R Davey (University of Melbourne, Aus-
tralia). Dentin matrix protein-1-Cre Dmp1Cre mice were obtained from
Prof L Bonewald (Indiana University) [12]. VDR-LoxP [13] (gift from
Dr. S Kato, University of Tokyo) and CYP27B1-LoxP [14] (gift from
Prof. R St-Arnaud, University of McGill) were mated with the Ctsk-Cre
mice to generate CtskCre/Vdr−/− and CtskCre/Cyp27b1−/− mice re-
spectively as well as VDR-LoxP or CYP27B1-LoxP litter-matched control
mice. VDR-LoxP mice were mated with Dmp1-Cre mice to generate
Dmp1Cre/Vdr−/− in order to determine whether the CtskCre/Vdr−/−
bone phenotype might be due to non-specific Vdr deletion in osteo-
cytes. All animal procedures were approved by the University of South
Australia, Animal Ethics Committee. Mice were housed in IVC caging,
with a maximum 5 gender-matched animals/cage and a standard 12 hr
light/dark cycle. Mice were provided ad libitum access to standard chow
and tap water.
2.2. DNA and mRNA analyses
DNA and mRNA were extracted from whole tibia from littermate
Vdrfl/fl and respective knockout mice by previously published proce-
dures [15]. The presence of mutated Vdr DNA was amplified using
specific primers (F: 5′-CCTTGGTGAGCTGAGTTTACTCTT-3′; R: 5′-CTT
CCCACCACTTTGTACTACCA-3′). Messenger RNA was analysed using
mRNA specific primers for Vdr, (F: 5′-TCGGATCTGTGGAGTGTGTG
GAG-3′, R: 5′-TTGTCCTTGGTGATGCGGCAATCT-3′). These mRNA
specific primers are design to specifically amplify mRNA in the region
of exon 2. The floxed VDR mice have exon 2 of the vitamin D receptor
gene flanked by short intronic loxP sites. Exon 2 encodes the 1 st zinc
finger of the DNA binding domain of the in D receptor. Previously, the
deletion of exon 2 was shown to result in a frame shift, resulting in
complete deletion of the vitamin D receptor protein [16]. Other primers
used include Cathepsin- K (5′-ggccaactcaagaagaaaactg-3′, R: 5′-tctctgt
accctctgcatttagc-3′); NFATc1 (5′-AGGACACCCCATTGTGCAGCT-3′, R:
5′- cgtcagccgtcccaatgaaca −3′), and VATPase (5′- GCTGCA-
GAGCGGCTCAAG-3′, R: 5′- AAGGGGAATGTGATGATGGTGTAG-3′).
2.3. Ovariectomy
Female Vdrfl/fl and CtskCre/Vdr−/− mice (n = 4-5/group) were
ovariectomised at 10 weeks of age. Briefly, mice received a bilateral
ovariectomy (OVX) under isofluorane induced anaesthesia. A small
incision (0.5 cm) on the mid-dorsal aspect of the mouse was created to
allow blunt-nosed scissors to separate the skin from the peritoneal layer
to cut through the peritoneal layer to retrieve and excise the ovary on
each flank.
2.4. Biochemistry
Serum calcium (Ca), phosphate (P) and alkaline phosphatase (ALP)
levels were measured using the KoneLab 20XT Clinical Chemistry
Analyser (ThermoScientific, MA, USA), using standard protocols and
reagents (ThermoScientific, USA). Serum C-terminal telopeptide (cross-
laps, CTX) was measured using a RatLaps EIA Kit (Immunodiagnostic
Systems Limited, UK).
2.5. Micro-computed tomography (μCT)
Right femora were subjected to ex vivomicro-computed tomography
(μCT) using the 1174 μCT system (Bruker). Micro-architecture was
analysed using high-resolution micro-CT in order to obtain multiple x-
ray transmission images. The scanning resolution had a voxel size of
6.5 μm/pixel, with an x-ray tube potential of 50 kVp and 800 μA. To
measure trabecular micro-architecture within the femur (metaphysis) a
rotation step of 0.4 ° and a frame averaging of 2 was used. Cross-sec-
tional images were reconstructed using the nRecon software (Version
1.6.9.18) (Bruker, BEL). Realignment of datasets was performed using
Dataviewer software (v.1.5.1, Bruker, BEL). All bone quantification
from reconstructed and realigned datasets was performed using CTan
software (v.1.7, Bruker, BEL). A 2 mm metaphyseal region of interest
was isolated from the distal femur. Parameters assessed include, bone
volume (BV/TV, %), trabecular thickness (Tb.Th, mm) and trabecular
number (Tb.N, #/mm). Analyses of trabecular volume parameters for
Ovariectomy intervention studies were undertaken using the Skyscan
1076 (Bruker, BEL) for live in vivo scanning of femurs of ovariectomised
animals (0.5 mm filter, 52 kVp and 112 μA, 9 μm pixel size, 5890 ms
exposure time, rotation step of 0.80 and a frame averaging of 1). All
analyses were done using the same software/programs as mentioned
above.
2.6. Histology
Femora were then subjected to ethanol dehydration steps prior to
being placed into a Methyl Methacrylate (MMA): Polyethylene Glycol
400 (PEG) solution (100% MMA: 10% PEG). Femurs were left in the
MMA: PEG solution for 14 days, at which time polymerisation was in-
duced using a solution containing MMA: PEG: Perkadox (0.4%).
Trimmed resin blocks were sectioned in the sagittal plane at 5 μm
thickness. Sections were prepared for TRAP staining or left unstained
for fluorochrome label analyses. TRAP stained slides were used to
measure metaphyseal osteoclasts numbers (N.Oc, #/mm), osteoclast
surface per bone surface (Oc.S/BS, %), number of osteoclasts per bone
perimeter (N.Oc/B.Pm, #/mm), and osteoclast size (nm2). Unstained
slides were used measurement of the mineralising surface (MS/BS)
mineral apposition rate (MAR, μm/day) and bone formation rate/bone
surface (BFR/BS, μm3/μm2/day). The All analyses were performed
using OsteoMeasure™ Version 3.3.0.2 (OsteoMetrics, Inc. Decatur, GA,
USA)
Expression of osteoclastic genes was analysed using real-time,
quantitative PCR using iScript Reverse Transcription Supermix for RT-
qPCR (BioRad). Relative gene expression was normalized to that of the
beta-2-microglobulin (β2 M) housekeeping gene using the comparative
cycle threshold (Ct) method (deltaCT).
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2.7. Bone marrow cultures
The role for the VDR in osteoclast formation and activity was as-
sessed in bone marrow cultures. Flushed diaphyseal bone marrow from
the femora and tibiae of Vdrfl/fl and CtskCre/Vdr−/− mice were sus-
pended in αMEM (Sigma Chemical Co., St Louis, MO, USA) containing
10% foetal calf serum (FCS), 1% penicillin and streptomycin, 2 nM L-
glutamine and 1% hydroxyethyl piperazineethanesulfonic acid
(HEPES). Cells were then seeded overnight at 37 °C before treating with
M-CSF (25 ng/mL, Millipore, Temecula, CA, USA), with or without
RANKL (100 ng/mL, Millipore, Temecula, CA, USA) in 10% stripped
FCS (HyClone, Logon, UT, USA). Cultures were fed fresh media and
cytokines every 3 days and harvested on day 9 of culture.
2.8. Statistical analysis
Either unpaired T-test or Analysis of Variance were used to analyse
datasets. The analysis was performed using GraphPad, Prism (Version
5.01) (GraphPad Software Inc., California, USA). A P value of less than
or equal to p < 0.05 was considered to be statistically significant.
3. Results
CtskCre/Vdr−/− and CtskCre/Cyp27b1−/− mice demonstrated dele-
tion of Vdr and Cyp27b1 within whole bone respectively as determined
by DNA analysis (data not shown) and by an approximate 70% and 90%
reduction in bone Vdr and Cyp27b1 mRNA expression in bone respec-
tively when compared to floxed littermate control levels (Fig. 1).
In both CtskCre/Vdr−/− and CtskCre/Cyp27b1−/− mice, body
weight and femur length were unchanged when compared to their re-
spective controls (Table 1). Likewise, serum measures of calcium,
phosphate were unchanged in both CtskCre/Vdr−/− and CtskCre/
Cyp27b1−/− mice when compared to Cyp27b1fl/fl levels. Serum CTX, a
biomarker for bone resorption, was not significantly different between
either CtskCre/Vdr−/− or CtskCre/Cyp27b1−/− and their respective
littermate controls (Table 1).
CtskCre/Vdr−/− mice demonstrated 15% reduction in BV/TV%
when compared to control mice (p < 0.05) (Fig. 2). The reduction in
CtskCre/Vdr−/− mice was due to reduced Tb.N (p < 0.05), rather than
Tb.Th. Despite a reduction in BV/TV% in CtskCre/Vdr−/− mice, no
significant differences were observed in osteoclastic parameters of
Oc.S/BS, N.Oc/B.Pm and Mean Oc.Size. Similarly, trabecular bone loss
in CtskCre/Vdr−/− mice was not associated with any change in the bone
formation parameters of MS/BS, MAR or BFR/BS (Fig. 2). In support of
these observations, no changes were observed in tibial RankL mRNA or
RankL:Opg (data not shown).
In contrast, despite the marked abrogation of Cyp27b1 in CtskCre/
Cyp27b1−/− mice, unchanged BV/TV%, Tb.N and Tb.Th when
compared to controls and unchanged osteoclastic parameters when
compared to control levels suggests that Cyp27b1 in mature osteoclasts
plays a negligible role under normal growing conditions (Fig. 3).
Since cathepsin K has been shown to be expressed in osteocytes
[17], non-specific Cathepsin-K-Cre mediated deletion in osteocytes may
contribute to the low bone volume phenotype in CtskCre/Vdr−/− mice.
To account for the potential of non-specific deletion of VDR in osteo-
cytes, Dmp-1Cre/VDR−/− were also generated to evaluate the effect on
bone mineral. However, despite a marked decline in mRNA levels for
Vdr in Dmp-1Cre/VDR−/− tibial cortical bone, no change in femoral
metaphyseal trabecular bone volume was observed in age-matched fe-
male (Suppl Fig. 1) or male mice (data not shown). In addition, no
changes to cortical bone were observed in Dmp-1Cre/VDR−/− mice
(data not shown).
To assess the effects of VDR deletion in osteoclasts under conditions
of accelerated bone loss, CtskCre/Vdr−/− female were subjected to bi-
lateral ovariectomy surgery to ablate oestrogen levels, as previously
described [18]. CtskCre/Vdr−/− mice exhibited a 33% (±0.05) re-
duction in BV/TV% over 28 days from surgery (Fig. 4A). The decline in
bone volume was comparable to femoral bone loss in Vdrfl/fl mice over
the same period of time and was predominantly due to a loss in Tb.N.
However, when trabecular thickness in CtskCre/Vdr−/− mice was ana-
lysed according the distribution of bone volume within partitions of
trabecular thicknesses ranging from 0.008 to 1.12 mm, significant dif-
ferences in bone volume were observed. CtskCre/Vdr−/− mice demon-
strated a marked decline in the proportion of thin trabeculae up to
0.06 mm in width when compared to Vdrfl/fl mice at 28 days post-sur-
gery(Fig. 4B). For trabeculae greater than 0.06 mm, bone volume was
comparable between CtskCre/Vdr−/− and Vdrfl/fl mice. Despite the
OVX-induced loss of thin trabeculae in CtskCre/Vdr−/− mice, no sig-
nificant changes in the osteoclast parameters of Oc.S/BS, N.Oc/B.Pm
and Mean Oc.Size occurred when compared to Vdrfl/fl control mice.
To further examine the effects of VDR deletion specifically within
osteoclasts, bone marrow-derived osteoclasts were generated under
osteoclastogenic conditions from CtskCre/Vdr−/− mice and compared
to Vdrfl/fl cultures (Fig. 5). At day 9 of culture, Vdr mRNA levels were
absent in CtskCre/Vdr−/− cultures. While osteoclast numbers were
marginally greater in CtskCre/Vdr−/− cultures, this did not reach sta-
tistical significance. Despite this, mRNA levels for Ctsk, Nfatc1 and
vATPase where markedly increased when compared to levels in Vdrfl/fl
cultures, suggesting enhanced osteoclastic activity.
4. Discussion
In this study, the conditional deletion of Vdr in osteoclasts in the
mouse model of CtskCre/Vdr−/− resulted in decreased femoral BV/TV
in young mice, despite no measurable changes to osteoclast recruitment
on the surface of bone or levels of circulating CTX. In addition, tibial
mRNA for genes, such as Rankl, was unchanged CtskCre/Vdr−/− mice
suggesting that osteoblastic and osteoclastic signalling did not con-
tribute to the change bone phenotype in these mice. Furthermore,
Dmp1Cre/Vdr−/− mice exhibit unchanged bone volume when com-
pared to control littermate mice, consistent with previous observations
[19], indicating that the bone-loss phenotype in CtskCre/Vdr−/− mice is
not due to non-specific VDR deletion in osteocytes.
To further examine the role of VDR in regulating osteoclastic ac-
tivity in CtskCre/Vdr−/− mice, females were ovariectomised to induce
accelerated bone loss via enhanced bone resorption [18,20–24]. While
the overall bone loss in CtskCre/Vdr−/− mice was comparable to that in
ovariectomised Vdrfl/fl mice, CtskCre/Vdr−/− mice exhibited markedly
increased loss of the thinner trabeculae than control mice. This in-
dicates that while osteoclastogenesis did not appear to be significantly
altered in CtskCre/Vdr−/− mice, the increased focal resorption, re-
sulting in loss of thinner trabeculae could be due to more active os-
teoclasts.
Consistent with this notion, CtskCre/Vdr−/− bone marrow cultured
Fig. 1. (A) Vdr or Cyp27b1 mRNA deletion in mouse tibia for floxed Vdr or Cyp27b1
control (Vdrfl/fl or Cyp27b1fl/fl) and osteoclast-specific Vdr or Cyp27b1 knockout female
mice (CtskCre/Vdr−/− or CtskCre/Cyp27b1−/−). Values are presented as means ± SEM,
n = 8. *p < 0.05.
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in osteoclast-forming conditions demonstrated an increased osteoclas-
togenic potential through elevated expression in genes generally asso-
ciated with resorptive activity. This is consistent with our previous
findings where by osteoclasts derived from mice with global deletion of
VDR (VDRKO) have increased survival propensity and increased re-
sorption events per osteoclast in culture [9].
In contrast to the role of VDR, the deletion of Cyp27b1 in the
CtskCre/Cyp27b1−/− mouse model resulted in no change in bone vo-
lume, suggesting that at least in this model of young animals, the
synthesis of 1,25(OH)2D3 in osteoclasts does not play an important role
in regulating bone resorption. This is in contrast to in vitro evidence
which demonstrates that the conversion of 25(OH)D3 to 1,25(OH)2D3,
which occurs via the Cyp27b1 enzyme, is important for regulating os-
teoclastic activity [8]. Splenocytes derived from Cyp27b1−/− mice
exhibit both reduced osteoclastogenesis, and yet increased resorptive
activity per osteoclast formed, suggesting that autocrine activities of
vitamin D in osteoclast precursor cells and mature osteoclasts has
specific roles defined by the stage of osteoclast development [8]. Since
the CtskCre/Cyp27b1−/− mouse model only examines the effect of
Cyp27b1 absence in mature osteoclasts, it remains to be determined
whether Cyp27b1 plays a significant role in the generation of osteo-
clasts, rather than activity in an in vivo setting. Furthermore, it remains
possible that Cyp27B1 activity in osteoclasts may play a role under
conditions other than during normal growth which would require fur-
ther investigation.
While further studies are required to determine the mechanisms, by
which vitamin D activity regulates osteoclastic bone resorption, our
findings suggest that VDR-mediated activity in mature osteoclast is
required moderate osteoclastic activity during growth and in OVX-in-
duced bone loss.
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Body weight (g), femur length (mm), Ca, Calcium; P, Phosphate and CTX, Cross-laps for floxed Vdr or Cyp27b1 control (Vdrfl/fl and Cyp27b1fl/fl) and osteoclast-specific Vdr or Cyp27b1
knockout (CtskCre/Vdr-/- and CtskCre/Cyp27b1-/-) female mice at 6 weeks of age. Values are presented as means± SEM, n = 8–15.
Vdrfl/fl CstkCre/Vdr-/- Cyp27b1fl/fl CtskCre/Cyp27b1-/-
Body weight (g) 20.41 ± 0.60 21.06 ± 0.39 21.10 ± 0.31 20.95 ± 0.52
Fem. length (mm) 13.70 ± 0.23 13.92 ± 0.11 13.83 ± 0.20 14.09 ± 0.19
Ca (mmol/L) 2.38 ± 0.06 2.55 ± 0.23 2.68 ± 0.13 2.62 ± 0.14
P (mmol/L) 2.16 ± 0.11 2.14 ± 0.12 2.91 ± 0.15 2.73 ± 0.18
CTX (ng/ml) 108.0 ± 26.5 88.8 ± 12.3 136.8 ± 41.6 143.6 ± 57.9
Fig. 2. Histomorphometric analyses of the distal femoral metaphysis
in CtskCre/Vdr−/− and Vdrfl/fl mice. Bone volume/tissue volume (BV/
TV, %); Trabecular thickness (Tb.Th, mm); Trabecular number (Tb.N,
#/mm); Osteoclast surface per bone surface (Oc.S/BS, %); Osteoclast
number per bone perimeter (N.Oc/B/Pm, #/mm); Mean osteoclast
size (Mean Oc. Size, μm2); Mineralised surface per bone surface (MS/
BS, %), Mineral apposition rate, (MAR, μm/d); Bone formation ate per
bone surface (BFR/BS, μm3 μm2/day), Values presented as
means ± SEM, n = 8–12. *p < 0.05.
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Fig. 3. Histomorphometric analyses of the distal femoral metaphysis
in CtskCre/Cyp27b1−/− and Cyp27b1fl/fl mice. Bone volume/tissue
volume (BV/TV, %); Trabecular thickness (Tb.Th, mm); Trabecular
number (Tb.N, #/mm); Osteoclast surface per bone surface (Oc.S/BS,
%); Osteoclast number per bone perimeter (N.Oc/B/Pm, #/mm);
Mean osteoclast size (Mean Oc. Size, μm2); Values presented as
means ± SEM, n = 8–12. *p < 0.05.
Fig. 4. (A) The effect of bilateral OVX on CtskCre/Vdr−/− and Vdrfl/fl mice with respect to (A) distal femoral metaphyseal bone of at 1, 14 and 28 days post-surgery and (B) distribution of
trabecular bone volume by thickness at Day 1 and Day 28 post-surgery. Bone volume/Tissue volume (BV/TV, %); Trabecular thickness (Tb.Th, mm); Trabecular number (Tb.N, #/mm);
Osteoclast surface per bone surface (Oc.S/BS, %); Osteoclast number per bone perimeter (N.Oc/B/Pm, #/mm). Values presented as means ± SEM, n = 4–5.
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Further analysis of the role of Vitamin D in osteoclastogenesis in co-
cultures with intact osteocyte-like signalling through the use of 
conditional Vdr knockout splenocytes 
 
This sub-chapter consists of unpublished data relating to the study by Reinke et al. 
(Chapter 6) and Starczak et al. (Chapter 7). Ex vivo co-cultures were conducted using 
the mouse MLO-Y4 osteocyte-like cell line together with splenocytes derived from 
Ctskcre/ Vdr-/- mice, using assays including TRAP staining, dentine bone resorption and 




In our previous studies (122, 133), we examined the effect of Vdr gene KO at the global 
level (VdrKO) and conditionally in mature osteoclasts (Ctsk-Cre.Vdrfl/fl) (139). Global 
deletion was examined using VdrKO ex vivo splenocyte cultures. The conditional KO 
was examined using in vivo Ctskcre/vdr-/- model. While both of these types of 
experimental techniques contribute to the elucidation of the role of VDR in the 
osteoclast, they examine different aspects of the vitamin D pathway in this lineage. The 
global VdrKO model has a germ-line deletion that potentially alters the development of 
osteoclast precursors as well as the activity of mature osteoclasts. This means that all 
stages of the osteoclast from precursor to final stage, mature multinucleated cells, are 
affected. This results in an inability to differentiate between effects on 
osteoclastogenesis and activity. Furthermore, the use of splenocyte monocultures 
means there is no influence of external endocrine/paracrine signalling, except that 
modelled by the addition of recombinant RANKL and M-CSF, reducing the similarity 
to in vivo physiological conditions. The Ctskcre/vdr-/-, on the other hand, enables the 
examination of the effects of Vdr ablation in mature multinucleated osteoclasts actively 
expressing cathepsin K, enabling the differentiation between activity and 
osteoclastogenesis. A potential limitation of the Ctskcre/vdr-/- model used in our previous 
study (139) is that VDR activity could only be studied in cathepsin K expressing cells, 
notably active osteoclasts but potentially also osteocytes (140). However, the use of an 
osteocyte-specific deletion mouse model, Dmp-1Cre/VDR-/-, demonstrated that there 
was no notable effect on bone density and formation in in vivo cultures (139), 




In this study, we modified the experimental technique used in the previous chapters to 
develop a co-culture system that enables a more complete examination of the vitamin 
D pathways in osteoclasts. We utilised the MLO-Y4 cell line in co-culture with the 
Ctskcre/vdr-/- splenocytes. The MLO-Y4 cell line was chosen as it is a widely accepted 
osteocyte model and has been demonstrated to support osteoclastogenesis. However, 
MLO-Y4 and Ctskcre/vdr-/- cells are both murine, preventing the ability to distinguish 
between osteocyte and osteoclast-derived gene expression. In these experiments, 
mature osteoclasts derived from Ctskcre/vdr-/- precursors lack the ability to respond to 
1,25D. However, VDR signalling in the stromal osteocyte compartment remains intact. 
This is important, since osteocytes have been demonstrated to be key controllers of 
osteoclastogenesis in adult mouse bone (51, 52, 141) (142). 
Experimental results from these cultures will enable us to identify the effect of vitamin 
D deletion on osteoclast activity, separate from osteoclastogenesis while enabling us to 
examine the contribution of stromal VDR signalling.  
 
7a.2 Methods 
Methods were followed, as detailed in Chapter 2, unless otherwise stated. The use of 
human derived SAOS-2 cell lines were tested as well as the MLO-Y4 cell line, in order 
to permit cell compartment-specific analysis of gene expression, by designing species-
specific oligonucleotide primers, as our group has done previously. Primers were 
identified from electronic comparison of gene sequences. In most cases this allowed the 
identification of gene sequences that were species-specific. The exception to this was 
Ctsk. The human and murine Ctsk sequences have 100% sequence identity and so were 
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not examined. Unfortunately pilot studies indicated that SAOS-2 cells were unable to 
sufficiently support osteoclastogenesis to be of use for this study. Monocultures of 
either MLO-Y4 or splenocytes without RANKL or M-CSF were used as negative 
controls. 
  
7a.3 Results and Discussion 
WT and Ctskcre/vdr-/- co-cultures in the absence of exogenously added 1,25D had 
decreased osteoclast formation than WT and Ctskcre/vdr-/- co-cultures under 1nM of 
exogenous 1,25D (Fig 7a.1). The decreased osteoclast formation was expected as this 
co-culture model specifically derives osteoclastogenesis instigating factors, such as 
RANKL, from the MLO-Y4 cell line. This cell line has been demonstrated to express 
RANKL and pro-osteoclastogenic factors under the presence of 1,25D (121).  
The ablation of VDR in cultures treated with 1,25D resulted in an increase in MNC 
number on day 9. The timing of the decrease coincides with the peak number of mature 
osteoclasts. Mature osteoclasts have the highest levels of cathepsin K expression and 
this would result in the highest level of VDR suppression due to the design of the 
Ctskcre/vdr-/- model. The reduction of MNC at peak osteoclast formation due to the 
ablation of the VDR in mature osteoclasts was unexpected and indicates the potential 
for the VDR to act as an inhibitor. This is further supported by previous studies (133). 
These studies indicated that decreased osteoclast number was observed when the VDR 
signalling pathway was intact in the presence of 1,25D. Additionally it was observed 
by (139) that the loss of VDR in mature osteoclasts resulted in decreased bone density, 
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Fig 7a.1: The effect of VDR deletion and vitamin D metabolite addition in mature 
osteoclasts under co-culture with MLO-Y4 cell line. Splenocytes were cultured under 
four treatments; 1) WT co-culture of spleen and MLOY-4, 2) WT co-culture of spleen 
+ MLO-Y4 + 1 nM 1,25D, 3) VdrKO co-culture of spleen and MLOY-4, 4) VdrKO co-
culture of spleen + MLO-Y4 + 1 nM 1,25D and assayed for TRAP+ multinucleated cell 
formation. Total TRAP positive cell numbers were combined from two independent 
experiments, each using splenocytes pooled from at least 4 animals/group, and shown 




Co-culture experiments under osteoclast inducing conditions without the addition of 
exogenous 1,25D had lower levels of resorptive activity compared with cultures that 
had exogenous 1,25D as expected. These results in conjunction with MNC number as 
seen in Figure 7a.1 indicate that the presence of 1,25D is required for optimal osteoclast 
formation in a MLO-Y4 co-culture. WT and Ctskcre/vdr-/-  splenocytes in MLO-Y4 co-
culture were not significantly different from each other in the absence of exogenous 
1,25D with equal levels of resorbed area on dentine (Fig 7a.2-7a.3). 
Average area resorbed was significantly increased (3.3 fold) under 1,25D signalling 
under the ablation of VDR in mature osteoclasts (Fig 7a.3a). Osteoclast activity was 
alternatively measured as average resorption per osteoclast. Resorption per osteoclast 
was also increased in the presence of exogenous 1,25D under the ablation of the VDR 
in mature osteoclasts but had a lower fold increase of 1.4 (Fig 7a.3b).  
The increase in osteoclast number and resorptive activity under exogenous 1,25D in 
mature osteoclasts with ablated VDR further reinforces the concept of exogenously 
added 1,25D acting as an inhibitor. Our previous papers have also demonstrated that 
the addition of exogenous 1,25D to WT spleen monocultures also resulted in a decrease 
in osteoclast formation and resorption (122, 133). The use of co-cultures in this case 
also allows us to observe the effect on VDR ablated mature osteoclasts, which was 
obscured in previous papers due to the germline deletion of VDR and CYP27B1. This 
indicates that there is a distinct but separate response to autocrine and exogenous 1,25D 
enhancing the importance of the role of the vitamin D receptor in the osteoclast. 
The increased resorptive activity observed in osteoclasts, concurs well with the study 
done by (139) in ovariectomised mice in physiological conditions which have decreased 
bone volume. VDR ablation in in vivo cell cultures showed reduced thin trabecular bone 
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volume. This reinforces the role of VDR in osteoclasts as that of inhibitory when 
exposed to exogenous 1,25D. The lack of response from Cyp27b1KO cultures in mature 
osteoclasts as stated in Starczak et al. (139) is a clear indicator that the stage of 
maturation of hematopoietic stem cells plays a critical role in the determination of 
osteoclast response to both autocrine and endocrine vitamin D and its metabolites. The 
stage of maturation does not seem to change the inhibitory effect exogenous 1,25D has 
in both developing and mature osteoclasts. 
To summarise, the deletion of the VDR specifically in the mature osteoclast resulted in 
increased; resorption, osteoclast number and resorption per osteoclast. The VDR in co-
culture acted to suppress osteoclast number and resorption, acting as another regulatory 
element restricting osteoclast numbers. This strongly suggests that direct effects of 
1,25D are more important physiologically than the indirect effects, at least in terms of 
osteoclast formation. Additionally, it also indicates that the changes in resorptive 
activity observed in global KO mice are likely caused by alterations to the osteoclast in 
maturation. This may indicate that the formation of the V-ATPase channels as seen in 
Chapter 5 occur during immature osteoclasts, as currently we hypothesise that increased 
hydrogen ion secretion is responsible for the increased resorption observed. Further 
work involving the use of Ctskcre/vdr-/- mice in a monoculture, using RANKL and M-
CSF to stimulate osteoclastogenesis would be worth undertaking. 
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Fig 7a.2: The effect of VDR deletion on osteoclast resorptive activity in mature 
osteoclasts. MLO-Y4 cells were seeded onto dentine and left over night. Splenocytes 
were then seeded at optimal density into the dentine containing 96-well plates and 
culture under cell supportive conditions. After 21 days of culture, dentine was removed, 
cleaned and analysed by scanning electron microscopy. Quantified data are means ± 








Fig 7a.3: The effect of VDR deletion on osteoclast resorptive activity in mature 
osteoclasts. Dentine was analysed using image J and Graphpad Prism. a) Average total 
area resorbed b) Average area resorbed per event. Quantified data are means ± SEM of 
quadruplicate wells and are representative of 2 independent experiments. Significant 
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The vitamin D endocrine system is an exceedingly complex system. The vitamin D 
receptor has been demonstrated to be almost ubiquitously expressed throughout the 
human body (1). The understanding of the endocrine system as an adjunct of the 
calcium and phosphate system is relatively well understood. However, the effect of 
vitamin D metabolism at the cellular level is poorly understood. Previous studies have 
established that the autocrine conversion of 25D to 1,25D occurs within the osteoblasts 
and osteoclasts and that as these cells mature the level of this conversion increases. This 
has been demonstrated in murine RAW264.7 and human PBMC cultures (Chapter 1). 
This indicates that the role of autocrine conversion of 25D and 1,25D plays a significant 
role in the regulation of bone remodelling. Initial examination was undertaken through 
the use of murine spleen cells extracted from Cyp27b1KO mice. Initial findings were 
inconsistent and indicated the need for further optimisation (Chapter 3). Optimisation 
of murine osteoclast cultures resulted in the key findings that cell density and FBS were 
the primary regulators of changes within osteoclast ex vivo cell cultures. It was also 
established that the use of a pooled population from multiple murine spleens resulted 
in more reproducible and consistent cultures in terms of resulting osteoclast numbers. 
The use of heterozygous murine model was untenable as either a positive or negative 
control as there was a lack of reproducibility in the cultures, with the results appearing 
to mimic those from either WT or KO cell cultures seemingly randomly. 
 
8.1 Deletion of CYP27B1   
Examination of Cyp27b1KO murine ex vivo cell model against WT littermate matched 
controls were undertaken through TRAP staining, Von Kossa staining, dentine 
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resorption assays and RT-PCR gene expression analysis. The deletion of CYP27B1 
resulted in increased osteoclast numbers, increased resorption per cell on osteoid and 
dentine and in particular, the derangement of prominent osteoclast genes including 
Nfatc1, Trap, C-fos and Ca2. The deletion of Cyp27b1 also resulted in the derangement 
of the ratio of Bax to Bcl-2 suggesting that the osteoclasts formed had reduced rate of 
apoptosis. 
The loss of CYP27B1 resulting in decreased gene expression and decreased TRAP+ 
MNC was expected, as it had been observed previously that the presence of 25D 
resulted in increased gene expression and osteoclast proliferation (3, 4, 7).  Increased 
resorptive activity per osteoclast was also observed, which is counterintuitive but highly 
consistent with our group’s findings that the addition of 25D to osteoclast forming 
cultures with CYP27B1 intact reduced the resorptive activity of osteoclasts formed; 
thus, it was proposed that circulating 25D levels may serve to optimise 
osteoclastogenesis by promoting osteoclastic gene expression while ameliorating 
resorption activity (3). This signified the potential for research into alternate pathways 
that could result in altered resorptive activity, such as, effects of vitamin D on the many 
sub-units of the V-ATPase pump.   
We investigated the effect of the conditional KO of Vdr and Cyp27b1 in mature 
osteoclasts derived from murine splenocytes (Chapter 7). Ctskcre/Vdr-/- mice maintain 
functional vitamin D metabolic pathways in all other cell types and additionally in the 
immature precursors of the osteoclast, since the promoter driving Cre-recombinase 
expression and gene deletion is that of Ctsk, a gene product normally expressed by 
mature, actively resorbing osteoclasts. The Ctsk-Cre model has been well validated as 
osteoclast-specific (143). This potentially allows us to examine the effect of autocrine 
vitamin D pathways in mature osteoclast in both in vivo and ex vivo models. It was 
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demonstrated that the loss of CYP27B1 in vivo in mature osteoclasts, as is the case in 
CtskCre-Cyp27b1-/- mice, had no effect on bone volume. The lack of resorption change 
in these mice was disappointing. It does however indicate that the effects seen in the ex 
vivo models may be related to changes in osteoclast precursors and immature 
osteoclasts that are not yet producing sufficient CTSK to trigger CYP27B1. In contrast, 
the loss of VDR in mature osteoclasts resulted in significantly reduced bone volume 
without affecting osteoclast number (139), consistent with the notion that vitamin D 
signalling specifically in mature osteoclasts reduces or ameliorates their activity.  
Ovariectomised mice were used as a model of pathologic bone loss and demonstrated 
bone loss was exacerbated in the absence of osteoclastic VDR. This increased loss of 
bone volume may be indicative of both altered survival and resorptive events by the 
osteoclast.  
This model provides useful insight into the role of vitamin D signalling in mice. In 
particular, this study demonstrates how much there is still to be elucidated about the 
role of autocrine vitamin D signalling in the osteoclast.  
 
8.2 Deletion of VDR 
The clear changes in osteoclastic fusion and resorption seen with splenocyte cultures 
from Cyp27b1KO mice implied that a similar response should be seen when Vdr was 
deleted (Chapter 6). 
The deletion of VDR from the osteoclasts resulted, as expected, in a similar reduction 
in osteoclast formation with decreased osteoclast numbers, decreased gene expression, 
and increased resorptive activity. Of particular note was that the gene expression 
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patterns were nearly identical between VdrKO and Cyp27b1KO osteoclast cultures for 
multiple sets of genes, strongly suggesting that overlapping metabolic pathways were 
affected.  
The ratio of Bax and Bcl-2 was also increased in VdrKO osteoclast cultures consistent 
with these osteoclasts having increased survival. This provided two potential and not 
mutually exclusive hypotheses for increased resorptive activity despite reduced gene 
expression. The first being increased survival resulting in osteoclasts that were active 
for longer. The second being changes to the osteoclasts’ primary form of hydrogen ion 
secretion, the V-ATPase pump. 
 
8.3 The Effect of 1,25D on Cyp27b1KO and VdrKO Osteoclasts. 
As hypothesised the addition of 1,25D to both KO mouse models was unable to 
restore functionality in the osteoclasts. The lack of response in VdrKO osteoclasts was 
expected if the KO of the VDR receptor was successful. The inability of exogenous 
1,25D to restore function in Cyp27b1KO osteoclasts indicated that the conversion of 
25D to 1,25D and the presence of the autocrine system within the osteoclast has its 
own functions.  The addition of 1,25D to WT cultures in this experimental set also 
resulted in decreased osteoclastic formation and activity. This indicated that 
osteoclastic cultures in the absence of stromal cell signalling responded to exogenous 




8.4 V-ATPase Modification Due to Loss of Autocrine Vitamin D 
Pathway. 
We also examined the effect of CYP27B1 deletion on all 26 subunits of the V-ATPase 
proton pump. It became apparent that the majority of genes were modified to some 
extent by the loss of the autocrine vitamin D pathway. The resultant gene expression 
indicated that the V-ATPase pump may become unstable and dysregulated when 
autocrine vitamin D metabolism is lost. We were unable to directly establish a link 
between altered gene expression and proton secretion with loss of the vitamin D 
metabolic pathway. This will require additional experimentation, including assessment 
of the protein levels of each of the subunits. 
8.5 Limitations and Future Direction 
The analysis in the above cell culture studies, in addition to examining osteoclast 
formation and activity, relied to a large extent on RT-PCR analysis. RT-PCR has 
positive attributes of being highly specific and quantitative. However, it would be 
preferable in future studies to include unbiased RNA approaches, such as RNA 
sequencing, to identify the full transcriptome of the genetically modified or treated 
cells. Coupled with bioinformatics, this could identify all cellular processes affected. 
During the course of this dissertation, the associated costs of RNA-Seq have reduced 
considerably, making this approach more feasible. Furthermore, changes in mRNA 
levels do not always result in equivalent changes in protein levels. This can be due to 
effects on promoter activity, post-translational processing, as well as protein turnover. 
It would be desirable to perform proteomic analysis, and similar to RNA-Seq, in an 
unbiased fashion. Even if the proteome was determined, it would still likely be 
necessary to perform antibody-based techniques to determine the composition of 
173 
 
specific structures such as the V-ATPase, as well as high fidelity imaging, in order to 
determine subtle changes. 
Work was planned for a caspase 3 apoptosis assay, however due to restrictions in the 
availability of the mice, the use of an RNA based system of Bax and Bcl-2 was used 
instead. Any further work in this area would ideally include a more thorough 
examination of apoptosis as well as senescence as possible cell fates.  
To improve in vivo examination of the role of vitamin D signalling in osteoclasts, an 
inducible approach, such as tetracycline-inducible conditional gene knockout, at 
various stages of osteoclastogenesis could be used to distinguish between 
developmental and functional effects. 
The findings within this thesis have added to the literature that autocrine activity of 
vitamin D has an important role in the regulation of the osteoclast. Furthermore, it has 
established that autocrine vitamin D metabolism affects osteoclast fusion, bone 
resorption activity, motility and precursor proliferation, and that these effects are still 
observable under the regulation of osteoblast-like cell cultures. This indicates that the 
regulation of vitamin D within the osteoclast lineage is an essential part of bone 
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